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Erik Thomas Dustrude 
INTERPLAY BETWEEN COLLAPSIN RESPONSE MEDIATOR PROTEIN 2 
(CRMP2) PHOSPHORYLATION AND SUMOYLATION MODULATES  
NaV1.7 TRAFFICKING 
 
The voltage-gated sodium channel Nav1.7 has gained traction as a pain target 
with recognition that loss-of-function mutations in SCN9A, the gene encoding Nav1.7, 
are associated with congenital insensitivity to pain, whereas gain-of-function mutations 
produce distinct pain syndromes due to increased Nav1.7 activity. Selective inhibition of 
Nav1.7 is fundamental to modulating pain via this channel. Understanding the regulation 
of Nav1.7 at the cellular and molecular level is critical for advancing better therapeutics 
for pain. 
Although trafficking of Nav1.7 remains poorly understood, recent studies have 
begun to investigate post-translational modifications of Navs and/or auxiliary subunits as 
well as protein-protein interactions as Nav-trafficking mechanisms. Here, I tested if post-
translational modifications of a novel Nav1.7-interacting protein, the axonal collapsin 
response mediator protein 2 (CRMP2) by small ubiquitin-like modifier (SUMO) and 
phosphorylation could affect Nav trafficking and function. Expression of a CRMP2 
SUMOylation incompetent mutant (CRMP2-K374A) in neuronal model CAD cells, 
which express predominantly Nav1.7 currents, led to a significant reduction in 
huwentoxin-IV-sensitive Nav1.7 currents. Increasing deSUMOylation with 
sentrin/SUMO-specific protease SENP1 or SENP2 in wildtype CRMP2-expressing CAD 
cells decreased Nav1.7 currents. Consistent with reduced current density, biotinylation 
revealed significant reduction in surface Nav1.7 levels of CAD cells expressing CRMP2-
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K374A or SENP proteins. Diminution of Nav1.7 sodium current was recapitulated in 
sensory neurons expressing CRMP2-K374A. 
Because CRMP2 functions are regulated by its phosphorylation state, I next 
investigated possible interplay between phosphorylation and SUMOylation of CRMP2 on 
Nav1.7. Phosphorylation of CRMP2 by cyclin dependent kinase 5 (Cdk5) was necessary 
for maintaining Nav1.7 surface expression and current density whereas phosphorylation 
by Fyn kinase reduced CRMP2 SUMOylation and Nav1.7 current density. Binding to 
Nav1.7 was decreased following (i) loss of CRMP2 SUMOylation, (ii) loss of CRMP2 
phosphorylation by Cdk5, or (iii) gain of CRMP2 phosphorylation by Fyn. Altering 
CRMP2 modification events simultaneously was not synergistic in reducing Nav1.7 
currents, suggesting that Nav1.7 co-opts multiple CRMP2 modifications for regulatory 
control of this channel. Loss of either CRMP2 SUMOylation or Cdk5 phosphorylation 
triggered Nav1.7 internalization involving E3 ubiquitin ligase Nedd4-2 as well as 
endocytosis adaptor proteins Numb and Eps15. Collectively, my findings identify a novel 
mechanism for regulation of Nav1.7. 
 
 
Nickolay Brustovetsky, Ph.D., Chair  
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INTRODUCTION 
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Pain is a relatable human experience. It developed as an evolutionary survival 
trait to help animals avoid injuries and dangerous situations. This basic drive for survival 
holds a great deal of power over our behavior and emotions. In disease and injury, pain 
can persist beyond what is useful to trigger a beneficial reaction. When this occurs, pain 
is a detrimental force to society that degrades quality of life and emotional state, 
decreasing a person’s level of function, and creates a financial burden. Conservative 
estimates from a NIH funded report ‘Relieving Pain in America’ warn that ~116 million 
American adults suffer from chronic pain states that cost the people of the United States 
between $560-635 billion each year in health care and lost productivity (Institute of 
Medicine Report from the Committee on Advancing Pain Research and Education, 
2011). The report attributes much of this cost to lack of effective therapies. To address 
this issue, the NIH report challenges researchers to investigate novel pain pathways as 
targets for future generations of pain-relieving drugs.  
This dissertation will describe one such pathway linking modifications of an 
axonal specification protein, the collapsin response mediator protein 2 (CRMP2) to the 
regulation of voltage-gated sodium channel Nav1.7, a channel linked inextricably to pain 
signaling. By identifying mechanisms governing the trafficking of Nav1.7, this work will 
contribute to enhanced understanding of the biology of Nav1.7 as well as identify 
possible novel targets for pain relieving therapeutics targeting Nav1.7. 
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1.1. Voltage-Gated Sodium Channel Nav1.7, a Molecular Target for Pain 
1.1.1. Ionic Conductance of Neurons – Historical Perspective 
Underlying the transmission of pain is the basic unit of cellular communication 
between excitable cells – the action potential. This wave of electric potential differences 
between the inside and outside of the cell was first described during the late 1930s by Sir 
Alan Hodgkin, Sir Andrew Huxley, Kenneth Cole, and Howard Curtis (Hodgkin, 1937a, 
b, Curtis and Cole, 1938). The action potential is an electrical wave that travels across the 
membrane neurons in milliseconds. The shape and duration of the action potential were 
identified to be choreographed changes in cell membrane permeability to different ionic 
species (Cole, 1949). Subsequent work identified the ionic species as inwardly flowing 
sodium ions and outwardly flowing potassium ions (Rothenberg, 1950, Keynes, 1951, 
Hodgkin and Huxley, 1952b). At its initiation, both the rate and amplitude of the action 
potential can be experimentally controlled by the concentration of extracellular sodium 
ions. These early studies concluded then that gain of sodium permeability underlies 
initiation of neuronal cell-cell communication (Hodgkin and Katz, 1949). Historical 
papers that outlined initial properties of the action potential laid the foundations for the 
development of voltage-clamp electrophysiology. Using an amplifier to control the 
voltage potential across the cell, researchers use this technique to study ionic 
contributions in neurons. These ionic currents can then be precisely quantified and 
compared between conditions. This tool has escalated in use over the past 60 years to 
study fundamental properties of neuronal communication. 
Early voltage-clamp experiments resolved that neuronal membranes are 
selectively permeable to sodium during the rise of an action potential, and that this 
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permeability is quickly lost as the membrane becomes permeable to potassium during the 
fall of an action potential (Hodgkin and Huxley, 1952a, c). These shifts in permeability 
were also determined to be both time and voltage-dependent. Expanding on this work, the 
existence of moving membrane voltage gates was proposed to control the opening and 
closing of permeability. Hodgkin and Huxley were able to accurately produce 
mathematical models of these voltage gates that fit the kinetics of sodium permeability 
driven activation and inactivation across the cell membrane (Hodgkin and Huxley, 
1952d). For their work on the initial descriptions of action potentials and ionic 
conductance, Sir Alan Hodgkin and Sir Andrew Huxley shared the Nobel Prize in 
Physiology or Medicine with Sir John C. Eccles in 1963. The channel proteins underlying 
their work on ionic conductions, however, would remain a mystery for several decades. 
 
1.1.2. Discovery, Structure, and Function of Voltage-Gated Sodium Channels 
 Identification of the 250kDa voltage-gated sodium channel (VGSC) protein was 
first achieved by Beneski and Catterall through covalent labeling of channel protein with 
the agonist, α-scorpion toxin (Beneski and Catterall, 1980). This toxin enhances neuronal 
activity, thus permitting identification of the proteins underlying this function. By 
covalent labeling of the channel, the toxin allowed for channel purification from lysate 
and identification using immunoblotting with antibodies. The discovery and use of this 
toxin and others greatly advanced the field of biophysics during the 1980s by allowing 
researchers to discover and characterize interactions with channel proteins. The use of 
toxins extended beyond their utility as probes to identify and purify channels to their 
perturbation of channel function, this latter feature was instrumental in early structure-
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function analyses to link molecular component of the protein to functional kinetic 
properties. In 1982, the paralytic shellfish toxin saxitoxin was used to purify an ~250kDa 
channel protein from rat brain. This protein was reconstituted in phosphatidylcholine 
vesicles (Talvenheimo et al., 1982) and formed functional channel pores that fluxed 
sodium and retained sensitivity to channel block by the puffer fish toxin tetrodotoxin 
(TTX) and stimulated sodium uptake by veratridine, a drug that preferentially binds to 
activated Na+ channels causing persistent activation that leads to increased nerve 
excitability (Sigel, 1987, Barnes and Hille, 1988). Similar studies followed with 
reconstitution of functional rabbit muscle VGSCs around the same time (Kraner et al., 
1985). Using a different method of protein reconstitution, channels from rat brain 
(Hartshorne et al., 1985) and rabbit T-tubular membranes (Furman et al., 1986) were 
functionally reconstituted into planar lipid membranes. This allowed for the resolution of 
single channel currents that displayed voltage-dependent activation. This important 
finding demonstrated that the voltage-dependence of activation is intrinsic to each 
channel protein and requires no additional machinery, thus supporting the Hodgkin and 
Huxley model of activation gates. 
Channel identification and purification lead shortly thereafter to breakthroughs in 
channel cloning and cDNA from Electrophorus electroplax was cloned and sequenced in 
1984 (Noda et al., 1984). The sequence of this sodium channel provided a stepping-stone 
to predicting channel structure that aided in identification of key channel features of 
gating and ion selectivity. Sequence analysis identified the channel as a single 250kDa 
polypeptide, 1820 amino acid in length. Analysis of secondary and tertiary protein 
structures predicted four homologous domains (DI-DIV) consisting of six transmembrane 
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spanning segments (S1-S6) each, and large intracellular N- and C-terminal domains (Guy 
and Seetharamulu, 1986). Segments S1-S6 are, relatively apolar, transmembrane helical 
domains, except for S4, which contains several positively charged residues which were 
hypothesized and later confirmed to function as activation particles (Stuhmer et al., 
1989). Between S5 and S6 segments of all four domains a reentrant loop bridges 
transmembrane regions to form a structure predicted, and later confirmed, to be the outer 
channel pore (Miller, 1991).  
The early model of VGSC protein structure provided a starting point for 
numerous structure-function relationship studies that followed. As identified by the first 
sequencing of VGSCs, S4 contains positively charged amino acid side chains that serve 
as prime candidates for a voltage-sensing mechanism comprising the activation gate. 
Mutagenesis of these residues and structural comparisons between channels supported 
this hypothesis. The spacing of positively charged lysine and arginine resides was ideal 
for uniform orientation towards the center of the channel pore, an organization shared by 
both calcium (Tanabe et al., 1987) and potassium channels (Tempel et al., 1987). Point 
mutations that neutralized these positive charges decreased the slope of the voltage-
dependence of activation and also shifted the voltage of half maximal activation to more 
depolarized potentials (Stuhmer et al., 1989). These kinetic shifts reduced channel ability 
to gate into open confirmations supporting their hypothesized role as the activation gate. 
During work with squid giant axons, it was discovered that termination of sodium 
channel currents by fast-inactivation was disrupted by perfusion of proteases into the 
cytosolic space (Armstrong, 1981). As such, it was proposed that an intracellular motif is 
responsible for fast-inactivation. Now armed with predicted protein structural topological 
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information, researchers identified a curious hydrophobic cluster within the cytoplasmic 
linker between DIII and DIV. When this cluster was mutated to neutral amino acids, 
sodium channel fast-inactivation was completely eliminated, identifying this motif as an 
inactivating particle (West et al., 1992). In another structure-function study, mutagenesis 
of negatively charged residues within S5-S6 linker that imparted tetrodotoxin and 
saxitoxin sensitivity introduced permeability of mono and divalent ions to sodium 
channels (Noda et al., 1989, Schlief et al., 1996). The S5-S6 linker was initially predicted 
to form an outer pore structure and the loss of selectivity following mutations in this 
region identify this structure as the selectivity filter. Analogous structures within a variety 
of ion channels further supported the finding that S5-S6 linker endows ion selectivity to 
channels (Miller, 1991, Liao et al., 2013). 
Recently, the crystal structure of the homotetrameric bacterial voltage-gated 
sodium channel was solved allowing comparison of sequence predicted models to a 
sodium channel in closed-pore confirmation with activated voltage sensors (Figure 1.1 
from Payandeh et al., 2011) (Payandeh et al., 2011). Confirmation of previously 
predicted features include arginine derived gating charges, a narrow selectivity filter near 
the extracellular surface, and voltage sensor mediated shifts of the voltage sensor 
domains themselves and the S4-S5 linker to dilate the central pore. The structure also 
prompted discovery of novel features including hydrogen bonding between gating 
charges and the protein backbone, and fenestrations into the central pore from the sides of 
the protein structure. These fenestrations are large enough to allow for entry of small, 
hydrophobic, pore-blocking molecules and confirmation of phenylalanine-203 side chain 
is hypothesized to alter size of the opening (Figure 1.1 C and D). The resolution of the 
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crystal structure provides excellent insights into the selectivity of the channel for sodium 
ions, which we now know requires passage of partially dehydrated sodium ions through a 
selectivity filter formed by the side chains of glutamate-177. Directly adjacent to this and 
further into the channel pore, a sodium ion hydrated by a square array of four water 
molecules can interact with threonine-175 or leucine-176 to pass fully hydrated sodium 
ions with low energy barriers between positions, a desirable characteristic of a pore that 
relies on gradient and not energy input to pass ions. 
 
1.1.3. Diversity of Voltage-Gated Sodium Channels and Specific Roles of Nav1.7 in Pain 
 Nine genes coding for voltage-gated sodium channels alpha pores have 
been reported to date – Nav1.1-Nav1.9 (Goldin, 1999, Dib-Hajj et al., 2002). These have 
been broadly classified by their pharmacology and kinetics with members Nav1.1–
Nav1.4 and Nav1.6–Nav1.7 being TTX-sensitive, displaying channel block in response to 
the toxin. In terms of kinetics, these channels are rapidly inactivating. Nav1.5, Nav1.8 
and Nav1.9 are TTX-resistant channels and also have slower inactivation kinetics than 
their TTX-sensitive counterparts (Caffrey et al., 1992). Additionally, Nav1.8, the primary 
TTX-R contributor to current amplitude displays depolarized voltages of half-maximal 
activation compared to TTX-S channels, i.e. they require more depolarized voltages to 
gate open. It is this difference in activation kinetics that allows for electrical separation of 
TTX-S currents from total currents in voltage-clamp experiments. Using pre-pulse 
inhibition protocol and post-hoc subtraction of the isolated TTX-R currents, TTX-S 
currents can be estimated from total currents of cells with heterogeneous expression of 
sodium channels (Roy and Narahashi, 1992). In neurons, multiple VGSCs are expressed 
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within the same cell. These channels have variable kinetics, voltage dependencies, sub-
cellular localizations, and expression levels that mediate different modalities and code for 
different electrical properties in the rodent nervous system. Within the nervous system, 
the nine identified sodium channel isoform display a generalized pattern of expression 
with Nav1.1, Nav1.2, Nav1.3 and Nav1.6 expression in the central nervous system, 
Nav1.4 expression in skeletal muscle, Nav1.5 expression in heart tissue, and Nav1.7, 
Nav1.8 and Nav1.9 expression in the peripheral nervous system (Catterall et al., 2005). 
These differences code for the diversity of neuronal functions and also make each cell 
type susceptible to different diseases and pharmacological tools dependent on differences 
between subtypes. A wide variety of diseases are the result of sodium channel 
dysfunction throughout the human body (Figure 1.2, adapted from (de Lera Ruiz and 
Kraus, 2015).  
A function ascribed to peripheral Nav channels is pain. Noxious stimuli signal 
along the axons of dorsal root ganglia (DRG) neurons making their compliment of 
channels very important to strategies that restrict neuronal signaling of pain. These 
ganglia of heterogeneous cells, just outside the spinal column, are responsible for 
nociception, touch and proprioception. Cells of each modality follow a generalized 
pattern of Nav1.1, Nav1.6, Nav1.7, Nav1.8 and Nav1.9 expression that also correlates to 
cell body size (Lawson, 2002, Ho and O'Leary, 2011). Large diameter (> 30 µm cell 
body) DRGs are predominately high conduction velocity, myelinated Aα/β fibers that 
transmit proprioceptive and touch information utilizing Nav1.1, Nav1.6, and to a lesser 
extent, Nav1.7 and Nav1.8. This contrasts with smaller diameter (< 30 µm cell body) 
DRGs that are predominately low condition velocity Aδ and C-fibers transmitting pain  
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Figure 1.1. Structure of bacterial VGSC pore and fenestrations to central pore. 
Adapted from (Payandeh et al., 2011). (A) Architecture of VGSC pore with Glu-
177 selectivity pore in purple, pore structure in yellow, pore helices in green and 
red, and transmembrane segments in purple. (B) Space filling model of channel 
with negative electrostatic potentials shown by deeper red color.  Lighter red color 
at pore exterior also depicts negative electrostatic potential in a red (-) to blue (+) 
scale. (C) Side view and (D) top view of pore with fenestrations highlighted by red 
wireframe. Confirmation of side Phe203 side chains (yellow) determine aperture of 
the opening, and different residues implicated in drug block indicated by green, 
blue and orange ball structures.  
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 Tissue Nav 
subtype 
Effect of dysfunction References 
A Central Nervous 
system 
1.1, 1.2, 
1.3, 1.6 
Epilepsy, migraine, autism, 
ataxia 
(Jurkat-Rott et al., 2010, Sanders et 
al., 2012, Cestele et al., 2013, 
Djamgoz and Onkal, 2013, 
Schmunk and Gargus, 2013, 
Catterall, 2014, Hoeijmakers et al., 
2014, Tavassoli et al., 2014) 
B Retnia 1.8, 1.9 Altered visual processing (O'Brien et al., 2008) 
C Olfactory sensory 
neurons 
1.7 Anosmia (Cox et al., 2006, Cox et al., 2010, Ahn et al., 2011) 
D Sensory neurons and 
vagal sensory 
neurons innervating 
airways 
1.7, 1.8, 
1.9 
Cough (Jurkat-Rott et al., 2010, Muroi and Undem, 2011, Sanders et al., 2012, 
Cestele et al., 2013, Djamgoz and 
Onkal, 2013, Schmunk and Gargus, 
2013, Catterall, 2014, Hoeijmakers 
et al., 2014, Tavassoli et al., 2014) 
E Heart Muscle 1.5, 1.8 Brugada syndrome, QT 
syndrome, atrial fibrillation 
(Antzelevitch et al., 2014, Hu et al., 
2014, van den Boogaard et al., 
2014) 
F Nerves, musculature 
involved in entilation 
TTX-S Respiratory cessation (TTX 
poisoning) 
(Cheng et al., 1968, Muroi and 
Undem, 2014) 
G Pancreatic β-cells 1.7 Diabetes (Jurkat-Rott et al., 2010, Sanders et al., 2012, Cestele et al., 2013, 
Djamgoz and Onkal, 2013, 
Schmunk and Gargus, 2013, 
Catterall, 2014, Hoeijmakers et al., 
2014, Tavassoli et al., 2014) 
H Skeletal muscle 1.4 Hyperkalaemic periodic 
paralysis, paramyotonia, 
congenital, hypokalaemic 
periodic paralysis 
(Jurkat-Rott et al., 2010, Sanders et 
al., 2012, Cestele et al., 2013, 
Djamgoz and Onkal, 2013, 
Schmunk and Gargus, 2013, 
Catterall, 2014, Hoeijmakers et al., 
2014, Tavassoli et al., 2014) 
I Skin 1.7, 1.8, 
1.9 
Pain disorders, paroxysmal 
itch 
(Dib-Hajj et al., 2013, Bennett and 
Woods, 2014) 
J DRG neurons 1.6, 1.7, 
1.8, 1.9 
Pain disorders, paroxysmal 
itch 
(Dib-Hajj et al., 2013, Leipold et al., 
2013, Bennett and Woods, 2014) 
K Metastatic cancer 
cells 
1.1-1.9 
and beta 
subunits 
Ovarian, cervical, prostate, 
breast, colon, small cell lung 
cancer, melanoma, lymphoma 
(Brackenbury, 2012, Black and 
Waxman, 2013, Frede et al., 2013, 
Fraser et al., 2014, Nelson et al., 
2014, Shan et al., 2014) 
Figure 1.2. Expression of VGSC subtypes and physiology or disease affected by channel dysfunction 
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information. Small and medium DRGs have lower expression of Nav1.1 and Nav1.6 and 
very high levels of Nav1.7, Nav1.8 and Nav1.9 (Ho and O'Leary, 2011). These 
differences in expression allow VGSCs expressed in small DRGs to be specifically 
targeted to attenuate pain. A strategy that does not show subtype specificity will produce 
more side effects due to targeting of all DRGs, other neurons, and heart and muscle 
tissues. 
Extensive studies with sodium channel toxins has recently advanced our 
understanding of VGSC expression patterns within small DRGs. The µ-conotoxins have 
differential blocking affinities for Nav1.1, Nav1.6, Nav1.7, Nav1.8, and Nav1.9 and have 
been utilized to resolve sodium currents in DRGs and to discern the fraction of current 
carried by each isoform. Using this approach, Nav1.7 has been identified as the dominant 
TTX-S subtype in small to medium sized DRGs representing nearly 80% of TTX-S 
current (Zhang et al., 2013) Nav1.7 expression throughout these cells is evident by high 
signal of Nav1.7 immunolabeling in DRG cell bodies, projections to spinal cord, axons, 
and peripheral terminals in the dermis (Black et al., 2012). Nav1.7 expression has also 
been functionally correlated to nociceptive signaling by Nav1.7 immunoreactivity in cells 
with long duration action potentials, slow conduction velocity, and small cell bodies (C-
fibers) (Djouhri et al., 2003). 
 The Nav1.7 channel, with high expression in nociceptive DRGs, conveys specific 
properties to dorsal root ganglia cells that are important for the summation of sensory 
inputs. Compared to other peripheral TTX-S channels, Nav1.7 displays slow closed-state 
inactivation when driven by a slow voltage ramp. This property is analogous to high 
responsiveness to inputs over long durations. The channel is able to respond to a broader 
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range of inputs, which allows it to function as a signal-processing channel for the 
generation of action potentials (Cummins et al., 1998, Herzog et al., 2003). Though the 
summation of signals, Nav1.7 generates threshold currents that determine action potential 
firing. Specific evidence of this property is found in human gain-of-function mutations 
wherein Nav1.7 becomes more conductive to sodium culminating in hyperexcitable 
DRGs (Dib-Hajj et al., 2007). Many unique Nav1.7 gain-of-function mutations have been 
identified as mechanisms for painful human diseases like inherited erythromelalgia 
(IEM), where a hyperpolarizing shift in channel activation makes Nav1.7 more available 
in response to voltage changes, and paroxysmal extreme pain disorder (PEPD), where 
depolarizing shifts in fast-inactivation slows inactivation to reduce the current threshold 
for subsequent action potentials (Dib-Hajj et al., 2008, Estacion et al., 2008, Estacion et 
al., 2011, Theile et al., 2011, Estacion et al., 2013). IEM and PEPD as well as Nav1.7 
mediated small fiber neuropathy (SFN) (Cannon, 2012, Han et al., 2012, Ahn et al., 
2013) present with symptoms such as pain triggered by warmth in the extremities and 
episodic pain of the face and extremities including burning sensations. The exact opposite 
effect on pain has been observed within patients harboring loss-of-function Nav1.7 
mutations. These individuals exhibit congenital insensitivity (CIP) to pain and completely 
lack thermal and mechanical pain thresholds (Cox et al., 2006, Kurban et al., 2010). The 
initial observation of CIP is typically made by parents when the child does not respond to 
injuries and during the first years of life lips, tongue, and finger tips are commonly 
damaged. In some cases, these self-induced injuries result in amputation if the injury is 
severe or secondary infection presents without any distress from the child (Bennett and 
Woods, 2014). In about one third of cases the families of these children are accused of 
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physical abuse and many children are initially misdiagnosed as mentally handicapped due 
to lack of painful feedback that allows for appropriate reaction to their environment. The 
high expression of Nav1.7 in nociceptive DRGs and phenotypes of human patients with 
Nav1.7 mutations conveys an importance of this channel in pain and has led many 
researchers to study Nav1.7 in rodent pain models. 
One important and powerful approach to examine the role of Nav1.7 in pain is the 
generation of transgenic mice. Early attempts suffered setbacks due to neonatal lethality 
of global Nav1.7 knockout (Nassar et al., 2004, Weiss et al., 2011). To overcome this 
obstacle, researchers cross-bred Nav1.7+/- heterozygote mice with sturdier mouse strains 
that are resistant to stress. They also employed extreme measures of human-aided 
postnatal care that allowed for a small fraction (~5%) of global Nav1.7-null mice to 
survive to adulthood. These mice have overall normal behavior and congenital 
insensitivity to pain in hot plate, tail clip, formalin, complete Freund's adjuvant, thermal, 
mechanical, chemical, and inflammatory pain behavioral tests (Gingras et al., 2014). 
Whereas global Nav1.7 deletion recapitulates congenital insensitivity to pain observed in 
human loss-of-function SCN9A mutations, mice that lack Nav1.7 and Nav1.8 from their 
nociceptive neurons undergo normal development of neuropathic pain (Nassar et al., 
2005) and mice that lack Nav1.7 in nociceptors versus all DRGs, or all sensory neurons 
display differential pain behaviors (Minett et al., 2012, Minett et al., 2014a).  
Using a Nav1.8-Cre mouse, Nav1.7 was specifically deleted from Nav1.8 positive 
nociceptors and these Nav1.7-null mice displayed reduced acute pain behavior measured 
by hind paw withdrawal threshold and reduced mechanical and thermal pain following 
inflammation induced by formalin or CFA injections (Nassar et al., 2004). In a follow up 
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study, Nav1.7 and Nav1.8 were both deleted from nociceptive neurons using the same 
Nav1.8-Cre mice. These Nav1.7/Nav1.8 double-knockout mice displayed normal motor 
coordination tested by stability on a rotarod, increased thermal and mechanical thresholds 
for acute pain, and a complete lack of inflammatory pain to formalin injection. These 
mice, however, underwent normal development of neuropathic pain following ligation of 
L5 spinal nerve. This pain state therefore is not dependent on Nav1.7 or Nav1.8 
expression in nociceptors despite strong evidence that both channels participate in the 
generation of painful stimuli (Nassar et al., 2005). 
Additional Nav1.7 mice in which Nav1.7 was deleted from specific populations 
of neurons was generated under control of Advillin promoter to knockout Nav1.7 from all 
DRG neurons and also Wnt1 promoter to knockout Nav1.7 from both sensory and 
sympathetic neurons (Minett et al., 2012). Nav1.7-Advillin knockout mice abolished 
mechanical and inflammatory pain much like other Nav1.7 and Nav1.7/Nav1.8 
knockouts. In addition, mice lacking Nav1.7 in all DRGs presented with increased 
threshold to thermal pain as assessed by Hargreaves’ test which was not observed in 
previous studies when Nav1.7 was knocked out the Nav1.8 promoter (Nassar et al., 
2005). Therefore, Nav1.7 activity in all DRG subtypes is required for thermal sensitivity 
to this test. Within the same study, Nav1.7-Wnt1 knockout mice displayed increased 
latency of withdrawal in the hotplate test that was not previously observed in Nav1.7 
knockout mice under Nav1.8- or Advillin-promoters. Knockout by the Wnt1 promoter 
removes Nav1.7 expression from all neural crest derived cells that differentiate into 
sensory and autonomic neurons. Therefore, restriction of Nav1.7 participation within 
sympathetic neurons is what likely attenuates thermal sensitivity (Minett et al., 2012).  
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The Nav1.7-Wnt1 knockout mice displayed complete reversal of neuropathic pain 
suggesting that development of this pain state requires Nav1.7 in sympathetic neurons. 
One study suggests, however, that some pain states are not dependent on classical 
nociceptors. In animals treated with the chemotherapeutic agent oxalipatin, complete lack 
of Nav1.7 was insufficient in preventing onset of pain (Minett et al., 2014b). Release of 
Substance P, which contributes to NMDA-mediated wind up and sensitization of 
nociceptive fibers (Herrero et al., 2000) was reduced in Nav1.7-Advillin knockout mice 
(Minett et al., 2012) as was the response to a small range of noxious cold stimuli (Minett 
et al., 2014a), suggesting that Nav1.7 in DRG neurons significantly contributes to 
mechanisms relating to the development of multiple, but not all, pain states.  
Due to these differences in Nav1.7 conditional knockouts, the role of Nav1.7 in 
generation of pain behavior is incompletely understood and appears to involve a variety 
of neuronal populations (Figure 1.3, adapted from (Minett et al., 2012)). Thus, it is still 
unclear if Nav1.7 is a necessary and sufficient determinant of pain behavior. 
Nevertheless, targeting of DRG Nav1.7 channels appears to be a highly pursued strategy 
to ameliorate several painful conditions as highlighted by research efforts of academic 
laboratories and pharmaceutical companies investing in Nav1.7-targeted therapies (Table 
1.1).  
Like mutations that alter channel kinetics, diseases that increase Nav1.7 channel 
surface expression can enhance current in DRGs and produce numerous pain states. 
Diabetes mellitus is one such disease frequently associated with hyperalgesic and 
allodynic pain states that have been correlated with increased TTX-R and TTX-S current 
density and channel expression (Hong et al., 2004). In animal models of diabetes, Nav1.7 
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undergoes a ~50% expression increase in small and medium diameter DRG neurons. 
Similarly, inflammatory pain mediated by 4% carrageenan injected into rat hind paws has 
also been associated with ~25% increased VGSC expression. In the carrageenan model, 
DRG expression of Nav1.3, Nav1.7 and Nav1.8 are increased and TTX-S currents 
undergo ~40% increase in density supporting the hypothesis that VGSC expression 
underlies inflammatory pain (Black et al., 2004). Nerve damage resulting from treatment 
with the chemotherapeutic agent paclitaxel results in hyperexcitability of DRGs and 
associated ~30% increase in Nav1.7 expression (Zhang and Dougherty, 2014). In 
addition to these examples, mechanical injury to nerves has been shown regulate VGSC 
expression. Immediately after injury a variety of inflammatory mediators are released, 
including bradykinin, prostaglandins, neurotransmitters, and neurotrophins. Many of 
these factors interact with cell surface receptors on neurons to alter signaling pathways, 
including PKA/PKC pathways known to modulate VGSCs (Julius and Basbaum, 2001). 
In the specific case of spared nerve injury, where the sural branch of the sciatic nerve is 
spared while the tibial and common peroneal nerves are ligated, Nav1.7 and Nav1.8 
current densities are increased. Additionally, Nav1.7 expression is increased ~100% 
along the sciatic nerve (Laedermann et al., 2013a). In addition, herpes vector-mediated 
knockdown of Nav1.7 in DRG sensory neurons significantly prevents the development of 
hyperalgesia (i.e. an increased response to a painful stimulus) in response to complete 
Freund's adjuvant (Yeomans et al., 2005).  
Spurred, in part, by studies that implicate Nav1.7 in painful human disease and 
injuries, the channel has become a popular candidate target for therapeutics. Tarantula 
peptide toxins are selective for Nav1.7 in vitro but fail to provide analgesia in pain   
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Figure 1.3. Requirement of Nav1.7 knockout from different populations of 
neurons to affect pain behavior. Figure adapted from (Minett et al., 2012). Nav1.7 
expression in Nav1.8-positive DRGs (brown: red/green overlap) is required for 
mechanical sensitivity, response to the second phase of formalin, and inflammatory 
pain. Nav1.7 expression in Nav1.8-negative DRGs (red) is required for acute thermal 
sensitivity, spinal reflex, and noxious cooling, but not extreme cold which is 
dependent on Nav1.8 (green). Nav1.7 expression in both DRGs and sympathetic 
neurons (orange: red/yellow overlap) is required for supraspinal heat response, 
neuropathic pain, and the first phase of formalin response. 
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Drug Mechanism Phase Indications Reference(s) 
Carbamazepaine Non-selective Nav block 4 Erythromelalgia Clinical Trial: NCT02214615 
Lacosamide Non-selective Nav block 3 Painful diabetic neuropathy, 
fibromyalgia 
(Beyreuther et al., 2006, Hao et 
al., 2006) 
Ralfinamide Non-selective Nav block 2 Evaluation in neuropathic pain (Veneroni et al., 2003) 
TV-45070 Nav1.7/Nav1.8 block 2 Chronic pain conditions (Bagal et al., 2014) 
PF-05089771 Nav1.7/Nav1.8 block 2 Diabetic peripheral Neuropathy (Bagal et al., 2014) 
Clinical Trial: NCT02215252 
TTX Non-selective TTX-S 
block 
2 Neuropathic pain Clinical Trial: 
NCT01655823 
CNV1014802 Nav1.7 block 1/2 Trigeminal neuralgia (Bagal et al., 2014) 
Clinical Trial: NCT02359344 
DSP-2230 Nav1.7/Nav1.8 block 1/2 Neuropathic pain (Bagal et al., 2014) 
AZD3161 Nav1.7 block 1 Neuropathic and inflammatory pain Clinical Trial: 
NCT01240148 
CNV-30000223 
CNV-3000164 
Nav1.7 block N.A Undisclosed 
Patented to target VGSCs 
(Shao et al., 2004, de Lera Ruiz 
and Kraus, 2015) 
Benziimidzaole 
Imidazoryrdine 
Nav1.7/Nav1.8 block N.A. Patented to target VGSCs (de Lera Ruiz and Kraus, 2015) 
PF-04856264 Nav1.7 block N.A Pain (McCormack et al., 2013, de 
Lera Ruiz and Kraus, 2015) 
HWTX-IV Nav1.7 block N.A. Inflammatory and neuropathic pain in 
rodents 
(Xiao et al., 2008, Xiao et al., 
2010, Liu et al., 2014a) 
ProTox-II Nav1.7 block N.A. N.A. (Smith et al., 2007, Schmalhofer 
et al., 2008, Xiao et al., 2010) 
µ-conotoxins Nav1.7 block and non-
selective Nav block 
N.A. N.A. (Wilson et al., 2011) 
Nav1.7 antibody  Nav1.7 block N.A. Itch and pain (Lee et al., 2014) 
Table 1.1. Compounds advanced for pain therapy with Nav1.7 mediated mechanisms of action. Compounds not undergoing 
clinical trials have been demonstrated to reduce Nav1.7 function in heterologous expression systems. 
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models (Theile and Cummins, 2011b), likely due to lack of penetration past the 
perineural barrier (Schmalhofer et al., 2008). A Nav1.7-selective centipede-venom 
peptide was recently reported to elicit analgesia in acute animal pain models, but has not 
been yet tested in more complex rodent pain models (Yang et al., 2013). A monoclonal 
antibody (SVmab1) against the voltage-sensor of Nav channels resulted in functional 
selectivity for Nav1.7, with partial effects on Nav1.6 (Lee et al., 2014). Several small-
molecule blockers of hNav1.7 have been described; but they generally lack subtype 
selectivity (Clare, 2010) (Table 1.1). The work in this thesis will focus on Nav1.7 as an 
important channel in the regulation of pain, but, importantly, the peripherally expressed 
Nav1.8 and Nav1.9 channels have also been put forward as important regulators of 
human pain states (Liu and Wood, 2011). Small-molecule blockers of Nav1.8 and Nav1.9 
channels are also of interest to pain researchers. 
Nav1.7 expression in the peripheral nervous system endows the channel with 
modalities other than transmission of pain. One such example is a cough response that is 
stimulated by the sensation of itch. This Nav1.7-mediated response is transmitted by the 
vagal nerve and is well-studied in guinea pigs (Muroi and Undem, 2011). Within the 
guinea pig nodose ganglion of the vagus nerve, Nav1.7 is the dominant TTX-S isoform. 
As a result of short hairpin interfering RNA (shRNA)-Nav1.7-mediated gene silencing in 
this ganglion, action potential frequency and cough response in awake guinea pigs were 
greatly reduced (Muroi and Undem, 2011) Recent work with Nav1.7-specific antibodies 
that block movement of the voltage-sensor paddle has shown that the channel also has a 
role in peripheral dermal itch sensations (Lee et al., 2014). Pre-treatment with a Nav1.7-
specific antibody provided complete recovery of itch-mediated behavior and synaptic 
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activity produced by chemically induced itch. The antibody also successfully attenuated 
pain behavior to directly link Nav1.7 activity to transmission of noxious information.  
Nav1.7 has been implicated in anosmia, the loss of olfaction. The channel is 
expressed highly in olfactory neurons and loss-of-function mutations have provided 
insight into the role of Nav1.7 in olfaction (Weiss et al., 2011). The University of 
Pennsylvania Smell Identification Test – a standardized 40-item smell test, assessed 
patients with congenital insensitivity to pain carrying SCN9A mutations. Compared to 
wildtype controls, none of these patients were able to detect any of the 40 odors. Several 
odors such as balsamic vinegar and perfume were described as unpleasant by nine normal 
(‘wildtype control’) individuals, and previous to this study none of the test subjects 
reported any complaints about the lack of smell (Weiss et al., 2011). Based on this result, 
a Nav1.7 conditional knockout mouse was created using the Cre-loxP system to delete the 
channel from cells that express olfactory marker protein (OMP) present in all classical 
olfactory sensory neurons. These mice displayed complete loss of synaptic activity in the 
olfactory glomerulus responsible for transduction of olfactory stimuli and also complete 
loss of preference for olfactory attractants and repellants including urine, peanut butter, 
and milk. This study therefore establishes a critical role of Nav1.7 in olfaction. 
 
1.1.4. Regulation of VGSCs: Focus on Nav1.7 
 Regulation of VGSCs has been reported to be dependent on post-translational 
modifications and alternative splicing of the channels, expression of accessory channel 
subunits, modulation of signaling cascades that control transcription, and channel 
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trafficking (Table 1.2). Phosphorylation by protein kinase A (PKA) and PKC were 
amongst the first identified modifications to exert modifying control over the channel. 
Interpretations of results from these studies are difficult, however, due to opposing effects 
depending on cell background. For example, activation of PKC attenuated Nav1.2 
(Cantrell et al., 2002), Nav1.4 (Bendahhou et al., 1995, Murray et al., 1997), Nav1.5 
(Schreibmayer et al., 1991), and Nav1.7 (Vijayaragavan et al., 2004) currents when 
channels are heterogeneously expressed in heterologous cell lines, but the same 
manipulations positively regulated the channels in primary cells like DRGs (Gold et al., 
1998). Heterologous expression systems remain important for identifying regulators of 
VGSCs because they provide a large amount of consistent experimental material that is 
sturdy enough to survive harsh experimental manipulations. However, cell-specific 
effects highlight the importance of studying mechanisms in cell types of interest where 
the mechanisms are physiologically relevant. In another mode of channel regulation, total 
DRG sodium current is positively correlated with activation of PKC and negatively 
correlated with activation of PKA (Vijayaragavan et al., 2004). Additionally, reduction of 
Nav1.7 by PKA requires prerequisite PKC activity, whereas PKC-mediated enhancement 
acts independently without any requirement of PKA (Gold et al., 1998). 
Nav1.7 is also regulated is by alternative splicing of exon 11. Coding for the L1 
cytoplasmic loop (Raymond et al., 2004) domain that is targeted by PKA phosphorylation 
(Cantrell et al., 2002), expression of different splice variants can alter Nav1.7 channel 
kinetics. After injury, an ‘11S’ variant that lacks 11 amino acids undergoes 
disproportionate upregulation compared to other variants. PKA phosphorylation of this 
particular variant produces a hyperpolarizing shift in activation, which, in addition to 
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upregulation in response to injury, appears to promote hyperexcitability of DRGs 
(Chatelier et al., 2008). 
Mitogen-activated protein (MAP) kinases can also regulate Nav1.7. These 
serine/threonine-specific kinases link membrane receptor activation to cytosolic signaling 
cascades (Seger and Krebs, 1995). In human neuromas, the upregulation of p38 and 
ERK1/2 MAP kinases has been correlated to upregulation of Nav1.3, Nav1.7, and Nav1.8 
(Black et al., 2008). Nerve ligation animal models support MAP kinase regulation of 
VGSCs in injury and pain models where inhibition of extracellular signal-regulated 
kinase (ERK), p38 and c-Jun N-terminal kinase (JNK) MAP kinases reversed mechanical 
allodyinia and p38 inhibition reversed thermal hyperalgesia (Obata et al., 2004). Both 
Nav1.6 and Nav1.8 are direct targets of p38 phosphorylation that occurs in the L1 
cytoplasmic loop of the channels suggesting that these two isoforms may mediate this 
effect without effect on Nav1.7, which is not phosphorylated by p38. Nav1.6 and Nav1.8 
channels are differentially regulated by p38 as Nav1.6 phosphorylation reduces peak 
current density (Wittmack et al., 2005) while Nav1.8 phosphorylation increases peak 
current density (Hudmon et al., 2008). Due to preferential expression of Nav1.8 in 
nociceptive neurons, p38-mediated increases in Nav1.8 link pro-inflammatory mediators 
to DRG hyperexcitability. 
VGSCs are heavily glycosylated proteins with carbohydrates representing up to 
30% of protein mass (Schmidt and Catterall, 1986). The cytosolic pool of unprocessed 
VGSCs are far less glycosylated than fully processed and folded surface VGSCs 
suggesting a role for this modification in the proper folding and surface trafficking of 
channels (Schmidt and Catterall, 1986). Heavy glycosylation of Nav1.9 produces a 
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hyperpolarized shift in channel activation making the channel more available to produce 
current (Tyrrell et al., 2001). Glycosylation of Nav1.4 can lead to sialylation of 
glycosylated groups that shifts channel gating to depolarized potentials (Ednie et al., 
2015). Nav1.7 glycosylation has some correlation to participation of beta subunits in 
trafficking as beta1 selectively traffics intermediately glycosylated channel protein 
(Laedermann et al., 2013b). Finally, glycosylation of Nav1.5 determines channel function 
in the membrane due to incompletely glycosylated protein displaying lower function than 
fully glycosylated Nav1.5 (Mercier et al., 2015). 
A prominent VGSC regulatory pathway involves modulation by accessory beta 
(β) channel subunits. Linked by disulfide bonds to the alpha subunit pore, β proteins 
introduce a variety of regulations and properties to channels, including altered kinetics, 
biosynthesis and trafficking, sub-cellular localization, and cell adhesion properties 
(Schmidt and Catterall, 1986, Isom et al., 1992, Srinivasan et al., 1998, Meadows et al., 
2002, Yu et al., 2003). Observation of the first identified β proteins, β1 and β2, occurred 
at the same time as the initial identification of the alpha protein pore (Schmidt and 
Catterall, 1986). It was noted that these ~35kDa proteins preferentially interacted with 
functional membrane channel proteins, suggesting a role in biosynthesis and channel 
membrane expression. This role was further supported by later studies in Xenopus 
oocytes where expression of either β1 (Isom et al., 1992), or β2 (Isom et al., 1995) was 
demonstrated to increase the trafficking and current density of Nav1.2. Expression of β1 
also shifted the curve of channel inactivation towards hyperpolarized potentials. The later 
identified β3 and β4 proteins can also mediate changes in channel kinetics with data 
showing hyperpolarized shifts in Nav1.3 activation following expression of β3 (Meadows 
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et al., 2002) and hyperpolarized shifts in Nav1.2 and Nav1.4 activation following 
expression of βIV (Yu et al., 2003). The extracellular domain of β subunits, which 
contain immunoglobulin-like domains that resemble other families of adhesion 
molecules, can mediate cell-cell interactions and sub-cellular localization. Specifically, 
the β2 protein interacts with tenascin-C and tenascin-R –extracellular matrix proteins 
(Srinivasan et al., 1998), and β1-null neurons display a loss of Nav1.6 organization at the 
axon initial segment (Brackenbury et al., 2010). These proteins can therefore alter 
cellular distribution and localization of sodium channels, which is important in 
determining channel function. Channel localization to peripheral terminals would suggest 
a role in summation of inputs, whereas localization to a Node of Ranvier would suggest a 
role in propagation of salutatory conduction. 
Several studies have suggested that Nav1.7 can be regulated by multiple beta 
subunits. In HEK293 cells, both β1 and β3 have been shown to upregulate heterologously 
expressed Nav1.7 channels and display lower levels of glycosylation than Nav1.7 
channels alone (Laedermann et al., 2013b). In sensory neurons of β2-null mice, Nav1.7 
channel expression and current density is greatly reduced highlighting an important role 
of βII in Nav1.7 trafficking (Lopez-Santiago et al., 2006). Importantly, β2-null animals 
display reduced inflammatory and neuropathic pain responses, suggesting the role, albeit 
indirectly, of Nav1.7 modulation in the development of pain. 
 Regulation of Nav1.7 in sensory neurons has also been demonstrated by the E3 
ubiquitin ligase – neural precursor cell expressed developmentally down-regulated 
protein 4 (Nedd4-2). Nedd4-2 monoubiquitinates Nav1.7 to mark it for endocytosis 
(Laedermann et al., 2013a). Following peripheral nerve injury, Nedd4-2 exhibits reduced 
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expression and therefore has limited activity on Nav1.7, which produces increases to 
channel expression, current density, and hyperexcitability of neurons. Viral delivery to 
overexpress Nedd4-2 to recover ligase expression reverses these effects on Nav1.7 in 
injured animals and alleviates mechanical allodynia.  
Surface expression and activity of Nav1.7 can also be altered by transcriptional 
regulation. Data from two studies suggest that both lithium (Yanagita et al., 2009) and 
insulin-like growth factor 1 (Yanagita et al., 2011) can inhibit glycogen synthase kinase 
3β (GSK3β) in the Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)-Akt-GSK3β 
signaling pathway to increase Nav1.7 transcriptional rate, mRNA levels, and surface 
expression. 
Despite the above studies, much remains still to be understood in the biology of 
Nav1.7. In particular, most studies to date have focused on the regulation of the channel 
directly by post-translational modifications or transcription versus regulation by 
classically defined accessory subunits or at the transcriptional level. There is very limited 
information on how other interacting proteins affect Nav1.7 activity and function. The 
next section provides a background on one such protein that confers a unique regulation 
on Nav1.7.    
 
1.2. Collapsin Response Mediator Protein 2 (CRMP2) 
1.2.1. Background 
 Collapsin response mediator 2 (CRMP2, also known as DPYSL2/DRP2, Unc-33, 
Ulip, TUC2) was first identified for its role in mediating axon growth and guidance of   
 27 
 
 
 
 
 
 
 
 
  
Mediated by Cell type Effect Reference 
PKA DRG Reduced expression (Gold et al., 1998) 
PKC DRG Increased expression (Gold et al., 1998) 
PKC Oocytes Decreased expression (Vijayaragavan et al., 
2004) 
Splice variant 
11S 
DRG Hyperpolarized activation (Chatelier et al., 
2008) 
MAP Kinases DRG Increased expression (Black et al., 2008) 
GSK3β Adrenal 
chromaffin cells 
Decreased transcription (Yanagita et al., 
2009) 
β1 HEK293 Increased trafficking (Laedermann et al., 
2013b) 
β3 HEK293 Increased trafficking (Laedermann et al., 
2013b) 
β2 DRG Increased trafficking (Lopez-Santiago et 
al., 2006) 
Nedd4-2 DRG Decreased trafficking (Laedermann et al., 
2013a) 
Lithium Adrenal 
chromaffin cells 
Increased transcription 
Increased expression 
(Yanagita et al., 
2009) 
Insulin-like 
growth factor 1 
Adrenal 
chromaffin cells 
Increased transcription 
Increased expression 
(Yanagita et al., 
2011) 
Table 1.2. Modifiers of Nav1.7. Modifiers and effects on Nav1.7 as well as cell 
types in which these modifications have been observed. 
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chick dorsal root ganglia neurons (Goshima et al., 1995). Analogs of the protein have 
been identified in Caenorhabditis elegans, Drosophila melongaster, rodents, and humans 
(Hedgecock et al., 1985, Geschwind and Hockfield, 1989, Minturn et al., 1995, Byk et 
al., 1996, Kitamura et al., 1999, Morris et al., 2012). In mammals, CRMP2 belongs to a 
family of five structurally similar proteins CRMPs 1–5 that share homology with the liver 
enzyme dihydropyrimidinase (Wang and Strittmatter, 1997a, Fukada et al., 2000, 
Schmidt and Strittmatter, 2007). The ‘bilobed-lung’ configuration of the protein, 
observed in the solved crystal structure is believed to be shared between all CRMPs (Deo 
et al., 2004, Stenmark et al., 2007). This shared configuration aids in formation of both 
homo- and hetero-tetramers between CRMP family proteins. As CRMPs display higher 
affinity for family proteins than itself, heterotetramers are more common than 
homotetramers (Wang and Strittmatter, 1997a, Yoneda et al., 2012), but because CRMP2 
is the most widely expressed, it is proposed that a high percentage of tetramers contain at 
least one CRMP2 protein (Wang and Strittmatter, 1996). The effects of oligomerization 
are not well described and functions of CRMP2 have not been experimentally separated 
by contribution of CRMP2 within tetramers or contribution of CRMP2 functioning as 
monomers. 
CRMP2 functions during early neurogenesis in axon guidance allow for use of the 
protein as an early marker of neuronal differentiation (Minturn et al., 1995, Byk et al., 
1996, Gaetano et al., 1997). The distal part of the axon is enriched in CRMP2 which 
influences axonal specification. In hippocampal neurons, over-expression of CRMP2 
induced supernumerary axons, axon elongation, and increased axonal branching, while its 
inhibition with a dominant negative protein suppressed the formation of the primary axon 
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(Inagaki et al., 2001a, Yoshimura et al., 2005b). Interestingly, CRMP2 can convert 
established dendrites to axon, is involved in the Sra-1/WAVE/kinesin cargo complex and 
is required for BDNF/NT3-induced axon outgrowth/branching (Inagaki et al., 2001a, 
Kawano et al., 2005, Yoshimura et al., 2005b). Axon elongation is ultimately achieved 
through microtubule assembly and extension, and actin reorganization and membrane 
genesis at the leading edge of the growth cone. CRMP2 may not only enhance 
microtubule polymerization but may also modulate membrane tremodeling through 
interaction with its partners, depending upon specific post-translational modifications 
(Inagaki et al., 2001b, Nishimura et al., 2003b, Brown et al., 2004, Cole et al., 2004, 
Yoshimura et al., 2005a, Morinaka et al., 2011) and secreted trophic factors. In 
hippocampal neurons, NT3 induces axonal growth and branching activity by inhibiting 
CRMP2 phosphorylation by GSK-3β (Yoshimura et al., 2005b). Conversely, Sema-3A 
induces axonal retraction by increasing CRMP2 phosphorylation by GSK-3β (Uchida et 
al., 2005). CRMP2 binds to cytoskeletal proteins tubulin, actin, and vimentin (Fukata et 
al., 2002a, Vincent et al., 2005, Vuaillat et al., 2008). It has been demonstrated that non-
phosphorylated CRMP2 binds strongly to tubulin leading to microtubule formation, while 
CRMP2, phosphorylated by Rho kinase, suppresses its binding to tubulin and Numb 
(Arimura et al., 2000a). Two other kinases working in tandem, CDK5 and GSK-3β, also 
control the interaction of CRMP2 with tubulin.  
Emerging literature has demonstrated novel functions of CRMP2, particularly as a 
trafficking protein via interaction with kinesin and dynein motor proteins (Nishimura et 
al., 2003b, Kawano et al., 2005, Kimura et al., 2005, Lykissas et al., 2007, Arimura et al., 
2009, Rahajeng et al., 2010). In the case of retrograde transport and dynein, CRMP2 has 
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been proposed to have roles in linking the dynein motor to vesicular cargo through 
interaction with endocytic vesicle complex protein MICAL-L1 (Rahajeng et al., 2010). 
Interaction of CRMP2 with endocytosis mediators Numb and α-adaptin proteins also 
facilitate CRMP2’s roles as a trafficking cop (Nishimura et al., 2003a). 
Recent work from the Khanna laboratory has expanded the CRMP2 interactome 
to include, heretofore unknown, partners that include voltage- and ligand-gated ion 
channels and exchangers. Initial work identified interactions with N-type voltage-gated 
calcium channels (Cav2.2) (Brittain et al., 2009, Chi et al., 2009a). Enhanced CRMP2 
expression mediated increased channel surface expression, enhanced calcium influx, and 
consequently enhanced neurotransmitter release from presynaptic vesicles (Brittain et al., 
2009a, Chi et al., 2009a, Hensley et al., 2011, Khanna et al., 2012). Later work then 
identified involvement of CRMP2 at the post-synaptic level where interaction with NR2B 
receptors were demonstrated to interact with NMDA receptors (Al-Hallaq et al., 2007). 
Other binding partners of CRMP2 include the calcium sensing protein calmodulin (Zhang 
et al., 2009) and the Ras-GAP neurofibromin protein (Lin and Hsueh, 2008). CRMP2 
binding to neurofibromin is proposed to contribute to Neurofibromatosis type 1 disease in 
which CRMP2 activity on other substrates becomes restricted due to sequestration of 
cytosolic CRMP2 by neurofibromin (Patrakitkomjorn et al., 2008). The CRMP2 
interactome also includes the plasmlemmal sodium/calcium exchanger NCX3 which 
increases cytosolic calcium by operating in reverse during glutamate toxicity 
(Brustovetsky et al., 2014). Incubation with Tat-CBD3, a peptide that binds CRMP2 
enhances interaction between CRMP2 and NCX3 in rat hippocampal neurons leading to 
NCX3 internalization and restriction of calcium influx. 
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1.2.2. CRMP2 Post Translational Modifications and Regulation of Function 
 As CRMP2 maintains no known enzymatic activity of the related 
dyhydropyrimidinase protein, its functions are endowed by direct protein interactions 
with partners in effector pathways (Wang and Strittmatter, 1997a). Post translational 
modifications, primarily phosphorylation, of CRMP2 allow it to direct interactions with 
different protein partners and engage in different cellular cascades. While high resolution 
crystal structures of CRMP2 have been determined, the C-terminal region of CRMP2 
wherein the protein is multiply phosphorylated is susceptible to proteolysis (Deo et al., 
2004), precluding structure-function analysis.  
As a regulatory mechanism, protein phosphorylation involves donation of a 
phosphate group (PO43-) from ATP to a serine, threonine, or tyrosine amino acid residue 
(Olsen et al., 2006). This transfer is catalyzed by protein kinases that recognize target 
structural motifs within proteins (Yaffe and Elia, 2001). First observation of this 
phenomenon was the activation of glycogen phosphorylase b to glycogen phosphorylase 
a in the rate limiting step of glycogenolysis (Fischer and Krebs, 1955). Sequencing of the 
human genome has allowed for identification of the human kinome, a full set of protein 
kinases, which predicts a total of 518 kinase members with a large pool of protein targets 
(Manning et al., 2002).  
 Introduction of phosphate groups at physiological pH introduces a double 
negative charge not found within any of the twenty-one eukaryotic amino acid side 
chains. This unique side chain charge modification introduces structural and functional 
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consequences to targeted proteins (Johnson and Lewis, 2001). Hydrogen bonds are 
largely responsible for these changes as the double negative charge provided by 
phosphorylation is ideal for hydrogen bond formation between nearby side chains. This 
acts to stabilize conformational states thus altering secondary and tertiary protein 
structure (Mandell et al., 2007). Altered protein confirmation can then lead to differential 
recognition or binding of other proteins (Filippakopoulos et al., 2008) including 
secondary kinases to provide further effects of phosphorylation (DePaoli-Roach, 1984, 
Fiol et al., 1988). Protein phosphorylation is made reversible by protein phosphatases that 
remove phosphate groups from targeted residues (Barford et al., 1998). This on/off 
regulation of protein phosphorylation acts as a signaling switch to direct protein activity 
and regulate mature protein function without modifying expression levels. 
 The canonical function of CRMP2 is regulated by phosphorylated states where 
CRMP2 is considered ‘active’ in neurite outgrowth when unphosphorylated. Upon 
phosphorylation CRMP2 becomes ‘inactive’ for outgrowth (Byk et al., 1996). Signaling 
requirements for CRMP2 function in growth cone collapse have been well described and 
are initiated by the neurite guidance cue Semaphorin 3A (Sema3A). Sema3A signaling 
cascade involves activation of multiple kinases and multiple modifications of CRMP2 
that culminate in a reduced affinity of CRMP2 for the cytoskeletal protein tubulin and, 
consequently, a reduced cytoskeleton stability (Fukata et al., 2002a, Kimura et al., 2005). 
The process is initiated when Sema3A binds neuropilin-1/plexin-A receptors to transduce 
the signal to the cytosolic space (Takahashi et al., 1999, Sasaki et al., 2002). 
Intracellularly, the src kinase Fyn becomes active (Sasaki et al., 2002) and hydrogen 
peroxide is generated through the microtubule associated monooxygenase, calponin and 
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LIM domain containing 1 (MICAL) protein which then oxidizes CRMP2 (Morinaka et 
al., 2011). Fyn kinase activates cyclin-dependent kinase 5 (Cdk5) allowing for Cdk5 
phosphorylation of CRMP2 at serine-522 (Brown et al., 2004). CRMP2 constructs that 
harbor serine to alanine mutations at this site, CRMP2-S522A, prevent addition of a 
phosphate group and restricts Sema3A-CRMP2 mediated growth cone collapse (Brown et 
al., 2004). Primary phosphorylation by Cdk5, and also disulfide linkage of oxidized 
CRMP2 to thioredoxin promotes a secondary phosphorylation of CRMP2 by glycogen 
synthase kinase 3β (GSK3β) (Eickholt et al., 2002, Uchida et al., 2005, Morinaka et al., 
2011) at CRMP2 threonine residues threonine-509, threonine-514, and threonine-518 
(Brown et al., 2004, Cole et al., 2004, Yoshimura et al., 2005a). In contrast, 
dephosphorylation of CRMP2-threonine-509/threonine-514 by the phosphatases PP1 and 
PP2A results in neurite outgrowth (Zhu et al., 2010, Astle et al., 2011). This effect is 
mediated only by loss of phosphorylation by GSK3β at CRMP2-threonine-509/threonine-
514 but not loss of phosphorylation by Cdk5 at CRMP2-Serine-522 because Cdk5 
phosphorylation is resistant to phosphatase activity (Cole et al., 2008).  
When CRMP2 is unphosphoryalted at threonine-509 and threonine-514 it binds 
and transports tubulin dimers from cell bodies to the distal, extending, projections 
(Fukata et al., 2002a, Kimura et al., 2005). In this unphosphorylated state, CRMP2 also 
stabilizes and promotes the intrinsic GTPase activity of tubulin, further promoting 
cytoskeleton expansion (Chae et al., 2009). GSK3β phosphorylation of CRMP2 
following Sema3A reverses this function by reducing affinity for tubulin to prevent 
CRMP2 participation in maintenance of the cytoskeleton resulting in neurite retraction 
(Yoshimura et al., 2005a).  
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In addition to Cdk5 and GSK3β, CRMP2 is also subject to phosphorylation by 
Fyn, RhoK, CaMKII, and Yes kinases. Evidence exists that in addition to activation of 
Cdk5 during Sema3A signaling, Fyn kinase also directly phosphorylates CRMP2 at 
tyrosine-32 to promote Sema3A mediated growth cone collapse (Uchida et al., 2009). 
Mutation of this tyrosine to phenylalanine, CRMP2-Y32F, reduces Sema3A CRMP2-
mediated effects on neurite retraction by roughly fifty percent. The phosphorylation of 
CRMP2 at threonine-555 by ras homolog (Rho) associated protein kinase 1 is yet another 
example of CRMP2 phosphorylation that promotes growth cone collapse by restricting 
interactions with tubulin (Arimura et al., 2005). This modification is the result of 
signaling in response to lysophosphatidic acid (Arimura et al., 2000a, Arimura et al., 
2005). Some evidence also suggests that this site can be targeted by Ca2+/calmodulin-
dependent protein kinase (CaMKII) in a neuroprotective mechanism following glutamate 
toxicity (Hou et al., 2009). 
Other interactions of CRMP2 and cytoskeletal proteins like actin and vimentin 
allow CRMP2 participation in cytoskeletal regulation outside its canonical function of 
neurite outgrowth and collapse (Arimura et al., 2005, Vincent et al., 2005). Interaction of 
CRMP2 and the intermediate filament protein, vimentin, has been described in a non-
neuronal function of CRMP2 in CXCL12-induced migration of T-lymphocytes (Varrin-
Doyer et al., 2009). This process involves the phosphorylation of CRMP2 by Yes kinase 
at tyrosine-479, which increases interaction of CRMP2 and vimentin to polarize 
lymphocytes, a hallmark of a migration in this cell type. Elimination of this modification 
by CRMP2-Y479F mutant completely prevents this function. 
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CRMP2 phosphorylation by Cdk5 at serine-522 can guide protein function by 
governing CRMP2 interactions with N-type voltage gated calcium channels (Brittain et 
al., 2009a, Chi et al., 2009a, Wang et al., 2010b). This phosphorylation increases 
CRMP2-Cav2.2 interaction to increase channel trafficking and insertion into the cell 
membrane. Consequences of this CRMP2 modification in neurons are increased calcium 
influx and a subsequent increase in neurotransmitter release. In DRG neurons, calcium-
dependent neurotransmitter release is responsible for transmission of painful stimuli, 
therefore targeting Cav2.2 has proved a useful strategy in pain treatments (Staats et al., 
2004, Winquist et al., 2005). By extension, targeting CRMP2-Cav2.2 interaction serves 
this pharmacological goal. A small peptide that mimics a CRMP2 interaction motif with 
the calcium channels was produced and made cell permeant with the HIV transduction 
domain ‘TAT’. When applied to neurons this peptide reduced Cav2.2 currents and 
synaptic transmission, and following subcutaneous injection of rats, inflammatory and 
chronic pain behaviors were attenuated (Brittain et al., 2011b).  
In addition to phosphorylation and oxidation, CRMP2 has been identified as a 
target of O-glycosylation, with a high coincidence of glycosylated CRMP2 found in 
nerve terminals. CRMP2 localization to this sub-cellular domain could aid in CRMP2 
activity in either outgrowth or voltage-gated calcium channel trafficking, but no specific 
evidence exists to support a functional consequence of this modification (Cole and Hart, 
2001). An additional way in which CRMP2 functions can be regulated is via differential 
expression of CRMP2 splice variants, CRMP2-S or CRMP2-L (Yuasa-Kawada et al., 
2003). The short version, CRMP2-S, is missing N-terminal residues 1-36 which can 
result in differential signaling dependent on CRMP2 phosphorylation at residue Y32. 
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CRMP2 can also be modified by cleavage. Calpain targeting of CRMP2 in a 
pathway that feeds back on NMDA receptors reduces receptor expression during bursts 
of cell hyperexcitability (Bretin et al., 2006). Finally, as shown by me in this thesis, 
CRMP2 undergoes modification by a small ubiquitin-like modifier (SUMO), which 
regulates voltage-gated sodium channel membrane expression and will be elaborated in 
this dissertation in Chapters 3 and 4 (Dustrude et al., 2013). 
 
1.2.3. CRMP2 Involvement in Disease and Injury 
 Studies of CRMP2 function have been motivated by identification of CRMP2 in a 
number of neurological diseases. The histological hallmarks of Alzheimer’s disease (AD) 
are neurofibrillary tangles and β-amyloid plaques (Hardy and Selkoe, 2002). Whether 
these changes have a correlative or causative effect on neuronal death associated with AD 
has not been investigated. Notwithstanding the link to AD pathophysiology, CRMP2 is 
found within neurofibrillary tangles of AD brains (Yoshida et al., 1998) where it is 
phosphorylated at threonine-509, threonine-518, and serine-522 (Gu et al., 2000). These 
are the same sites that become phosphorylated during Sema3A-mediated growth cone 
collapse to prevent CRMP2’s participation in stabilization and elongation of 
microtubules. Loss of CRMP2 participation in its canonical pathway of cytoskeleton 
dynamics could therefore contribute to AD pathology of neuronal death. In addition, 
CRMP2 expression becomes down regulated in AD, which would predictably add to the 
effect of reduced CRMP2-mediated cytoskeleton outgrowth and stability (Lubec et al., 
1999). 
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The canonical function of CRMP2 in axonogenesis and cytoskeletal regulation is 
possibly linked to the generation of certain epilepsies. As a multifactorial disease, 
epilepsy results from a combination of effects including loss of neuronal circuit 
inhibition, increased excitability, and reorganization of circuitry (Pitkanen and Lukasiuk, 
2009). The last of these is observed in the form of mossy fiber sprouting within the 
epileptic hippocampus (Nadler, 2003). Aberrant innervation of the molecular layer of the 
hippocampus by mossy fiber projections can produce redundant excitatory circuits that 
continuously feed-forward upon themselves to contribute to seizures. CRMP2 is reduced 
in the hippocampus of patients with temporal lobe epilepsies (Czech et al., 2004), and the 
growth of mossy fiber sprouting is associated with a reduced activity of Sema3A 
repulsion (Holtmaat et al., 2003). Both of these findings support dysregulation of CRMP2 
in these forms of epilepsy. Interestingly, the antiepileptic drug lacosamide, which has 
primary function on VGSCs to reduce neuronal hyperexcitability, also directly interacts 
with CRMP2 (Wilson and Khanna, 2014, Wilson et al., 2014). Targeting CRMP2 with 
this functionalized amino acid shows promise in restricting tubulin-binding properties of 
CRMP2 to restrict activity dependent neurite outgrowth in the development of epilepsy. 
Calpain cleavage of CRMP2 has been described following ischemia (Jiang et al., 
2007), neurotrauma (Zhang et al., 2007), excitotoxicity (Bretin et al., 2006), as well as 
nerve growth factor deprivation induced-neurite degeneration (Touma et al., 2007). In 
cortical neurons challenged with NMDA-stimulated excitotoxicity, the NR2B NMDA 
receptor subunit underwent a reduction in surface expression. CRMP2 preferentially 
associates with NR2B-containing NMDA-receptors (Al-Hallaq et al., 2007), and 
reduction of NR2B surface expression was enhanced by over-expression of CRMP2 
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(Bretin et al., 2006). Together these data suggest that down regulation of NR2B is a 
CRMP2 driven neuroprotective mechanism. 
 A connection between CRMP2 and neurofibromatosis 1 (NF1) has also been 
uncovered (Lin and Hsueh, 2008). NF1 is an autosomal dominant disorder in which 
patients are prone to nervous system tumors, or neurofibromas, due to mutations that 
truncate the NF1 gene encoding for a tumor repressor protein. CRMP2 was shown to 
interact with the c-terminal of the neurofibromin protein in rat brain (Lin and Hsueh, 
2008). Furthermore, knockdown of NF1 in PC12 cell line restricts outgrowth of neurite-
like processes and is correlated to increased phosphorylation of CRMP2 protein by Cdk5, 
GSK3β, and RhoK, each of which blunts CRMP2 participation in outgrowth 
(Patrakitkomjorn et al., 2008).  
 
1.3. Protein SUMOylation, a novel post-translational modification of CRMP2 
1.3.1. Background 
The first Small Ubiquitin-like MOdifier (SUMO) protein was identified in 1996 
for associating with RAD51 and RAD52 DNA repair pathway proteins in humans. 
Named ubiquitin-like 1 (UBL1) gene for its moderate homology for both ubiquitin and 
ubiquitin cross-reacting proteins (Shen et al., 1996), SUMO and ubiquitin are of similar 
size, 11 kDa and 8 kDa, respectively, and both target lysine residues for covalent 
modification of target proteins. The forward reaction of protein SUMOylation resembles 
ubiquitination in its involvement of three enzymes, E1-activating, E2-conjugating and 
E3-ligase (Takahashi et al., 2001) to form isopeptide bonds between ɛ-amino group of the 
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target lysine residue and the carboxyl group of SUMO’s C-terminal. Despite these 
similarities, sequence homology between the SUMO1 and ubiquitin proteins is only 
~18% (Muller et al., 2001). 
Initial studies of SUMO1 (UBL1, also known as PIC1, sentrin, GMP1, and 
Smt3c) described the protein as a binding partner of nuclear pore proteins and regulator 
of cell cycle, transcription, and chromatin organization (Boddy et al., 1996, Matunis et 
al., 1996, Okura et al., 1996, Lapenta et al., 1997). The first identified target of covalent 
modification by SUMO was RanGAP1, a nuclear pore protein (Matunis et al., 1996, 
Mahajan et al., 1997). Discovery of SUMO1 allowed for prediction of other SUMO 
proteins via chromosome mapping (Lapenta et al., 1997), leading to the identification of 
SUMO2, SUMO3, and SUMO4. SUMO2 and SUMO3 were identified as additional 
covalent modifiers within the protein family (Kamitani et al., 1998a, Kamitani et al., 
1998b), but because SUMO4 was found to lack introns and is not endogenously 
expressed, it is considered a pseudogene (Bohren et al., 2004). 
Some protein substrates are preferentially modified by one particular SUMO 
isoform whereas others display overlapping modification by several isoforms (Vertegaal 
et al., 2006). Evidence to determine how SUMOylation machinery or protein targets 
display these preferences is lacking. SUMO2 and SUMO3 proteins share 95% sequence 
homology, but only 50% homology with SUMO1 (Johnson, 2004). Unlike SUMO1, they 
contain internal, N-terminus, SUMOylation motifs that allow for poly-SUMO2/3 chains 
(Tatham et al., 2001). The length of unanchored SUMO2/3 polymers can reach eight 
SUMO proteins when enhanced by overexpression of SUMOylation machinery proteins 
in cell culture. As SUMO1 lacks internal motifs, it functions as a chain-terminating 
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addition and expression of SUMO1 drastically reduces the formation of poly-SUMO 
(Matic et al., 2008). The length and function of poly-SUMO2/3 chains in vivo is poorly 
understood and has hypothesized roles in protein–protein interactions governed by non-
covalent interactions with SUMOs by SUMO Interacting Motifs (SIMs) which scaffold 
interactions involved in SUMO2/3 signaling (Sun and Hunter, 2012). 
 
1.3.2. SUMOylation Machinery 
SUMO proteins are formed as inactive pro-SUMOs precursors that become active 
when the C-terminal is cleaved by sentrin/SUMO-specific protease (SENP) family 
proteins (Melchior et al., 2003, Mukhopadhyay and Dasso, 2007). Conjugation of SUMO 
to a target protein is then activated by E1-SUMO-Activating Enzymes (SAEs) 1 and 2, a 
heterodimer which forms a thioester bond between the SUMO protein and SAE2 (Gong 
et al., 1999). SUMO is then transferred to the active site of Ubiqutin-conjugating 9 
(Ubc9) enzyme to form a highly reactive intermediate that can SUMOylate a target 
protein (Johnson and Blobel, 1997). Ubc9 is the sole SUMO E2 enzyme in yeast and 
invertebrates and is predicted to be the only SUMO E2 in vertebrates as well (Desterro et 
al., 1997, Johnson and Blobel, 1997, Hayashi et al., 2002). Therefore, Ubc9 is responsible 
for all protein SUMOylation in mammals, and represents the rate limiting step of the 
forward reaction. For many substrates, Ubc9 is sufficient to recognize and transfer 
SUMO, and in other cases E3-ligases bind Ubc9 and scaffold the E2 to its targets 
(Desterro et al., 1999, Okuma et al., 1999). 
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SUMOylation most commonly occurs on a lysine within a SUMO-consensus 
motif ψKxD/E, where ψ is a large hydrophobic amino acid (Xu et al., 2008). In some 
cases, the inverted sequence D/ExKψ also functions to serve as a SUMOylation signal 
(Matic et al., 2010). Presence of downstream negatively charged residues further 
classifies a target motif as negative charge-dependent SUMOylation motif (NDSM) 
which aids Ubc9 interaction (Henley et al., 2014). This negative charge can also be 
introduced to a motif by protein phosphorylation and allows SUMOylation motifs to be 
switched on and off in response to kinase and phosphatase activity (Picard et al., 2012). 
Despite well over 1000 proteins being reportedly SUMOylated, only ~60% of known 
SUMOylation targets conform to the SUMO-consensus motif. Moreover, not all 
consensus sequences are SUMOylated (Ulrich, 2009). The consensus motif within 
CRMP2 at lysine-374 conforms to the more stringent NDSM motif and is conserved 
throughout all CRMP2 family members CRMPs 1–5 as well as between species 
(Dustrude et al., 2013). As Ubc9 represents the only E2 enzyme, restricting its function 
prevents protein SUMOylation globally. In cell lines, knockdown of Ubc9 causes cell 
death by apoptosis (Hayashi et al., 2002), and Ubc9-knockout mice embryos die at an 
early post-implantation stage due to deficits in nuclear organization (Nacerddine et al., 
2005). Several SUMO1 knockout mice have been produced with between 10% and 100% 
viability (Alkuraya et al., 2006, Evdokimov et al., 2008, Zhang et al., 2008), with viable 
mice showing enhancement of SUMO2 and SUMO3 modification, suggesting 
compensation. Viable mice however, display reduced body weight (Mikkonen et al., 
2013), reduced inflammatory responses (Venteclef et al., 2010), and congenital heart 
disease (Wang et al., 2011a).  
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Reversing modification of proteins by SUMO requires SENP proteins. This 
family of proteins, SENP1-3 and SENP5-7 (SENP4 is a paralogue) are responsible for 
activation of pro-SUMOs and mediate cleavage of SUMO from target proteins by an Ulp 
domain at their C-terminus (Mukhopadhyay and Dasso, 2007). Of the SENPs, SENP1 
and SENP2 have broad specificity for all three SUMO proteins with opposing 
specificities. SENP1 is more effective at removal of SUMO1, whereas SENP2 is more 
effective at removal of SUMO2 and SUMO3 (Gong et al., 2000). The remaining SENPs 
are only able to remove SUMO2 and SUMO3 from targets (Gong and Yeh, 2006), with 
SENP6 and SENP7 displaying chain editing properties of poly-SUMO chains 
(Mukhopadhyay et al., 2006, Shen et al., 2009). In many cases, the SUMOylated fraction 
of a protein amounts to less than 1% (Johnson, 2004). This general feature of 
SUMOylation turnover puts forward the hypothesis that consequences of protein 
SUMOylation or deSUMOylation may persist in time after the modification is altered 
(Hardeland et al., 2002). In this way, only 1% of a substrate might be SUMOylated, but a 
much greater percentage of protein has undergone SUMOylation recently enough to exert 
effects of a SUMOylated protein. 
 
1.3.3. Consequences of Protein SUMOylation 
As a molecular switch, the SUMOylation of a target protein can have one of three 
effects. First, SUMOylation may block a binding site of an enzyme or binding partner. 
The nuclear factor kappa B (NFκB) provides such an example, where SUMOylation and 
ubiquitination compete for lysine-21. When NFκB is SUMOylated it is then protected 
from ubiquitin degradation (Desterro et al., 1998). Second, the attached SUMO protein 
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itself can participate in the binding of new protein partners to change the target’s 
interactome. The first identified target of SUMOylation, RanGAP1, is an example of this 
case. Interaction of the SUMO protein and RanGAP1, together, recruit RanBP2 for 
transport to the nuclear pore (Matunis et al., 1996, Mahajan et al., 1997). Third, 
SUMOylation can alter protein conformation, which can alter activity of the target or 
change its ability to become modified by additional post-translational modifications. 
GSK3β is an example of this, where SUMOylation enhances kinase activity and stability 
(Eun Jeoung et al., 2008) (Figure 1.4).  
Turnover of SUMOylation can be regulated by activity of the SUMOylation 
machinery. The level of Ubc9 expression can govern the rate of SUMOylation and the 
level of the chain-terminating SUMO1 expression can govern the propensity of SUMO2 
and SUMO3 to form poly-SUMO chains (Matic et al., 2008). The SUMO E1 heterodimer 
SAE1/SAE2 can undergo disulfide binding to E2-Ubc9 following exposure to reactive 
oxygen species (Bossis and Melchior, 2006). This bond halts further activation and 
conjugation activities by the SUMOylation machinery to pause further modifications. 
Additionally, E1 SAE1/SAE2 heterodimer can be inhibited by SUMOylation of the E1-
activating enzyme itself (Truong et al., 2012), and Ubc9 can be inhibited from targeting 
some NDSM targets by acetylation (Hsieh et al., 2013). By these modifications to 
expression and activity of the SUMOylation machinery, global SUMOylation can 
become upregulated or inhibited to exert effects on overall cellular SUMOylation. In 
neurons, compartmentalized cell regulation of sub-cellular SUMOylation has been 
observed in presynaptic membrane fractions (Feligioni et al., 2009). 
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Figure 1.4. SUMOylation cycle and consequences on SUMOylated substrates. 
SUMOylation is a reversible modification which relies on a cascade of E1-
activating, E2-conjugating, and E3-ligating enzymes in the forward reaction. The 
reverse reaction as well as maturation of Pro-SUMO protein is achieved by 
cleavage via SENP proteins. Upon SUMOylation, protein function can be altered in 
one of three major ways. 1) Restriction of interaction and 2) promotion of 
interaction with different protein partners can alter activity and can also affect 
protein stability. 3) Altered confirmation may also occur following SUMOylation to 
mediate secondary modifications or alter substrate activity. 
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1.3.4. Interplay Between SUMOylation and Other Post Translational Modifications 
The best understood regulation of protein SUMOylation is substrate-specific 
control by post-translational modifications of the substrate itself to change the rate of 
SUMOylation (Table 1.3). Similar to how CRMP2 post-translational modifications direct 
the protein’s activity, ubiquitination, phosphorylation, and acetylation can all enhance or 
prevent SUMOylation of certain proteins and have functional consequences on the 
proteins activity.  
There are several examples of membrane proteins that undergo changes in 
trafficking in response to SUMO signaling. For instance, estrogen receptor β (ERβ) is 
subject to multiple post-translational modifications (Picard et al., 2012). At lysine-4, ERβ 
contains a non-consensus SUMOylation motif that is made available for Ubc9 binding 
following downstream phosphorylation at serine-6 RasV12. This phosphorylation confers 
a negative charge dependent Ubc9 binding to ERβ that leads to SUMOylation. 
SUMOylated ERβ is prevented from becoming ubiquitinated thus sparing ERβ from 
being degraded. Additionally, SUMOylated ERβ prevents the receptor from being 
transcriptionally regulated by estrogen-responsive element (Picard et al., 2012). In 
another example, SUMOylation of kainate receptor 2 (GluK2) is both activity- and 
phosphorylation-dependent and marks the receptor for endocytosis (Martin et al., 2007a, 
Konopacki et al., 2011).  
SUMOylation also plays a role in controlling the endocytosis of α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors that respond to the 
effects of the neurotransmitter glutamate. AMPA receptors themselves are not 
SUMOylated, but are regulated by interaction with the SUMOylated protein Arc 
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(Chowdhury et al., 2006, Craig and Henley, 2012, Craig et al., 2012). Activity-regulated 
cytoskeleton-associated protein (Arc) is an immediate-early gene expressed at excitatory 
synapses with described interactions with AMPA receptors, endocytic proteins, CaMKII, 
and stargazin, an AMPA receptor interacting protein (Zhang et al., 2015). Following TTX 
induced suppression of AMPA currents for 24 hours, AMPA receptors undergo an 
increase in surface expression that is correlated to reduced SENP1 activity and increased 
SUMO1 conjugation, both of which increase protein SUMOylation (Craig et al., 2012). 
By recovering the rate of protein deSUMOylation with SENP1 overexpression, increases 
to AMPA receptor expression are prevented. TTX-mediated increases to AMPA receptor 
surface expressions are also prevented when cells express a SUMO-null Arc mutant that 
prevents Arc SUMOylation and Arc localization to dendrites (Chowdhury et al., 2006, 
Craig and Henley, 2012, Craig et al., 2012). Increased AMPA receptor surface expression 
in this case is therefore interpreted as an Arc and Arc SUMOylation dependent process. 
An interaction between Arc and endocytic proteins is predicted to be an important 
determinant of this pathway, but has not yet been tested (Craig et al., 2012, Henley et al., 
2014). In this thesis, I will describe how SUMOylation of CRMP2 recruits the endocytic 
machinery, in a manner similar to that proposed in Arc-AMPA receptor regulation, to 
mediate expression of Nav1.7. 
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Modified protein Consequences of modification Reference 
Nuclear factor kappa-light-
chain-enhancer of activated B 
cells (NFκB)  
Ubiquitin competes with SUMO to prevent degradation of NFκB (Desterro et al., 1998) 
Promyelotic leukemia protein 
(PML) 
Phosphorylation of PML restricts SUMOylation of PML to prevent PML 
solubility in nucleus and restrict self-aggregation to preserve activity 
(Muller et al., 1998, 
Kadare et al., 2003) 
Wnt/JNK signaling protein 
Axin 
deSUMOylation of Axin restricts interaction with MEKK and prevents JNK 
phosphorylation cascade 
(Rui et al., 2002) 
E3 SUMO ligase PIAS1 Acetylation competes with SUMOylation on PIAS1 and 
SUMOylation of the ligase restricts transcription factor SP3 expression 
(Sapetschnig et al., 2002) 
Focal adhesion kinase (FAK) SUMOylation of FAK activates FAK autophosphorylation which promotes 
FAK binding to Src family kinases to activate signaling pathways 
(Kadare et al., 2003 
Transcription factor Elk-1 Phosphorylation of Elk-1 by MAP kinases triggers activation, but 
SUMOylation of Elk-1 blocks activation 
(Yang et al., 2003) 
Heat-shock factors (HSF) 1 
and 4b 
Phosphorylation of either HSF is required for secondary SUMOylation which 
suppresses HSF transcriptional activity  
(Hietakangas et al., 2003, 
Hietakangas et al., 2006) 
Myocyte enhancer factor 2 
(MEF2) 
Phosphorylation of MEF2 is required for secondary SUMOylation which then 
suppresses MEF2 transcriptional activity 
(Gregoire et al., 2006) 
Tumor suppressor HIC1 Acetylation competes with SUMOylation of HIC1 and HIC1 SUMOylation 
reduces transcriptional activity 
(Stankovic-Valentin et al., 
2007) 
p53 Ubiquitination of p53 promotes secondary SUMOylation (Carter et al., 2007) 
DNA binding protein SATB1 Phosphorylation of SATB1 restricts secondary SUMOylation (Tan et al., 2010) 
GluK2 Kainite receptor Phosphorylation of GluK2 is required for secondary SUMOylation which 
promotes GluK2 endocytosis 
(Konopacki et al., 2011) 
Estrogen receptor β (ERβ) Phosphorylation of ERβ is required for secondary SUMOylation which 
prevents ubiquitination and endocytosis of ERβ 
(Picard et al., 2012) 
Microtubule stabilizing Tau 
protein 
SUMOylation of Tau promotes Hyperphosphorylation and 
Hyperphosphorylation of Tau promotes SUMOylation in a feed forward cycle 
– Both modifications promote Tau protein stability in the cytosol 
(Luo et al., 2014) 
Table 1.3. Interplay between phosphorylation and SUMOylation status. Examples of proteins that undergo phosphorylation and 
SUMOylation and the regulation these modifications provide over each other. 
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1.4. Thesis Aims 
A major goal of my work was to identify novel functional interacting partners of 
the voltage-gated sodium channel Nav1.7. An additional aim of my work was to describe 
the mechanisms affecting Nav1.7 trafficking. I identified CRMP2 as a novel partner of 
Nav1.7 and identified its post-translational regulation by the SUMO modification. The 
studies were hampered by lack of suitable pharmacological tools or genetic models to 
interrogate these questions. So, my work employed strategies to overexpress or 
knockdown various proteins in the SUMOylation pathway as well as to overexpress 
mutant CRMP2 proteins (mimicking loss of SUMOylation, loss of phosphorylation, or 
constitutive phosphorylation) and then examine the effects of these manipulations on 
Nav1.7 currents, surface expression, and biochemistry. For these studies, I employed both 
heterologous and primary cells to interrogate Nav1.7. In particular, I had the following 
aims: 
1. Determine, using biochemical techniques, if CRMP2 is SUMOylated, if 
CRMP2 interacts with Nav1.7, and if CRMP2 SUMOylation status regulates 
Nav1.7 currents (in heterologous cells).  
2. Determine if CRMP2 SUMOylation-dependent regulation of Nav1.7 currents 
involves Nav1.7 trafficking (in heterologous cells) using cell surface 
biotinylation and if CRMP2 SUMOylation-dependent regulation of Nav1.7 
currents is specific to Nav1.7 (in heterologous cells and sensory neurons) 
using whole-cell patch clamp electrophysiology. 
3. Determine if CRMP2 SUMOylation and CRMP2 phosphorylation by Fyn, 
Yes, GSK3β, Cdk5, or RhoK/CaMKII kinases are interdependent or exclusive 
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in their effects on regulating Nav1.7 currents (in heterologous cells and 
sensory neurons). 
4. Identify trafficking mechanisms by which CRMP2 SUMOylation mediates 
Nav1.7 current density (in sensory neurons). 
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CHAPTER 2.  
 
MATERIALS AND METHODS 
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2.1. CRMP2 sequence analysis and cDNA constructs 
2.1.1. Sequence analysis to identify putative motifs of CRMP2 SUMOylation 
CRMP2 protein sequences (Mus musculus NCBI reference sequence: 
NP_034085.2, and Rattus norvegicus NCBI reference sequence: NP_001099187.1) were 
analyzed using SUMOplot Analysis Program (Abgent) to identify putative SUMOylation 
motifs. Five motifs were identified and ranked by likelihood of SUMOylation. Of the 
predicted SUMOylation motifs, lys-20, lys-374, lys-390, lys-269, and lys-472, the first 
three met threshold criteria to be considered ‘likely SUMOylated’ by SUMOplot 
software. Predicted lysine targets were compared for conservation within the family of 
CRMP proteins (CRMPs 1–5) (Figure 2.1). 
 
2.1.2. Recombinant proteins 
 Mouse CRMP-2 cDNA (Mus musculus accession # NM_009955.3) was cloned 
into plasmid pDsRed2-N1 using PCR amplification followed by restriction digest and 
ligation by Dr. Joel Brittain, a former Khanna laboratory member. A CRMP2-3xFLAG 
construct was provided by Dr. Akihiro Kurimasa (Tottori University, Tottori, Japan). 
From these parent CRMP2-dsRed and CRMP2-3xFLAG constructs, recombinant 
CRMP2 cDNAs were created to study CRMP2 phosphorylation and SUMOyaltion by Dr. 
Aubin Moutal. CRMP2 mutants were created to harbor SUMO-null mutations, phospho-
null mutations, phospho-mimietic mutations, and combinatorial mutations harboring 
multiple –null or –mimetic residues. CRMP2 mutant constructs were made using 
QuikChange II XL (Agilent) (Figure 2.2). 
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Figure 2.1. CRMP2 putative SUMOylation motifs and conservation. (A) CRMP2 
sites that conform to SUMOylation consensus motifs (ranked by Abgent SUMOplot™ 
Analysis Program). The rat sequence was used for this prediction. (B) Conservation of 
putative SUM-targeted lysines within family of CRMP proteins (green check marks 
denote conservation of residues between all CRMPs, black X denotes non-conserved 
residues). 
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Type of 
Mutation 
Substitutions Targeted 
by 
References 
SUMO-null K20A 
K374A 
K390A 
Putative 
SUMO 
Putative 
This Thesis 
 
Phospho-null Y32F 
Y479 
T509A/T514A 
S522A 
T555A 
 
Y32F/S522A 
Fyn 
Yes 
GSK3β 
Cdk5 
RhoK/ 
CAMKII 
(Uchida et al., 2009) 
(Varrin-Doyer et al., 2009) 
(Yoshimura et al., 2005b) 
(Brittain et al., 2012) 
(Arimura et al., 2000a) 
(Hou et al., 2009) 
Phospho-mimetic S522D  This Thesis 
SUMO-null/ 
Phospho-null 
Y32F/K374A 
K374A/Y479F 
K374A/T509A/T514A 
K374A/S522A 
K374A/T555A 
 This Thesis 
SUMO-null/ 
Phospho-mimetic 
K374A/S522D  This Thesis 
 
 
 
 
  
Figure 2.2. Summary of post-translational modifications of CRMP2 and constructs 
used in this thesis. Top: The kinases that phosphorylate CRMP2 are shown above the 
linear sequence of mouse CRMP2. The predicted SUMOylation motif in CRMP2 showing 
lysine-374 (underlined), where SUMO is added the E2 Ubiquitin ligase Ubc9. The two 
other predicted SUMO sites are not shown. Bottom: Table of constructs used in this thesis 
including SUMO-null, phospho-null, phospho-mimetic, and combinatorial 
SUMO/phospho mutants created in a plasmid also encoding the Discosoma red 
fluorescent protein (DsRed).  
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Constructs were purified from DH5α E. coli using NucloBond Xtra Maxi kit (Macherey-
Nagel), and verified by DNA sequencing. HA-SUMO-1, HA-SUMO-2, HA-SUMO-3, 
and HA-Ubc9 plamids were obtained from Addgene (Cambridge). 
 
2.2. Cell cultures 
2.2.1. Primary cortical neuron culture, transfection and neurite outgrowth analysis 
Rat cortical neuron cultures were prepared from dissected cortices of day 19 
(E19) embryonic rats as described (Goslin and Banker, 1989), with minor modifications. 
Briefly, cortices were dissociated enzymatically and mechanically (trituration through 
Pasteur pipette) in a Papain solution (12 U/ml; Worthington) containing Leibovitz’s L-15 
medium (Invitrogen), 0.42 mg/ml cysteine (Sigma), 250 U/ml DNase 1 (type IV; Sigma), 
25 mM NaHCO3, penicillin (50U/ml)/streptomycin (50 μg/ml), 1 mM sodium pyruvate, 
and 1 mg/ml glucose (Invitrogen). After dissociation, the cells were gently washed by 
sequential centrifugation in Neurobasal medium containing either 2 mg/ml or 20 mg/ml 
BSA and Pen/Strep, glucose, pyruvate, and DNase1 (as above) and then plated on poly-
D-lysine-coated coverslips or 96-well plates at ~400 cells per mm2. Growth media (1 
ml/well or 100 µl/well for 12- and 96-well plates, respectively) consisted of Neurobasal 
medium containing 2% NuSerum, 2% NS21 (Chen et al., 2008), supplemented with 
penicillin/streptomycin (100 U/ml; 50 μg/ml), 0.1 mM L-Glutamine and 0.4 mM/L-
glutamax (Invitrogen). 5-fluoro-2′-deoxyuridine (1.5 μg/mL) (Sigma) was added 48 h 
after plating to reduce the number of nonneuronal cells. After 4 d in culture, half of the 
growth medium was replaced with medium without 5-fluoro-2’-deoxyuridine.  
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Neurons were transfected with various cDNA’s via Lipofectamine 2000 
(Invitrogen) per the manufacturer’s instructions at DIV4. Briefly, transfection reagent and 
cDNA’s were separately incubated in a serum-free media base (Neurobasal) (Invitrogen) 
for 5 min. Mixtures were combined and incubated for 25 min. The combined reagent 
mixture was added to cells in a drop-wise manner. Cultures were returned to normal 
culture conditions (37°C, 5% CO2) for 3-4 h, at which point transfection reagents were 
washed off with normal media. At DIV6, cells were fixed with 4% paraformaldehyde 
(Sigma) and imaged using the ImageXpress Micro Widefield High Content Screening 
System (Molecular Devices). Multiple parameters involved in neurite outgrowth were 
examined via the neurite outgrowth application module within the MetA Xpress software. 
This analysis combines the following measurements: number of primary neurites, number 
of branches, mean process length, and maximum process length to determine a summary 
of total outgrowth per cell. In some instances, Sholl analysis was used in place of 
ImageXpress analysis. Sholl analysis was performed with ImageJ software using an 
automated Sholl analysis plug-in, in which the soma boundary is approximated by an 
ellipsoid, and neurite intersections are assessed at radial distances (20 µm increments) 
from the soma. Images were acquired with a Nikon Eclipse 90i microscope by an 
experimenter blinded to transfection/drug conditions. Images were acquired across 3 
separate culture wells.  
 
2.2.2. Primary dorsal root ganglia (DRG) culture and transfection 
DRG neurons were isolated from 150 to 174 g female Sprague-Dawley rats. Rats 
were anesthetized using isoflurane and decapitated. The dorsal side was then cut to 
 56 
 
expose the vertebrae and transected in the thoracic region to allow access to the spinal 
cord. Cutting parallel to the dissection stage, just under the vertebral bone processes,  
dorsal vertebral bones were removed to expose DRGs just outside the spinal cord. 
Lumbar dorsal root ganglion were trimmed adjacent to their roots and placed in ice cold 
bicarbonate free, serum free, sterile Dulbecco’s modified Eagle’s meadium (bfDMEM). 
Excised ganglion were then placed in a 15 ml conical with 3.125 mg Neutral Protease 
(dispase) and 5 mg collagenase, type 1 (Worthington Biochemical Corporation) in 3 ml 
bfDMEM and gently rocked at 37 ºC for 40 minutes. Following enzymatic digestion, 
cells were gently titrated with glass polished pipettes to further disassociate cells into a 
single cell suspension suitable for patch clamp experiments and then gently centrifuged to 
collect tissue at the bottom. Disassociation media was then removed and cells 
resuspended in 200 µl supplemented nucleofector solution (Lonza). Cells were then split 
into two to three groups, 100 µl each, containing 2 µg wildtype or mutant CRMP2 
plasmid. Cell suspensions were then transferred to glass cuvettes for electroporation 
transfection (Amaxa program O-003, Lonza). Following electroporation, cells were 
diluted in DMEM, plated on 12-mm BD BioCoat poly-D-lysine/lamanin-coated glass 
coverslips (BD Biosciences, Franklin Lakes, NJ), and maintained at 37 ºC, 5% CO2 in 
DMEM supplemented with nerve growth factor (30 ng/ml), 10% fetal bovine serum 
(FBS), and 1% penicillin/streptomycin (100% stocks, 10 000 U/mL penicillin G sodium 
and 10 000 μg/mL streptomycin sulfate) (Leclere et al., 2005, Chi et al., 2009a). Under 
these conditions, transfection efficiencies of ~10–20% were routinely observed along 
with ~10–20% cell death. Cells were used for patching experiments at 48 to 72 h after 
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transfection and small cells (< 30 µm) were chosen as in order to target Aδ- and c-fiber 
nociceptive neurons (Harper and Lawson, 1985, Lawson, 2002). 
 
2.2.3. HEK cell culture and transfection 
 Human Embryonic Kidney (HEK) cell lines were obtained from Dr. Theodore R. 
Cummins (Indiana University School of Medicine). cDNA gene encoding Nav1.1 from 
human was subcloned into the vector pTarget, cDNA genes encoding Nav1.3 from rat 
and Nav1.7 from human were subcloned into the vector pcDNA3.1-mod, and cDNA 
encoding Nav1.5 from human was cloned into vector pRcCMVII. Constructs were 
transfected into HEK293 cells using the calcium phosphate precipitation technique. After 
48 h, the cells were passaged into 100 mm dishes and treated with G418 
(geneticin, Invitrogen) at 800 μg/ml to select for neomycin-resistant cells. After 2 weeks, 
colonies were picked and split. The colonies were then tested for functional channel 
expression using whole cell patch clamp technique. Expression of Nav1.1 (King et al., 
2012), Nav1.3 (Cummins et al., 2001), Nav1.5 (Smith et al., 2007), and Nav1.7 (Theile 
and Cummins, 2011a) was maintained by 500 µg/ml G418 applied at each passage. 
Stable cell lines were grown under standard tissue culture conditions (5% CO2 at 37 ºC) 
in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin (100% stocks, 
10 000 U/mL penicillin G sodium and 10 000 μg/mL streptomycin sulfate). For patch 
clamp experiments cells were transfected with 1 µg/µl of polyethyleneimine (PEI, 
Sigma), 2 µg of various CRMP2 constructs, and 1 µg/each SUMOylation machinery 
when applicable to the experiment (SUMO1-3, Ubc9, SENP1-2).  Under these conditions 
efficiencies of ~50% were observed. Cells were plated at 24 h and sodium currents were 
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recorded at 48 h. For several biochemistry experiments, transfection was achieved with 
Lipofectamine 2000 (Invitrogen) per manufacturer instructions and experiments 
performed 48 h after transfection. Under these conditions efficiencies of ~80% were 
observed. 
 
2.2.4. CAD cell culture 
 Mouse neuron model catecholamine A differentiated (CAD) cells were grown 
under standard tissue culture conditions (5% CO2 at 37 ºC) in DMEM/F12 supplemented 
with 10% FBS and 1% penicillin/streptomycin (100% stocks, 10 000 U/mL penicillin G 
sodium and 10 000 μg/mL streptomycin sulfate) as previously described (Wang et al., 
2010a, Wang et al., 2011b, Wang et al., 2011c). CAD cells were transfected by 
polyethyleneimine (Sigma) method for patch clamp experiments as described above for 
HEK cells with ~50% efficiency. CAD cells were transfected by Lipofectamine 2000 
(Invitrogen) for biochemistry experiments with ~80-95% efficiency. All experiments 
were performed 48 h after transfection.  
CAD cells predominantly express Nav1.7 and the channel accounts for ~90% of 
total Nav mRNA (Wang et al., 2011b). The current-voltage (IV) protocol (Figure 2.3B, 
top left) was used to survey properties of current-voltage relationship like peak current 
and activation, and the fast inactivation protocol (Figure 2.3B, bottom left) was used to 
survey fast inactivation. Representative families of traces for each of these protocols is 
found in the right half of Figure 2.3B. Highlighted in red in the IV protocol is a voltage 
pulse to +10 mV which elicits peak sodium current density in Figure 2.3C and is also 
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near the half-maximal voltage of activation displayed in Figure 2.3D. Highlighted in red 
in the fast inactivation protocol is a voltage pulse to -70 mV which produces a median 
current response and is hence near the half-maximal voltage of inactivation displayed in 
Figure 2.3D. CAD cell currents (Figure 2.3C) typically include a peak current between 0 
mV and +10 mV, activation of currents beginning around -40 mV, and reversal potential 
around +70 mV. The current density of CAD cells undergoes a slight drift between 
passages, but averages around 60 pA/pF peak currents. Due to drift, controls were 
repeated within each experiment to normalize data. Importantly, all relationships between 
conditions were conserved regardless of drift. 
CAD cell sodium current densities are between ~50% and ~80% Nav1.7 as 
resolved by five minute incubation of Nav1.7 specific toxins 125 nM Huwentoxin-IV 
(Figure 2.3E & F, 80% block, HWTX-IV) (Alomone Laboratories) (Xiao et al., 2008) 
and 5 nM ProTox-II (Figure 2.3G & H, 50% block; this block typically develops slowly 
and thus inhibition here is an underestimate of the steady state inhibition observed) 
(Schmalhofer et al., 2008). The difference of current block resolved by HWTX-IV versus 
ProTox-II results from differences in development of block as both toxins are highly 
specific to Nav1.7 at the concentrations used. To accommodate for the slower onset of 
block by ProTox-II, experiments utilizing ProTox-II involved a 15 minute incubation 
period and titration of ProTox-II in the extracellular bath that was not possible in paired 
recording, post-baseline application, studies, like the ones shown in Figure 2.3E-H. CAD 
cells do not display use-dependent properties of sodium currents at 10 Hz under naïve 
conditions (Figure 2.3I-K). The protocol used is shown in Figure 2.3I and equivalent 
currents to each pulse #1 - #30 in Figure 2.3K. 
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 previous page...Figure 2.3. Properties of CAD cell VGSC currents. (A) Quantitative RT-
PCR for the indicated NaV1.x genes from CAD cells. mRNAs for Na+ channel isoforms NaV1.1, 
1.3, 1.7, and 1.9 were detected from CAD cells. Data are expressed as percent of L27 mRNA (a 
ribosomal internal control gene) ± SEM (n = 6 for each). Nav1.7 is the dominant transcript. (B) 
Protocols used to generate current-voltage (IV) relationship and activation (top left) and fast 
inactivation (bottom left) and families of current traces generated by these protocols (right). 
Description of voltage pulses and durations for these protocols can be found in section 2.3.3. 
Highlighted by a red voltage step in the IV voltage protocol is a pulse to 0 mV that corresponds to 
the peak current observed in the representative family of traces (right) and summary IV 
relationship in C. This voltage is also typically near the half-maximal voltage of activation shown 
in D. Highlighted by a red voltage step in the fast inactivation protocol is a pulse to -65 mV 
which corresponds to the median current response observed in the representative family of traces 
(right) and is typically near the half-maximal voltage of inactivation shown in D. (C) Summary of 
IV relationship. The sodium current-voltage relationship of CAD cells displays activation of 
currents starting at around -40 mV, a peak current between 0 mV to +10 mV (0 mV in this 
experiment), and a reversal potential for sodium around +70 mV. (D) Typical fast inactivation 
(left curve, boxes) and activation (right curve, circles) observed in CAD cells. Red data points 
represent half-maximal values of activation and inactivation curves fitted using Boltzmann 
equation: y = 1/(1 + exp(V½ − V)/k), in which V½, V, and k represented midpoint voltage of 
kinetics, test potential, and slope factor, respectively. (E) Representative peak current traces 
before and 5 minutes after application of 125 nM Huwentoxin-IV or (G) 5 nM ProTox-II. (F) 
Summary data of CAD cell peak currents before and after application Huwentoxin-IV or (H) 5 
nM ProTox-II. (I) Protocol used to test use-dependency of CAD cells. A 20 ms pulse to -10 mV 
was applied at 10 Hz for 30 consecutive pulses. (J) Representative traces of CAD cell currents in 
response to pulse 1 (black) and pulse 30 (red). (K) CAD cells under naïve conditions do not 
display use-dependent sodium currents as indicated by equivalent currents in pulses 1 through 30. 
Error bars are hidden by symbols. Asterisks denote statistical significance compared to pre-drug 
(Student’s t-test). Data are means with SEM. n=5-9 cells per condition for each property shown. 
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2.3. Patch Clamp Electrophysiology 
2.3.1. Equipment 
 Whole cell voltage-clamp recordings were performed at room temperature using 
HEKA EPC 10 USB amplifier and PatchMaster acquisition software (HEKA 
Electronics). Electrodes were pulled from standard-walled borosilicate glass capillaries 
(Warner Instruments) with a P-97 electrode puller (Sutter Instrument). Final electrode 
resistances were 1-3 MΩ when filled with internal solutions. Whole cell capacitance and 
series resistance were partially compensated by the amplifier (70%-90%). Linear leak 
currents were digitally subtracted by P/4. Signals were filtered at 10 kHz and digitized at 
10-20 kHz. Analysis was performed using Fitmaster (HEKA Electronics) and Origin 9.1 
(OriginLab Corporation). 
 
2.3.2. Patch Clamp Solutions 
 Na+ recording solutions for HEK cells and DRG cells were identical. To isolate 
sodium currents, external solutions contained TEA-Cl (tetraethylammonium chloride) to 
block voltage-gated potassium channels, and CdCl2 to block voltage-gated calcium 
channels. All solutions were adjusted for pH with HCl in HEPES buffer and for 
osmolarity with sucrose, 290-310 mosM/L for internal solutions and 310-315 mosM/L 
for external solutions (Table 2.1) 
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2.3.3. Patch Clamp Voltage Protocols 
 Various voltage protocols were utilized to examine different components of 
sodium channel activity (i.e. current densities and kinetics). For total sodium current from 
HEK and CAD cells, a standard current-voltage relationship (IV) protocol was used. 
Cells were depolarized from a holding potential of -80 mV to potentials between -70 mV 
and +60 mV for 15ms in 5 mV increments. IV protocol allows for analysis of the I-V 
curve to identify peak sodium currents that are normalized to cell size to determine peak 
sodium current density (pA/pF). IV protocol also allows for analysis of activation 
kinetics. HEK and CAD cell fast-inactivation kinetics are analyzed from a protocol 
designed to elicit fast-inactivation (FI) of sodium channels. Cells are depolarized to 
various voltage potentials between -120 mV and -10 mV for 500 ms in 5 mV increments 
to elicit varying degrees of inactivation prior to testing available current with a voltage 
pulse to 0 mV for 20 ms. Total current was tested at the end of this protocol to verify use-
dependence inactivation did not contribute to analysis of fast-inactivation kinetics. CAD 
cell slow inactivation was examined using a pre-pulse inhibition protocol with 
hyperpolarized recovery phase. Cells are subjected to voltage pulses between -110 mV 
and +20 mV in 10 mV increments for 5s to elicit varying degrees of sodium channel fast-
inactivation and slow-inactivation. Fast-inactivated channels are then allowed to recover 
by -120 mV hyperpolarizing pulse for 150 ms such that a 0 mV, 15ms test pulse will 
resolve changes in available current mediated by slow-inactivation with minimal 
contribution of fast-inactivation.  
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Electrophysiology recording solutions 
[Concentrations in mM] 
Internal Solution Cell type External Solution 
140 CsF  
 
 
HEK293 
/DRG 
 
 
130 NaCl 
15 HEPES 30 TEA-Cl 
10 NaCl 10 HEPES 
1.1 Cs-EGTA 10 D-glucose 
  3 KCl 
  1 CaCl2 
  1 MgCl2 
  0.05 CdCl2 
     
110 CsCl  
 
 
CAD 
100 NaCl 
25 HEPES 10 HEPES 
10 EGTA 10 TEA-Cl 
5 MgSO4 10 D-glucose 
4 Na2-ATP 4 4-AP 
  1 CaCl2 
  1 CdCl2 
  1 MgCl2 
  0.1 NiCl2 
Table 2.1. Electrophysiology recording solutions 
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 Recordings from dorsal root ganglia cells utilize separate protocols that aid in 
separation of current contributions by various sodium channel isoforms. To resolve total 
sodium current in dorsal root ganglia (DRG) cells, DRG-IV protocol is used. Cells are 
held at -100 mV to account for hyperpolarized inactivation kinetics of DRG Nav1.X 
subtypes and then subjected to various depolarizing voltage potentials between -70 mV 
and +60 mV in 5 mV increments. In the presence of 500 nM tetrodotoxin, tetrodotoxin-
resistant (TTX-R, Nav1.8 & Nav1.9) peak current density can be analyzed using the 
voltage pulse to 0 mV. To isolate tetrodotoxin-sensitive (TTX-S, Nav1.1-Nav1.7) peak 
current densities, the pre-pulse inactivation protocol H-infinity is used. H-infinity is 
named for the ‘h’ constant referring to sodium current inactivation in the Hodgkin and 
Huxley model for sodium channel kinetics (Hodgkin and Huxley, 1952d) and takes 
advantage of differential fast-inactivation kinetics of TTX-S and TTX-R channels to 
electrically isolate and subtract TTX-R/TTX-S current contributions (Roy and Narahashi, 
1992). Cells are held at -120 mV and subjected to 1 s voltage pulses between -120 mV 
and +10 mV in 10 mV increments before available current is tested at 0 mV for 200 ms. 
These voltage pulses inactivate the compliment of voltage-gated sodium channels to 
various degrees. TTX-S currents inactivate at more hyperpolarized potentials than TTX-
R currents such that the -40 mV pre-pulse reveals only TTX-R current. This TTX-R-only 
trace can then be digitally subtracted from previous traces that include the entire 
complement of TTX-R and TTX-S currents to reveal isolated TTX-S currents (Figure 
2.4) 
 
 
 66 
 
 
 
 
 
 
Figure 2.4. Voltage clamp protocols utilized to examine Na+ currents. (A) Standard 
current-voltage relationship, IV, (B) Fast-inactivation, FI, (C) Slow-Inactivation, SI, (D) 
DRG current-voltage for tetrodotoxin-resistant currents, DRG-IV, (E) DRG pre-pulse 
inhibition for tetrodotoxin-sensitive currents, H-infinity. 
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2.3.4. Data analysis of current recordings 
 Sodium channel current recordings were analyzed for peak current density by 
normalizing the maximum current (Imax, pA, typically found at depolarization between -
10 and +10 mV) by cell size (pF) to account for variation in cell size. Outlier cells, 
defined by greater or less than 2x S.D. for cell size or peak current, were removed from 
datasets. Averaged pA/pF values were compared between datasets following 
normalization to controls. Steady-state activation was analyzed using IV protocol data for 
channel conductance, G, at each voltage step and dividing by maximum conductance 
(Gmax). G/Gmax, where G=I/(Vpulse-Erev), I is maximum current in response to Vpulse mV, 
and Erev is the reversal potential of the cell determined by Fitmaster software (HEKA 
Electronics, Germany). G/Gmax values for each recording were fit to Boltzmann function 
in Origin 9.1 (OriginLab Corporation, Northampton, MA) then averaged to determine 
values of half-maximal voltage of activation V1/2 and slope factor of activation, k, which 
were compared between conditions. Boltzmann equation: y = 1/(1 + exp(V½ − V)/k), in 
which V½, V, and k represented midpoint voltage of kinetics, test potential, and slope 
factor, respectively 
 Steady-state fast inactivation was analyzed using FI protocol data for channel 
current, I, at each voltage step and dividing by maximum current (Imax). Normalized 
I/Imax values were fit to Boltzmann function in Origin 9.1 (OriginLab Corporation, 
Northampton, MA) and averaged within datasets to determine values of half-maximal 
voltage of fast inactivation V1/2 and slope factor of fast inactivation, k, which were 
compared between conditions. 
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 Slow inactivation was analyzed by using SI protocol current data, I, for each 
inhibitory pre-pulse and normalizing to maximum current (Imax). Values of inactivation 
were averaged and plotted for comparison between datasets. 
 
2.3.5. Compounds used in patching 
For patching experiments the following compounds were utilized: Tetrodotoxin 
(TTX) to block TTX-S Nav1.1—Nav1.7 currents (Alomone Laboratories); Pitstop2 – an 
inhibitor of pit formation during clathrin-mediated endocytosis (Abcam); and Lactacystin 
– an inhibitor of the proteasome complex responsible for cellular proteolysis degredation 
of proteins (Sigma). All compounds were dissolved in DMSO immediately prior to use. 
 
2.4. Biochemistry 
2.4.1. Biotinylation to detect cell surface Nav1.7 
 48 h after transfection, CAD cells were incubated with sulfosuccinimidyl 2-
(biotinamido)ethyl-1,3′dithiopropionate (EZ-link Sulfo NHS-SS-biotin; 1 mg/mg protein, 
Pierce) for 30 min at 4 °C in cold PBS (pH 8.0) to label transmembrane protein fractions. 
Excess biotin was quenched with PBS containing 100 mM glycine and washed three 
times with ice-cold PBS. Cells were then transferred from tissue culture dishes to sterile 
Eppendorf tubes and lysed in RIPA buffer. Following resuspension, samples were 
triturated 10 times (with a 25-gauge needle) and centrifuged at 100,000 × g for 20 min. 
The biotinylated proteins were separated from clear solubilizate by adsorption onto 
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streptavidin-agarose beads (Novagen) for 2–4 h at 4 °C. Beads were washed 3–5 times 
with RIPA buffer, and bound biotinylated proteins were gently eluted off the beads with 
RIPA buffer containing 2% Triton X-100 and 650 mM NaCl by end-over-end incubation 
for 1 h at 30 °C. The biotinylated and total fractions were subjected to immunoblotting 
with β-tubulin and pan-Nav or Nav1.7 antibodies. 
 
2.4.2. Immunocytochemistry 
Naïve DRG cells were fixed with 4% paraformaldehyde (diluted in 0.1 mM PBS) 
for 10 min at room temperature, permeabilized with 0.2% Triton X-100 for 10 min, and 
then washed three times with 0.01 mM PBS. Cells were then pre-incubated with 10% 
bovine serum albumin (diluted in 0.1 mM PBS) for 1 h at room temperature to block 
nonspecific binding with the primary antibody. Nav1.7 (Neuromab) and CRMP2 (Sigma) 
primary antibodies were diluted (in 0.1 mM PBS) to 1:500 and applied to the cells. After 
incubation for 2 h at room temperature, the DRG cells were washed again with PBS, and 
secondary antibodies (anti-mouse Alexa 488, 1:500; Molecular Probes) were incubated in 
blocking solution for 45 min at RT. Coverslips were mounted in Prolong Gold Antifade 
mounting media (Molecular Probes). DRG cells were imaged on a Nikon Ti swept-field 
confocal microscope using a ×60, 1.4 NA lens with a cooled Cascade 512B digital 
camera (Photometrics). Z stack image pairs were captured through the sample. Images 
were deblurred off line by an iterative deconvolution protocol (Nikon Elements version 
3.0) using a theoretical point-spread function. 
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2.4.3. siRNA knockdown of CRMP2 
Validated small interfering RNAs (siRNAs) against the rat CRMP2 (5′-
ACTCCTTCCTCGTGTACAT-3′) sequence (Nishimura et al., 2003) and controls 
(scrambled sequence with approximately the same percentage of GC but no sequence 
homology) were used for CRMP2 knockdown (Invitrogen) as previously described 
(Brittain et al., 2009a, Chi et al., 2009b, Brittain et al., 2011a, Brittain et al., 2011c). DRG 
and CAD cells were transfected with 250 nM control or CRMP2-specific siRNA along 
with EGFP or dsRed-CRMP2 constructs to allow visualization. Experiments were 
performed 48 h following transfection. siRNA knockdown was verified by Western blot 
in CAD cells, but not DRGs, due to differences in transfection efficiencies that make 
CAD cells the ideal cell to test siRNA function. As reported previously (Chi et al., 
2009b), we observed a loss of CRMP2 immunoreactivity following knockdown of 
CRMP2 compared to control siRNA (Figure 2.5). Knockdown of CRMP2 with this 
siRNA has also previously been verified in cultured neurons via immunocytochemistry 
(Brustovetsky et al., 2014). 
 
2.4.4. Co-Immunoprecipitations 
CAD cells were lysed into the immunoprecipitation buffer containing 20 mM 
Tris-HCl pH=7.4, 50 mM NaCl, 2 mM MgCl2, 10 mM N-Ethylmaleimide (NEM), 1% 
(vol/vol) NP-40, 0.5% (mass/vol) sodium deoxycholate, 0.1% SDS with 
Protease/phosphatase inhibitors cocktails (Calbiochem) and Benzonase (50U.mL-1).   
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Figure 2.5. siRNA knockdown of CRMP2. Levels of CRMP2 and tubulin in CAD cells 
following 48 h incubation of control or CRMP2 -siRNA (200 nM). 
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Total protein concentration was determined by BCA protein assay (Thermo scientific) 
then 500 μg of total protein was incubated with 2 μg of CRMP2 antibody (Sigma) 
overnight at 4°C under gentle agitation. Protein G magnetic beads (Life Technologies) 
pre-equilibrated with the immunoprecipitation buffer, were added to the mixture and 
allowed to incubate for 1 h at 4°C to recover antibody-captured-complexes. The beads 
were washed 4 times with the immunoprecipitation buffer before re-suspension in 
Laemmli buffer and boiling at 95°C for 5 min prior to immunoblotting. For SUMO1 
immunoprecipitation, lysates were denatured prior to incubation with SUMO1 antibody 
in order to identify endogenously SUMOylated protein in accordance with previously 
described methods (Becker et al., 2013). 
 
2.4.5. Immunoblot analyses 
 Samples were loaded on 4-20% Novex® gels (Life Technologies). Proteins were 
transferred for 1h at 100 V using TGS (25mM Tris pH=8.5, 192mM glycine, 0.1% SDS), 
20 % methanol as transfer buffer to polyvinylidene difluoride (PVDF) membranes 
0.45μm, blocked at room temperature for 1 h with 5% non-fat dry milk then incubated 
separately in indicated primary antibodies overnight at 4°C. Following incubation in 
horseradish peroxidase conjugated secondary antibodies (Jackson immunoresearch), blots 
were revealed by enhanced luminescence (Millipore) before exposure to photographic 
film. Films were scanned, digitized, and quantified using Un-Scan-It gel version 6.1 
scanning software (Silk Scientific Inc). 
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2.4.6. Plasmids and Antibodies 
Antibodies were purchased from commercial vendors: Nav1.7 (NeuroMab, Davis, 
CA), pan Nav (Alomone Laboratories, Jerusalem, Israel), βIII-Tubulin (Promega, 
Madison, WI), CRMP2 (Sigma, St. Louis, MO), Numb (Abcam, Cambridge, MA), Eps15 
(Abcam, Cambridge, MA), Nedd4-2 (Abcam, Cambridge, MA), Itch (BD biosciences, 
San Jose, CA). HA-SUMO-1, HA-Ubc9 plasmids were obtained from Addgene 
(Cambridge, MA). CRMP2 cDNA mutations were introduced by QuikChange II XL 
(Agilent, Santa Clara, CA) in the pdsRed2-CRMP2 plasmid. Plasmids were purified from 
DH5α E. coli using the NucleoBond® Xtra Maxi kit (Cat# 740414, Macherey-Nagel, 
Germany). Introduced mutations were verified by DNA sequencing. Cdk5, Fyn, and 
DNFyn plasmids were purchased from Addgene (Cambridge, MA). 
2.5 Statistical analysis 
All data points are shown as mean ± S.E., and n is presented as the number of the 
separate experimental cells. Steady-state activation and inactivation curves were fitted 
using the Boltzmann equation as follows: y = 1/(1 + exp(V½ − V)/k), in which V½, V, 
and k represented midpoint voltage of kinetics, test potential, and slope factor, 
respectively. Statistical differences between control and experimental conditions were 
determined by using Kruskal-Wallis non-parametric one-way ANOVA with a Dunnet’s 
post hoc test or a Student's t test when comparing only two conditions. Values of p < 0.05 
were judged to be statistically significant. Asterisks or pound symbols are used to denote 
significance and defined in figure legends. All data was compared using OriginPro9.1 or 
R-project software.  
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CHAPTER 3. 
 
IDENTIFICATION OF CRMP2 AS A TARGET OF SUMOYLATION  
AND BINDING PARTNER OF NaV1.7 
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3.1. Introduction 
 It is well established that post-translational modifications of CRMP2 direct its 
activity in neurons (Khanna et al., 2012). Mapping the CRMP2 interactome has 
unraveled novel targets which enable it to have broad roles in regulation of microtubule 
dynamics, protein endocytosis, vesicle recycling, and synaptic assembly within neurons 
(Khanna et al., 2012). Trafficking of ligand- and voltage-gated calcium channels has been 
recently demonstrated as novel roles for CRMP2 (Bretin et al., 2006, Brittain et al., 
2009b, Chi et al., 2009c, Brittain et al., 2011a). In addition to protein targets, CRMP2 is 
the presumptive secondary target of the anti-epileptic drug (R)-lacosamide [(2R)-2-
(acetylamino)-N-benzyl-3-methoxypropanamide; LCM], which has its primary action on 
voltage-gated sodium channels (VGSCs) (Errington et al., 2006, Errington et al., 2008). 
By stabilizing sodium channels in the slow-inactivated state, LCM is believed to reduce 
the pathological activity of hyperexcitable neurons typified by prolonged depolarizations, 
without affecting normal physiological activity (Errington et al., 2008). Work from the 
Khanna laboratory previously demonstrated that mutations within putative LCM-binding 
pockets in CRMP2 reduced LCM-induced shifts in slow inactivation of sodium channels 
compared to channels in the neuronal model CAD cells expressing wild type CRMP2 
(Wang et al., 2010a). The data has also demonstrated CRMP2 labeling by fluorescent 
analogs of LCM could be competitively displaced by excess LCM in rat brain lysates, 
implying binding of LCM to CRMP2 (Wang et al., 2010a). In contrast to these findings, 
radiolabeled LCM was not found to bind to lysates from CRMP2-injected oocytes (Wolff 
et al., 2012). Thus, the exact mechanism by which CRMP2 modulates LCM-induced 
slow inactivation of sodium channels remains unclear. CRMP2 modulation of voltage-
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gated sodium channels may be predicated on involvement of a tertiary protein or 
modification of either protein.  
The Khanna laboratory is interested in delineating the mechanisms by which 
CRMP2 is directed to its many effectors and how it regulates their functions. Previous 
studies have implicated post-translational modifications, particularly phosphorylation, in 
directing CRMP2 interactions and regulating the function of the partner proteins. For 
instance, phosphorylation by Cdk5 enhances interaction between CRMP2 and voltage-
gated calcium channels to modulate calcium influx (Brittain et al., 2012). 
Phosphorylation by glycogen synthase kinase 3β or Rho-associated protein kinase 
(ROCK) lowers the capability of CRMP2 to bind to tubulin heterodimers leading to 
microtubule destabilization, culminating in axon retraction/growth cone collapse 
(Arimura et al., 2000b, Arimura et al., 2005, Yoshimura et al., 2005b). Oxidation of 
CRMP2 has been shown to link the redox protein thioredoxin to regulation of CRMP2 
phosphorylation and semaphorin 3A-induced growth cone collapse (Morinaka et al., 
2011). Proteolysis of CRMP2 by calpains has also been reported and is believed to 
contribute to neurodegeneration and cell death (Zhang et al., 2007, Brittain et al., 2011a).  
Therefore, here I tested how CRMP2 post-translational modifications relate to 
modulation of voltage-gated sodium channels. 
 
3.2. Knockdown of CRMP2 reduces VGSC current density in CAD cells and DRG 
neurons 
  To investigate the relationship between VGSCs and CRMP2, I manipulated 
endogenous CRMP2 levels in CAD cells using a siRNA against CRMP2 as well as 
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overexpression of a CRMP2 construct refractory to CRMP2 knockdown, shresCRMP2. 
CRMP2 siRNA almost completely deleted endogenous CRMP2 from CAD cells (Figure 
3.1A, top blot: lower band, open arrow) but did not prevent expression of exogenously 
added shresCRMP2 (Figure 3.1A, top blot: top band, closed arrow). For 
electrophysiology studies, successfully transfected cells were identified by fluorescence 
of the co-transfected dsRed plasmid and subjected to voltage protocols to assess 
quantitative measurements of current density, fast inactivation, and activation (see Figure 
3.1D). Together these protocols allow for assessment of effects on the channel including 
shifts in voltage-dependence and changes to overall current production. CAD cells were 
initially used in these studies as they endogenously express CRMP2 protein (Brittain et 
al., 2012) and mRNAs for VGSC subtypes Nav1.1, Nav1.3, Nav1.7, and Nav1.9. 
Notably, in these cells, Nav1.7 is the dominant sodium channel, representing about ~95% 
of total VGSC gene transcripts and 80% functional channel determined by Nav1.7-
selective block with 125nM huwentoxin-IV (Figure 2.3)(Wang et al., 2011b). 
 Knockdown of CRMP2 resulted in an ~70% reduction of sodium current density 
(Figure 3.1B, C; green bar) without any change in the kinetics of fast inactivation or 
activation analyzed by Boltzmann properties of half maximal activation (V1/2) and slope 
(k) (Figure 3.1E). Addition of shresCRMP2 into CAD cells concomitantly with deletion 
of endogenous CRMP2 with a CRMP2 siRNA resulted in a recovery of current density to 
control levels (87.4 ± 11.5% of that observed in CRMP2 control; Figure 3.1E; brown 
open symbols).   
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Figure 3.1. CRMP2 controls Nav1.7 current density in CAD cells. (A) Western 
blot of CAD cells displaying successful knockdown of endogenous CRMP2 by 200 
nM siRNA-CRMP2 and ‘add-back’ of exogenous CRMP2 by overexpression of a 
wildtype CRMP2 that is resistant to the siRNA (shresCRMP2). (B) Voltage 
protocols used to measure peak current and activation (left) and fast inactivation 
(right) in CAD cells (C) Representative family of traces of sodium currents from 
CAD cells expressing wildtype shresCRMP2 (black), CRMP2 siRNA (green), or 
both (brown). (D) Box plot of peak current density (pA/pF) measured at 0 mV for 
shresCRMP2, CRMP2 siRNA, or shresCRMP2 and CRMP2 siRNA transfected 
CAD cells. Data are normalized to the shresCRMP2 condition. Box plot borders 
represent SEM and median, square indicates mean, diamonds are individual data 
points. Asterisk indicates statistically significant differences between 
siRNACRMP2 and shresCRMP2 expressing cells (p < 0.05, one-way ANOVA with 
Tukey’s post-hoc test). (E) Representative Boltzmann fits for activation and steady-
state inactivation for CAD cells transfected with the indicated constructs are shown. 
The calculated values for V1/2 and k of activation and steady-state inactivation for 
all conditions tested and the associated statistics are presented in Table 3.1. Sodium 
current fast inactivation (left curves) and activation (right curves) were unaffected 
by knockdown or add-back of CRMP2. 5-7 cells per condition, data is presented as 
means ± SEM. 
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The shape of all CAD cell currents tested were equivalent within these experiments 
(Figure 3.1C) with peak current densities observed in within 1-2 ms of a voltage pulse to 
0 mV  and decay of current (τ, Tau, by exponential fit) of 550 ± 40 µs regardless of 
condition, current density, or day of recording. Overexpression of CRMP2 alone did not 
alter Na+ current densities compared to CAD cells expressing EGFP (94.3 ± 30.2% of 
CRMP2 control) or compared to untransfected cells (101.8 ± 19.6% of CRMP2 control). 
In addition, CAD cells transfected with a control siRNA yielded currents no different 
from CAD cells expressing shresCRMP2 (98.8 ± 14.9% of CRMP2 control). Based on 
these data, I can conclude that (i) CRMP2 overexpression does not augment Na+ current 
density in CAD cells, (ii) CRMP2 depletion removes all but 30% of CAD cell Na+ 
currents. 
The effect of CRMP2 knockdown and add-back on Na+ currents was examined in 
acutely isolated primary rat DRG cultures. The sodium currents were electrically (post-
hoc subtraction; protocols shown in Figure 3.2A) and pharmacologically (TTX, 500 nM) 
isolated into tetrodotoxin-sensitive (TTX-S) and tetrodotoxin-resistant (TTX-R) fractions. 
Small sensory neurons (< 30 µm) were chosen as these are likely Aδ- and c-fiber 
nociceptive neurons and express high levels of Nav1.7 (Harper and Lawson, 1985, 
Lawson, 2002, Djouhri et al., 2003, Zhang et al., 2013). The TTX-S sodium current 
fraction in DRGs electroporated with a CRMP2 siRNA was reduced by ~62% compared 
to DRGs expressing shresCRMP2 (Figure 3.2D, F). Concomitant electroporation of 
DRGs with shresCRMP2 and CRMP2 siRNA rescued the reduction in current density to 
85.6 ± 12.3% of control (i.e. shresCRMP2 only) levels.  
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Figure 3.2. CRMP2 controls TTX-S current density in DRG neurons. (A) Voltage 
protocols used to measure peak TTX-R (top) and peak TTX-S (bottom) currents from 
DRG cells. Purple and red voltage pulses in H-infinity protocol represent the conditioning 
pulses used to separate TTX-S current by post-hoc subtraction. (B) Post-hoc subtraction of 
TTX-S traces. Purple trace (labeled 3) represents total sodium current. Red trace (labeled 
2) represents current elicited after –40 mV prepulse, a voltage at which the TTX-S current 
has completely inactivated; this is the TTX-R current. Blue trace (labeled 1) is the digital 
subtraction of 3 from 2 (3-2=1) and represents the TTX-S current. Box plots of 
normalized peak currents (pA/pF) of TTX-R. Representative family of TTX-R (C) or 
TTX-S (D) sodium current traces, in response to the voltage protocol shown in A, from 
DRG neurons transfected with the indicated conditions. Box plots of TTX-R (E) and 
TTX-S (F) peak currents measured at 0 mV for shresCRMP2, CRMP2 siRNA, or 
shresCRMP2 and CRMP2 siRNA transfected DRGs. Data are normalized to shresCRMP2 
expressing cells. (G) Representative confocal images of untransfected DRG neurons 
immunolabeled for Nav1.7 (green) and CRMP2 (red). All cells imaged displayed surface 
colocalization of CRMP2 and Nav1.7. Scale bar is 10 microns. Data are normalized to the 
shresCRMP2 condition. Box plot borders represent SEM and median, square indicates 
mean, diamonds are individual data points. Asterisk indicates statistically significant 
differences between siRNACRMP2 and the two other conditions tested (p < 0.05, one-
way ANOVA with Tukey’s post-hoc test). n=5-8 cells per condition.  
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In contrast, the TTX-R current fraction was completely unaffected with current 
density levels reaching 111.7 ± 23.1% in DRGs electroporated with shresCRMP2 and 
120.0 ± 15.1% for DRGs electroporated with both shresCRMP2 and CRMP2 siRNA 
(Figure 3.2C, E). As TTX-S currents were reduced upon CRMP2 depletion, the data 
suggests that CRMP2 regulation of sodium currents may be limited to a certain subtype 
of VGSCs. To observe CRMP2 expression in small diameter DRGs together with 
Nav1.7, CRMP2 and Nav1.7 were co-stained. (Figure 3.2G). 
Given the dominance of Nav1.7 in CAD cell currents (Figure 2.3) and in small 
DRG neurons (Zhang et al., 2013), I predicted that of TTX-S subtypes, at least Nav1.7 
isoform is affected by CRMP2 SUMOylation state, and conclude that total TTX-R 
currents are not affected. Nav1.9, however, can have very small contribution to total 
current amplitude and still function to alter neuronal activity. This function is endowed 
by slow kinetics and a persistent current that lasts several hundred milliseconds longer 
other VGSC current responses. As a result Nav1.9 currents in DRGs, like Nav1.7, can 
underlie painful conditions (Lolignier et al., 2015). Nav1.9 currents are not explicitly 
tested in this thesis; however, results suggest that any potential role for CRMP2 
regulation of Nav1.9 does not prevent Nav1.7-mediated reduction of neuronal activity 
(see Figure 5.2). In a later section I separate the contribution of DRG TTX-S currents 
using the Nav1.7 specific toxin ProTox-II to verify  my Nav1.7-mediated hypothesis (see 
Figure 3.6).  
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3.3. Analysis of CRMP2 primary amino acid sequence reveals a stringent and conserved 
SUMOylation motif that affects VGSC currents in CAD cells and DRG neurons 
 As discussed in the Introduction (see section 1.2.2), CRMP2 is subject to multiple 
post-translational modifications that endow CRMP2 with a diversified portfolio of 
functional outcomes. However, whether all such CRMP2 modifications have been 
discovered is unknown. An analysis of CRMP2 primary amino acid sequence identified 
at least 5 sequences that conformed to the SUMO-consensus motif ψKxD/E (see Chapter 
1.3) (Figure 3.3A). Notably, these sequences were conserved between most of the other 
CRMP family members (Figure 3.3B).  
Previous investigations of protein SUMOylation have demonstrated that mutating 
the SUMOylated lysine to either an arginine or alanine eliminates the site of addition of 
SUMO by Ubc9 (Duprez et al., 1999, Sampson et al., 2001, Perdomo et al., 2005, Merrill 
et al., 2010). In one study, mutation to arginine lead to false results due to the charge of 
an arginine residue interfering with voltage-gated potassium channel gating (Feliciangeli 
et al., 2007). In my thesis I use voltage stimuli to probe ionic currents and therefore 
choose to mutate putatively targeted lysine residues to uncharged alanine residues. 
CRMP2-dsRed mutants harboring lysine to alanine (KA) mutations were produced to 
eliminate putative SUMOylation motifs that scored as ‘likely SUMOylated’ by Abgent 
SUMOplot™ analysis program: K20, K374, and K390 (Figure 3.3B). Of these sites, 
K374 was particularly interesting due to (i) its perfect conservation between CRMPs 1–5, 
(ii) conformity to the SUMO-consensus motif ψKxD/E (see Chapter 1.3), and (iii) the 
presence of downstream aspartic and glutamic acid residues that typify this motif as the 
more stringent negative charge dependent SUMO motif. In a NDSM, interaction with 
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SUMO-E2 enzyme, Ubc9, can be promoted by the additional negative charges (Henley et 
al., 2014). Current density and channel kinetics of fast inactivation and activation were 
analyzed in CAD cells expressing CRMP2-K20A, CRMP2-K374A, and CRMP2-K390A 
mutants. CAD cell Nav1.7 sodium currents (Figure 3.3C) in cells expressing CRMP2-
K20A or CRMP2-K390A, were unchanged compared to those of CAD cells expressing 
wildtype CRMP2 (Figure 3.3C, D). In contrast, the peak current density observed at 0 
mV following CRMP2-K374A expression in CAD cells reduced Nav1.7 current density 
by ~57% compared to CAD cells expressing wildtype CRMP2 (Figure 3.3C, D). This 
reduction in Nav1.7 current density was similar in magnitude to that observed in CAD 
cells in which CRMP2 had been depleted with siRNA-CRMP2 (Figure 3.1D, green box). 
This CRMP2-K374A mediated current reduction was not associated with any changes in 
fast inactivation or activation kinetics (Figure 3.3E, Table 3.1) compared to CAD cells 
expressing wildtype CRMP2. CRMP2 SUMO-null mutant had these effects in the 
presence of endogenous CRMP2 suggesting that it functions as a dominant negative. This 
could be indicative of the status of CRMP2 SUMOylation in cells, where only a low 
fraction of unSUMOylated CRMP2 is required for modulation of sodium currents. 
Alternatively, it could indicate that function of CRMP2 on sodium channels involves 
CRMP protein tetramerization (Wang and Strittmatter, 1997b) where only one copy of 
unSUMOylated CRMP2 is required for reduction of currents. 
To gain a deeper understanding of the possible importance of this putative 
SUMOylation site in CRMP2, I compared this SUMOylation motif and the surrounding 
residues (amino acids 368-381) of human CRMP2 with various species using a Universal 
Protein Resource (UniProt) database Basic Local Alignment Search Tool (BLAST). A 
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high rate of conservation within this region would be indicative of negative selection, a 
process by which important genetic regions are conserved by selection related to an 
important function or evolutionary advantage (Charlesworth et al., 1993). I found that 
lysine-374 and 13 flanking residues were perfectly conserved within CRMP2 for 
mammal species of cat, new world and old world monkeys, mouse, rat, cow, human, 
panda, pig, treeshrew, ferrets, yak, and bats. These 14 amino acid residues were also 
perfectly conserved within at least 35 species of Aves and 3 species of Reptiles. Human 
CRMPs 1, 3, and 4 were 92.9% homologous within this region while CRMP5 was 71.4% 
homologous. Additionally, 5 fish species had 71.4% conservation of this region. The high 
rate of conservation within human CRMPs and also CRMP2s of a variety of species 
indicates that this SUMOylation motif endows important protein function (Figure 3.4). 
Putative CRMP2 SUMOylation is not conserved, however, in CRMP proteins of 
Caenorhabditis elegans or Drosophila melanogaster suggesting that the role of CRMP2 
SUMOylation is likely not present, at least within this sequence motif, and thus may not 
endow protein function in these reductionist model organisms. Furthermore, BLAST 
analysis suggests that CRMP2 SUMOylation at lysine-374 does not exist outside of 
phylum Chordata.   
To further elucidate the role of CRMP2 SUMOylation on sodium channel 
currents, I next utilized expression of deSUMOylationg SENP proteins. If SUMOylation 
is important for determining Nav1.7 currents in CAD cells, then overexpression of 
SENP1 and SENP2 proteases to enhance deSUMOylation should result in a reduction of 
Nav1.7 currents similar to that I had observed following overexpression of the SUMO-
null CRMP2-K374A mutant. Consistent with this expectation, expression of SENP1 and 
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SENP2 reduced CAD cell Nav1.7 current density by ~67% compared to CAD cells 
expressing wildtype CRMP2 without affecting Boltzmann kinetic properties of activation 
or fast inactivation (Table 3.1). Manipulation of the SUMOylation machinery in CAD 
cells in the opposite direction by boosting SUMOylation with overexpression of Ubc9 
was unable to enhance Nav1.7 currents above those observed in CAD cells expressing 
wildtype CRMP2 (82.9 ± 14.5% of control) (Table 3.1), suggesting that Nav1.7 
regulation is provided by constitutive CRMP2 SUMOylation. 
Reduced current densities can result from several modifications to sodium 
channels including altered channel kinetics, reduced membrane expression, reduced open 
probability, or reduced single channel conductance. In any of these cases, the 
complement of channels are less able to pass current because they are less responsive to 
voltage stimuli or because there are a fewer number of the channels in the plasma 
membrane. Equivalence of fast inactivation and activation data between conditions 
contradicts the first possibility of altered kinetics. Therefore, next we performed cell 
surface biotinylation experiments to test the second possibility of reduced membrane 
expression. CAD cells expressing either wildtype CRMP2 or the SUMO-null CRMP2-
K374A alone or in the additional presence of the deSUMOylating enzymes SENP1 and 
SENP2 were subjected to cell surface biotinylation as described previously (Brittain et 
al., 2011a, Brittain et al., 2011b). Immunoblotting with Nav1.7 of streptavidin-enriched 
complexes from biotinylated CAD cells showed decreased Nav1.7 surface expression in 
cells expressing CRMP2-K374A versus wild type CRMP2 (Figure 3.5A, top blot, 
compare lanes 1 with 3). Surface Nav1.7 levels, normalized to total tubulin levels, in  
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Figure 3.3. CRMP2 lysine-374 controls sodium currents in CAD cells. (A) 
CRMP2 (Mus musculus, GenBankTM accession number NM_009955.3) 
sequences identified by Abgent SUMOplot™ as potential candidates for 
SUMOylation. Higher scores denote higher probability of SUMOylation. (B) 
Sequence analysis of identified putative motifs identify strong conservation of all 
motifs, and perfect conservation of K374A motif throughout all CRMPs. (C) 
Representative family of sodium current traces from CAD cells expressing the 
indicated CRMP2 alanine mutants. (D) Box plot of peak current density (pA/pF) 
measured at 0 mV from CAD cells transfected for the indicated CRMP2 
plasmids. Data are normalized to the CRMP2 condition. Boxes represent 
quartiles, each data point represents 1 cell. Error bars are behind data symbols in 
some cases. (E) Representative Boltzmann fits for activation and steady-state 
inactivation for CAD cells transfected with the indicated constructs are shown. 
The calculated values for V1/2 and k of activation and steady-state inactivation for 
all conditions tested and the associated statistics are presented in Table 3.1. 
Sodium current fast inactivation (left curves) and activation (right curves) were 
unaffected by knockdown expression of CRMP2 mutants. 5 cells per condition, 
data is presented mean ± SEM. Asterisk indicates statistically significant 
differences between CRMP2-K374A and all other conditions tested (n=5; p < 
0.05, one-way ANOVA with Tukey’s post-hoc test). 
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Condition 
 
Peak Current n          Activation Fast Inactivation 
V1/2        k n V1/2        k n 
CRMP2 100.0 ± 9.7 5 3.0 ± 1.3 10.8 ± 1.0 5 -64.4 ± 1.9 5.6 ± 0.7 5 
Untransfected 101.8 ± 17.9 6 2.9 ± 2.8 11.0 ± 1.2 5 -68.9 ± 1.1 5.6 ± 0.6 4 
siRNA-control 98.8 ± 14.9 6 3.4 ± 2.0 14.1 ± 1.7 5 -68.0 ± 1.3 6.2 ± 0.7 4 
siRNA-CRMP2 30.2 ± 7.8 * 7 -1.6 ± 3.2 13.4 ± 2.1 3 -71.4 ± 2.6 8.0 ± 1.4 3 
siRNA-CRMP2 + 
shresCRMP2 
87.4 ± 11.5 6 -1.4 ± 1.8 11.8 ± 1.2 5 -69.8 ± 1.3 6.9 ± 0,6 4 
shresCRMP2-K374A 42.9 ± 10.0 * 5 3.4 ± 1.4 10.5 ± 0.9 4 -63.7 ± 3.1 5.7 ± 0.9 3 
siRNA-CRMP2 + 
shresCRMP2-K374A 
34.1 ± 2.4 * 5 4.3 ± 1.1 10.8 ± 0.7 4 -67.5 ± 0.9 4.7 ± 1.1 3 
SENP1 + SENP2 36.9 ± 9.0 * 5 3.5 ± 1.6 10.4 ± 0.8 4 -65.5 ± 2.2 6.1 ± 1.4 3 
CRMP2-K20A 109.3 ± 16.5 5 2.2 ± 1.9 9.8 ± 0.9 3 -63.5 ± 0.6 5.6 ± 0.4 3 
CRMP2-K390A 93.4 ± 5.0 5 -0.1 ± 1.3 9.3 ± 0.9 3 -62.2 ± 2.0 6.7 ± 1.3 3 
Table 3.1. Comparative current densities and Boltzmann–fits of voltage–dependence of 
channel activation and fast-inactivation for the respective transfection conditions in 
CAD cells. Values for V1/2, the voltage of half–maximal activation and fast inactivation, and 
slope, were derived from Boltzmann distribution fits to the individual recordings and 
averaged to determine the mean and standard error of the mean (± S.E.M.). n values 
indicates the number of cells per condition. All transfection conditions contained EGFP or 
dsRed for identification of construct expression.  Asterisks represent statistically significant 
differences as compared to control (i.e. CRMP2 alone condition) within tested groups 
(p<0.05, ANOVA with Tukey’s post–hoc test or Student’s t–test).   
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Figure 3.4. Phylogenetic tree of species with perfectly conserved CRMP2 
SUMOylation motif and flanking residues. Created using ‘Interactive Tree of Life’ 
(iTOL2.0) software (Letunic and Bork, 2007, 2011), this tree lists the genus and species 
of a sample of organisms with perfectly homology for Mus musculus, (GenBankTM 
accession number NM_009955.3) SUMOylation motif and flanking residues (residues 
368-381 shown below tree, which includes the SUMOylated lysine 374 in bold). Species 
are listed at the end of tree ‘branches’ and generalized class or order classifications are 
listed within the lower ‘branches’ of the tree in brown text. Separation into different 
branches represents a divergent evolutionary relationship. Surrounding the tree is a 
sampling of species listed by their common names, matched by color of text. Blue color 
represents animals of the Class Aves (Birds). Due to the high number of birds identified 
to have homology within the CRMP2 sequence, only a select number are listed here. 
Orange represents Order Testudines (shelled reptiles) and green represents Order 
Squamata (scaled reptiles). Red represents class Mammalia which is subdivided by 
density of red color into subclasses and orders which are listed by their common names 
along lower tree ’branches’. No homology exists within the CRMP2 SUMOylation motif 
and CRMP proteins from Caenorhabditis elegans or Drosophila 
melanogaster. Homology appears to be limited to Chordata phylum animals that 
encompass all listed species. 
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Figure 3.5. CRMP2-K374A and increasing deSUMOylation reduces Nav1.7 
surface expression. (A) Cell–surface expression of Nav1.7 was monitored using a 
biotinylation assay.  CAD cells expressing wild type CRMP2 or CRMP2-K374A alone 
or in the presence of deSUMOylating proteases SENP1 and SENP2 were biotinylated, 
the cell-surface proteins were harvested from the cell lysates, and the precipitates were 
analyzed by immunoblotting with Nav1.7 (top 2 blots) and βIII-tubulin (bottom 2 blots) 
antibodies. Equal amounts of samples were used for the precipitation of biotinylated 
proteins.  Of these samples, the entire biotinylated fraction (surface) and 10% of the 
non-biotinylated (total) fraction were loaded.  CRMP2-K374A overexpression 
decreased the amount of Nav1.7 at the cell surface compared to CRMP2-transfected 
cells.  No change was observed in the total levels of Nav1.7 or tubulin. (B) Averaged 
Nav1.7 surface expression, normalized to total Nav1.7 and then to total tubulin. (C) 
VGSC surface expression monitored by biotinylation assay described in A. panNaV 
antibody was used to immunoblot lysates. (D) Averaged VGSC surface expression, 
normalized to total VGSC expression and then to total tubulin. Asterisks indicate 
statistically significant differences between CRMP2 and all other conditions tested (p < 
0.05, one-way ANOVA with Tukey’s post-hoc test). Experiments performed with help 
of Dr. Weina Ju. 
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CRMP2-K374A–expressing CAD cells were 15.1 ± 2.5% of those in cells expressing 
wild type CRMP2 (Figure 3.5A). 
Increasing deSUMOylation with the sentrin/SUMO-specific proteases SENP1 and 
SENP2 (Mukhopadhyay and Dasso, 2007), decreased levels of surface Nav1.7 to 14.2 ± 
3.9% of those in cells expressing wild type CRMP2 (Figure 3.5B). Under these 
conditions, surface Nav1.7 levels in CRMP2-K374A–expressing CAD cells were reduced 
to 7.9 ± 2.1% of those in cells expressing wild type CRMP2 (Figure 3.5B). Additional 
experiments with a panNav antibody also demonstrated a substantial reduction in surface 
expressed Nav channels in CAD cells expressing CRMP2-K374A (Figure 3.5C and D). 
These results are consistent with the reduction in Nav1.7 current density in CRMP2-
K374A–expressing CAD cells observed earlier. Thus, reduced CRMP2 SUMOylation 
likely accounts for Nav1.7 surface trafficking impairment.  
I next examined whether changes in CRMP2 SUMOylation could alter sodium 
currents in DRGs. Only whole-cell patch clamp electrophysiology experiments were used 
to test this as the low (~10–20%) transfection efficiencies precluded performing 
biotinylation experiments in DRGs. 
As before, sodium currents were electrically (post-hoc subtraction; protocols as shown in 
Figure 3.2) and pharmacologically (TTX, 500 nM) isolated into tetrodotoxin-sensitive 
and tetrodotoxin-resistant fractions. Small sensory neurons (< 30 µm) were chosen for 
these recordings. The time courses and current delay of estimated TTX-S and TTX-R 
currents perfectly resemble descriptions of these current types from the first study to 
electrically isolate these separate components of DRG sodium currents suggesting 
appropriate patch clamp technique and appropriate separation of currents (Roy and 
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Narahashi, 1992). As in this paper, TTX-S currents were fast activating and fast 
inactivating, with less than ~10% current remaining after 5 ms. It was not uncommon for 
~50% of TTX-R current to remain after the same duration. The fast activating, fast 
inactivating TTX-S sodium current fraction (Figure 3.6A) was isolated in DRGs 
electroporated with a CRMP2-K374A SUMO-null plasmid and currents were reduced by 
~74% compared to DRGs expressing wildtype CRMP2 (Figure 3.6A, C). Electroporating 
the SENP1 + SENP2 proteases to reduce SUMOylation decreased the TTX-S sodium 
current fraction by ~48% compared to DRGs expressing wildtype CRMP2 (Figure 3.6A, 
C). The slower activating and inactivating TTX-R sodium current fractions (Figure 3.6B) 
were not different between the conditions tested (Figure 3.6B, D). Contributions by 
Nav1.9 to total TTX-R current can be overshadowed by the predominance of Nav1.8 
current in these experiments. For this reason, we cannot rule out contribution by possibly 
altered Nav1.9 though. Nevertheless, effects on TTX-S current are sufficient to result in a 
net reduction of DRG sodium currens. This hypothesis was confirmed in a later 
experiment (see Figure 5.2). 
 
3.4. CRMP2 mediated VGSC current reductions are isoform specific 
 Reduction of TTX-S, but not TTX-R, currents in DRGs following loss of CRMP2 
SUMOylation suggests that CRMP2 modulation is Nav isoform specific. To address this 
possibility, HEK cells stably expressing isoforms hNav1.1 (King et al., 2012), rNav1.3 
(Cummins et al., 2001), hNav1.5 (Smith et al., 2007), and hNav1.7 (Theile and Cummins, 
2011a) (cells, not expressing additional beta subunits, provided by Dr. Theodore R. 
Cummins (Department of Pharmacology and Toxicology, Indiana University School of 
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Figure 3.6. CRMP2-K374A and increasing deSUMOylation reduces TTX-S, but 
not TTX-R, current density in DRG neurons. Representative TTX-S (A) and (B) 
TTX-R sodium current traces from small DRGs expressing CRMP2, CRMP2-K374A, 
or SENP1 + SENP2 proteases. Box plots of peak TTX-S (C) and (D) TTX-R current 
density (pA/pF) normalized to CRMP2 condition. Box plot borders represent SEM and 
median, square indicates mean, diamonds are individual data points. 7-8 cells per 
condition, error is ± SEM. Asterisks denote statistical significance compared to 
CRMP2 by one-way ANOVA, * p < 0.05.  
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Medicine)) were transfected with CRMP2 or CRMP2-K374A SUMO-null plasmids and 
currents were analyzed sodium channel biophysical properties including peak current 
density, fast inactivation, and activation. Ubc9 and SUMO1 were also cotransfected in 
these studies due to the low level of expression of these elements of the SUMOylation 
machinery as determined by quantitative RT-PCR (Dustrude et al., 2013). Of these four 
HEK-Nav1.X cell lines, only Nav1.7 displayed reduced current density (44.9 ± 10.6% 
with CRMP2-K374A compared to cells expressing wildtype CRMP2) (Figure 3.7). No 
changes in channel kinetics were observed for any cell line between the wildtype and 
SUMO-null CRMP2 conditions (Table 3.2).  
 TTX-S currents in small DRGs consist of contributions from Nav1.1, Nav1.6, and 
Nav1.7, with Nav1.7 being the predominant subtype (Zhang et al., 2013). Separation of 
these TTX-S channels by conopeptides have demonstrated that Nav1.7 produces ~80% of 
the TTX-S current in the subset of small diameter DRGs (Zhang et al., 2013). To test if 
CRMP2 regulation is specific to Nav1.7 or if it also can regulate Nav1.1 and Nav1.6, a 
TTX-S pre-pulse inhibition protocol was repeated in DRGs following block of Nav1.7 
with 5 nM ProTox-II. ProTox-II is 100X more selective for Nav1.7 versus other DRG 
expressed VGSC subtypes allowing for analysis of the cumulative contributions of 
Nav1.1 and Nav1.6 in the absence of Nav1.7 currents (Schmalhofer et al., 2008). These 
TTX-S/ProTox-II-R currents were unchanged by expression of CRMP2-K374A 
demonstrating that currents via Nav1.1 and Nav1.6 are not regulated by changes in 
putative CRMP2 SUMOylation, and that the observed reduction in total TTX-S current is 
solely due to Nav1.7 (Figure 3.8A, B). 
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Figure 3.7. Nav1.7, but not Nav1.1, Nav1.3, and Nav1.5, current density is affected by expression of the CRMP2-
K374A SUMO-null mutant. (A-D) Exemplar family of current traces from HEK293 cells stably expressing Nav1.1, Nav1.3, 
Nav1.5, or Nav1.7 transfected with either CRMP2 (black) or CRMP2-K374A (purple). (E-H) Averaged peak current 
densities (pA/pF). Only Nav1.7-expressing HEK293 cells exhibited a significant current reduction. (I-L) Representative 
Boltzmann fits for activation and steady-state inactivation for all cells transfected with the indicated constructs are shown. 
The calculated values for V1/2 and k of activation and steady-state inactivation for all conditions tested and the associated 
statistics are presented in Table 3.2.  Asterisk denotes statistical significance (n=6-8; Student’s t-test, * p < 0.05). 
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Condition Peak Current Activation     Inactivation 
  n V1/2                                     k n V1/2                                     k n 
Nav1.1     
CRMP2  100.0 ± 35.1 7 -15.5 ± 0.9 6.8 ± 0.4 7 -60.1 ± 1.9 6.2 ± 1.1 7 
CRMP2-K374A  93.2 ± 23.8 7 -15.4 ± 1.8 6.2 ± 1.0 7 -63.7 ± 3.5 5.0 ± 2.1 7 
Nav1.3         
CRMP2  100.0 ± 14.2 6 -22.6 ± 3.2 4.1 ± 0.8 6 -54.1 ± 1.8 5.0 ± 0.9 6 
CRMP2-K374A  90.7 ± 21.1 6 -25.0 ± 0.6 3.7 ± 0.2 5 -56.9 ± 1.0 6.0 ± 0.6 5 
Nav1.5         
CRMP2  100.0 ± 14.2 5 -32.5 ± 0.4 5.5 ± 0.2 5 -76.9 ± 1.6 4.4 ± 0.6 5 
CRMP2-K374A  106.3 ± 22.5 6 -34.4 ± 0.6 5.1 ± 0.3 4 -75.1 ± 0.5 5.2 ± 0.3 6 
Nav1.7         
CRMP2  100.0 ± 14.1 7 -15.9 ± 0.7 7.7 ± 0.9 7 -64.6 ± 3.5 5.9 ± 1.8 7 
CRMP2-K374A  44.9 ± 10.6 * 5 -15.2 ± 1.1 6.4 ± 0.3 5 -60.6 ± 2.7 4.8 ± 2.0 5 
Table 3.2. Comparative current densities and Boltzmann parameters of voltage–
dependence of channel activation and fast–inactivation for the respective 
transfection conditions in HEK293 cells expressing Nav1.1, Nav1.3, Nav1.5, or 
Nav1.7 channels. Values for V1/2, the voltage of half–maximal activation and fast 
inactivation, and slope, were derived from Boltzmann distribution fits to the individual 
recordings and averaged to determine the mean and standard error of the mean (± 
S.E.M.). n values are indicated.  All transfection conditions had SUMO1 and Ubc9 to 
boost endogenous SUMOylation. Asterisks represent statistically significant differences 
as compared to control (i.e. CRMP2 condition) within each tested group (p<0.05, 
ANOVA with Tukey’s post–hoc test). 
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Figure 3.8. CRMP2 regulation of DRG TTX-S currents does not involve Nav1.1 
or Nav1.6. (A) Representative peak TTX-S current traces at 0 mV from small DRGs 
expressing CRMP2 or CRMP2-K374A following 5 nM ProTox-II treatment. (B) 
Summary box plot showing peak sodium current in each condition. There was no 
difference in peak current density in DRG neurons expressing CRMP2-K374A 
compared to those expressing wild type CRMP2 (p < 0.05, Student’s t-test). Boxes 
represent quartiles, each data point represents 1 cell. Error bars are behind data 
symbols in some cases. Normalized mean current densities were equivalent meaning 
remaining current carried by Nav1.1 and Nav1.6 is unaffected by loss of CRMP2 
SUMOylation. 11 cells per condition, error is ± SEM. Asterisks denote statistical 
significance Student’s t-test, * p < 0.05. 
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3.5. CRMP2 is SUMOylated and this modification controls its interaction with Nav1.7 
 To directly test if CRMP2 is endogenously SUMOylated, a protocol for detecting 
SUMOylated proteins was implemented (Becker et al., 2013). There is no antibody that 
selectively recognizes SUMOylated CRMP2. Moreover, SUMOylated species are lost 
upon cell lysis in nondenaturing buffers, owing to highly active SUMO isopeptidases. 
Therefore, in order to detect SUMOylated CRMP2 but not CRMP2 that may bind to 
SUMO, the following experiment was performed by Dr. Aubin Moutal, a post-doctoral 
fellow in the Khanna laboratory. First, CAD cell lysates were prepared in a denaturing 
lysis buffer containing 1% SDS and 10 mM N-ethylmaleimide, then heat denatured to 
completely unfold and disrupt protein complexes (i.e. non-covalent interactions) and to 
inactivate SUMO isopeptidases (Xiao et al., 2015), respectively, and then performed an 
immunoprecipitation (IP; Figure 3.9A) with a SUMO1 antibody followed by 
immunoblotting with a CRMP2 antibody to detect SUMOylated CRMP2. As shown in 
Figure 3.9A, SUMOylation of wildtype, but not K374A, CRMP2 was detected (Figure 
3.8B; the ~100 kDa representing SUMOylated dsRed-CRMP2). The loss of 
SUMOylation translated into a reduction in the relative binding between Nav1.7 and 
CRMP2 (Figure 3.9D, E). CRMP2-Nav1.7 interaction is demonstrated by CRMP2 IP. 
Altering one protein partner and observing an altered interaction is further evidence that 
proteins are likely directly interacting as was observed for the CRMP2-Nav1.7 interaction 
when CRMP2 SUMOylation was prevented by expression of CRMP2-SUMO-null 
mutant. In addition, these proteins are both available in the same sub-cellular fractions 
meaning that experimental conditions of cell lysis does not mix separated compartments 
that individually contain Nav1.7 and CRMP2. Therefore, no artificial interaction is 
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created to cloud interpretation of the CRMP2 IP results. Lastly, functional data showing 
regulation of Nav1.7 by alterations of CRMP2 expression and post-translational 
modifications support my finding of CRMP2-Nav1.7 interaction in protein complex. 
Thus, these data establish that (i) endogenous CRMP2 is SUMOylated,(ii) CRMP2 
interacts with Nav1.7, and (iii) SUMO-null CRMP2 has a reduced propensity for 
interaction with Nav1.7.  
 
3.6. CRMP2 SUMOylation does not alter CRMP2-mediated enhancement of neurite 
outgrowth 
 The Khanna laboratory and others have previously shown that CRMP2 expression 
specifies axonal ramification and dendritic complexity of neurons (Inagaki et al., 2001a, 
Wilson et al., 2012). To test whether mutation of a putative SUMOylation motif affects 
this canonical function of CRMP2, we tested axonal outgrowth in DIV6 cortical neurons 
or DIV2 DRGs expressing EGFP, CRMP2-K374A or wild type CRMP2. EGFP co-
expression was used to identify transfected cells for analyses. Cortical neurons were used 
due to their extensive past use in studies of CRMP2-mediated outgrowth and DRGs were 
used for their relevance to my thesis work investigating the role of CRMP2 in trafficking 
of Nav1.7. Moreover, testing the effect in cortical cells would rule out any cell-specific 
regulation by SUMO-null CRMP2. Compared to EGFP-expressing neurons, both wild 
type CRMP2 and CRMP2-K374A increased the number of processes per neuron, the 
number of branches per neuron, the mean and maximum process lengths, and overall 
total outgrowth (Figure 3.10A, B).  
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Figure 3.9. Blunted SUMOylation of K374A CRMP2 and binding of the 
mutant to NaV1.7. (A) Schematic of denaturing IP. (B, C) Loss of CRMP2 
SUMOylation at K374 reduces SUMO-bound CRMP2 compared to control. (D, E) 
Loss of CRMP2 SUMOylation at K374 reduces CRMP2’s interaction with Nav1.7. 
*, p < 0.05 vs. wildtype Student’s t-test (n=3). Experiment performed by Dr. Aubin 
Moutal. 
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On average, the processes per neuron were increased by 21% and 29% for 
CRMP2 (n=538) and CRMP2-K374A (n=669), respectively, compared to EGFP 
expressing neurons (4.6 ± 0.1, n=682, p<0.05). Branches per neuron were increased by 
134% and 90% for CRMP2 and CRMP2-K374A, respectively, compared to EGFP 
expressing neurons (25.7 ± 1.1, n=682, p<0.05). The mean and maximum process lengths 
per neuron were increased by 75% and 120% for CRMP2 and 18% and 76% for CRMP2-
K374A, respectively, compared to EGFP expressing neurons (191.6 ± 7.9, n=682, p<0.05 
and 613.1 ± 28.8, n=682, p<0.05). Finally, overall total outgrowth – a sum of all the 
above parameters – was 113% and 74% greater in CRMP2 (n=538)- and CRMP2-K374A 
(n=669)-, respectively, expressing neurons compared to EGFP expressing neurons 
(Figure 3.10B). Collectively, these results suggest that replacement of CRMP2’s lysine 
(residue 374) or all three residues within the putative SUMO motif (data not shown) 
maintains CRMP2-mediated axonal specification and dendritic complexity implying that 
the mutant protein is functional. Similar results were observed in DRGs with total 
outgrowth being unaffected by the SUMO-null CRMP2 K374A mutant (Figure 3.10C, 
D). These data support the conclusion that CRMP2-mediated neurite outgrowth is not 
dependent on its SUMOylation or on the cell type. 
 
3.7. CRMP2 SUMOylation does not alter the pharmacological action of (R)-LCM on 
VGSC slow inactivation 
 The FDA approved clinical drug Vimpat® ((R)-LCM) stabilizes Navs in a slow-
inactivated state (Errington et al., 2006, Errington et al., 2008, Sheets et al., 2008). 
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Figure 3.10. CRMP2 SUMOylation does not alter CRMP2-mediated outgrowth of cortical or DRG neurons. (A) 
Representative inverted black and white image (left) and computer tracing (right) of a cortical neuron at 4X magnification, scale 
bar is 200 µm. (B) Average number of processes, branches, mean and maximum length of processes, and summary outgrowth of 
cortical cells expressing EGFP, CRMP2, or CRMP2-K374A. (C) An example image showing the overlay of EGFP fluorescence 
(green), nuclear staining with Hoechst (blue) together with the brightfield Hoffman image of transfected DRG neurons.  Scale bar 
equals 50 µm and applies to both panels.  Note the similar degree of neurite complexity between the wild type and mutant 
CRMP2 conditions. * represents statistical significance versus EGFP (ANOVA), # represents statistical significance between 
CRMP2 plasmids (ANOVA) (D) Number of processes and branches, mean and maximum (max.) process length, and normalized 
total outgrowth for cells co-expressing EGFP and CRMP2 (n=54 from 4 wells), or co-expressing EGFP and CRMP2-K374A 
(n=72 from 4 wells). There were no statistical differences for any of the parameters between the two conditions (p > 0.05, 
Student’s t-test). Experiment performed by Dr. Sarah Wilson, a former member of the Khanna laboratory. 
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The Khanna laboratory had previously shown that mutating a LCM-coordinating pocket 
within CRMP2 reduced LCM-dependent enhancement of slow inactivation (Wang et al., 
2010a). How this CRMP2 mutation changes LCM’s efficacy towards the sodium channel 
is unknown. Having established SUMOylation of CRMP2 as a novel post-translational 
modification affecting Nav1.7 channel trafficking and current density, here I tested 
whether SUMOylation of CRMP2 modifies LCM-induced enhancement of slow 
inactivation. Using the whole cell patch clamp configuration, I analyzed the effects of 
LCM on CAD cell VGSCs in the presence of overexpressed wildtype CRMP2 or SUMO-
null CRMP2-K374A. The E2-conjugating enzyme Ubc9, which adds SUMOs 1–3 
(Wilkinson et al., 2008), and SUMO2 were also expressed; SUMO2 was transfected as 
preliminary studies revealed no differences between any of the SUMOs on VGSC current 
densities. Transfected CAD cells were conditioned to potentials ranging from –110 mV 
to +20 mV (in +10 mV increments) for 5 s, and then fast-inactivated channels were 
allowed to recover for 150 ms at a hyperpolarized pulse to –120 mV, and the fraction of 
channels available was tested by a single depolarizing pulse, to 0 mV, for 15 ms (Figure 
3.11). 
Addition of 100 μM LCM to cells expressing wild type CRMP2 or CRMP2-
K374A significantly decreased the fraction of current available compared to those in the 
absence of LCM. For comparison, representative current traces at –50 mV are highlighted 
(Figure 3.11B and C). At this potential, the channels are predominantly undergoing slow-
inactivation, as it is near the action potential threshold (Wang et al., 2010a, Wang et al., 
2011b).   
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Figure 3.11. CRMP2 SUMOylation does not alter VGSC slow inactivation or 
response to (R)-LCM.  (A) Voltage protocol for slow inactivation: currents were 
evoked by 5-s prepulses between −120 and +20 mV and then allowed to recover 
from fast inactivation for 150 ms at −120 mV. The fraction of available current 
was analyzed by a 15-ms test pulse to 0 mV. Cells were treated for 10 min with 
either 100 μM LCM or vehicle, 0.1% DMSO prior to whole cell patch clamp 
analysis. (B) Representative current traces from CAD cells expressing CRMP2 
with Ubc9 and SUMO2 in the absence (control, 0.1% DMSO, left) or (C) 
presence of 100 μM LCM (+LCM, right). To highlight the extent of slow 
inactivation, the maximum elicited current (prepulse to −110 mV) is compared 
with the trace elicited by a prepulse to −50 mV (D) Summary of steady-state slow 
inactivation curves for CAD cells expressing both Ubc9 and SUMO2 and either 
CRMP2 (squares) or CRMP2-K374A (diamonds) in the absence (open symbols) 
or presence (closed symbols) of 100 µM LCM.  Some error bars are smaller than 
symbols. All data are represented as means ± SEM. (e) Summary of the fraction 
of available current at −50 mV for the same conditions presented in B. Asterisks 
indicate statistically significant differences in fraction between LCM-treated and 
untreated CAD cells expressing the indicated constructs (p < 0.05, one-way 
ANOVA with Tukey’s post-hoc test) n=5-6 cells per condition. 
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The slow inactivation versus voltage curves for the transfected cells in the 
absence and presence of 100 µM LCM are plotted in Figure 3.11D and illustrate a 
marked reduction in current available (i.e. an enhancement in slow inactivation) in the 
presence of drug that was not different between the conditions tested (p>0.05; ANOVA 
with Tukey’s post-hoc test). At -50 mV, ~48% (n=8) (calculated as 1 minus the 
normalized INa) of the Na+ current was available in LCM-treated CRMP2-expressing 
cells compared to 43% in CRMP2-K374A-expressing cells (Figure 3.11E; p>0.05; 
ANOVA with Tukey’s post-hoc test). These results demonstrate that disruption of the 
SUMOylation site in CRMP2 does not affect the pharmacological action of LCM-
induced enhancement of sodium channel slow inactivation.   
 
3.8. Discussion 
 Accumulating evidence indicates that the CRMP2 functional proteome is far 
greater than previously appreciated (Khanna et al., 2012). It is also becoming evident that 
post-translational modifications, in particular phosphorylation, can influence CRMP2’s 
interactions and in doing so recruit its involvement in different signaling pathways (Ju et 
al., 2013). In this chapter, I describe a novel modification for CRMP2, SUMOylation, 
which can alter the trafficking of Nav1.7 (Figure 3.5). The functional regulation of 
CRMP2 by SUMOylation was studied by (i) creating constructs in which the consensus 
lysine in the SUMOylation motif was mutated to alanine, and (ii) by manipulating 
expression of the SUMOylation machinery with (a) overexpression of Ubc9 and SUMOs 
to boost SUMOylation and (b) overexpression of SENP1 and SENP2 to decrease 
SUMOylation.  
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Although putative SUMO motifs are typically investigated by mutating the target 
lysine to arginine (Duprez et al., 1999, Sampson et al., 2001, Perdomo et al., 2005, 
Feliciangeli et al., 2007, Zhu et al., 2008, Merrill et al., 2010), this is not always the case. 
For instance, mutation of the SUMO target lysine in the potassium leak channel K2P1 to 
an arginine had no effect on channel activity, whereas an alanine mutation increased 
activity consistent with an increase observed in the presence of SENP1 (Rajan et al., 
2005). For this reason as well as the fact that alanine residues have been the preferred 
choice in demonstrating SUMOylation of several proteins including Ran GTPase 
activating protein 1 (Sampson et al., 2001), acute promyelocytic leukaemia protein 
(Duprez et al., 1999), the polycomb protein Pc2/Cbx4 (Merrill et al., 2010), and basic 
Kruppel-like factor/Kruppel-like factor 3 (BKLF) – a zinc finger transcription factor 
(Perdomo et al., 2005), I chose to mutate the CRMP2 SUMO target lysine residues to 
alanine to study CRMP2 SUMOylation in this thesis.  
While interrogating the potential effects of CRMP2 SUMO mutants on VGSCs, I 
noticed a clear reduction in macroscopic sodium currents in CAD cells expressing 
CRMP2-K374A, but not CRMP2-K20A, or CRMP2K390A (Figure 3.3). CAD cells 
express mRNAs for Nav1.7 (>90% of total Nav mRNA), Nav1.1 and Nav1.3 (Wang et 
al., 2011b), and treatment with 125 nM huwentoxin-IV confirmed that ~80% of the CAD 
cell sodium current was carried via Nav1.7. This current was dramatically reduced by 
expression of CRMP2 SUMO-null mutant in CAD cells as well as expression of 
deSUMOylating enzymes, SUMO/sentrin-specific peptidases (SENP) 1 or SENP2, 
suggesting a contribution for SUMOylation of CRMP2 in trafficking of Nav1.7 (Table 
3.1). Cell surface biotinylation under the same conditions revealed reduced Nav1.7 
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surface expression, corroborating the reduction in current density (Figure 3.5), and 
suggesting that CRMP2 SUMOylation reduces current density likely via reduced 
trafficking similar to what has been reported for the kainate receptor subunit GluR6 
wherein SUMOylation facilitates endocytosis of this receptor (Martin et al., 2007b). 
Therefore, by genetic or enzymatic manipulation, the removal of CRMP2 SUMOylation 
leads to reduced Nav1.7 current (Table 3.1). Co-expression of deSUMOylating enzymes 
SENP1 or SENP2 did not further reduce Nav1.7 current densities in CAD cells 
expressing CRMP2 SUMO mutants, suggesting that the mutants may serve in a dominant 
negative manner for Nav1.7 trafficking. Biochemical studies supported the above 
findings by demonstrating a previously unreported interaction between CRMP2 and 
Nav1.7 (Figure 3.9D and E) and this novel binding is blunted by prevention of CRMP2 
SUMOylation at lysine-374 (Figure 3.9B and C). 
The Nav1.7 isoform is preferentially expressed in the peripheral nervous system 
within ganglia related to nociceptive pain, including dorsal root ganglia, trigeminal 
ganglia and sympathetic ganglia. In nociceptive neurons responsible for the transduction 
of pain signals, the channel modulates current threshold required to fire action potentials 
in response to stimuli (Momin and Wood, 2008, Estacion et al., 2011). Gain-of-function 
mutations, i.e. those that lower Nav1.7 current threshold for initiation of action potentials, 
produce allodynia – a lowered stimulus threshold for pain. Such mutations are the cause 
of pain syndromes including erythromelalgia, paroxysmal extreme pain disorder, and 
small fiber neuropathy (Estacion et al., 2011). A loss-of-function mutation of Nav1.7 can 
cause equally detrimental modifications in pain sensation, where stimuli never reach 
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threshold to propagate pain. Patients with such mutations display a complete loss of pain 
sensation (Cox et al., 2006).  
Of the tetrodotoxin-sensitive voltage-gated sodium channels present in the 
nervous system, only Nav1.7 lacks a putative SUMOylation motif (Benson et al., 2009). 
Thus any modification of the channel by SUMOylation may be due to indirect 
modification of accessory proteins, such as CRMP2 demonstrated in this study. 
Importantly, only 60% of SUMOylated proteins conform to the SUMOylation consensus 
sequence meaning that we cannot rule out the possibility of Nav1.7 SUMOylation by 
sequence analysis alone (Ulrich, 2009). However, by modification of only CRMP2 
expression or SUMOylation, this channel is affected in the absence of regulating total 
cellular SUMOylation. This demonstrates that changes to Nav1.7 current density in my 
data are due solely to modifications of CRMP2. Mechanisms that specifically or 
preferentially regulate Nav1.7 are of particular relevance due to the role of Nav1.7 in 
transduction of peripheral pain. Separation of TTX-S and TTX-R currents in small DRGs 
revealed that reduction of TTX-S current density, but not TTX-R current density was 
mediated by expression of CRMP2-K374A or deSUMOylating SENP proteins (Figure 
3.6). I therefore conclude that TTX-R channel total current density is not subject to 
regulation by CRMP2. To test if CRMP2 regulation is specific to Nav1.7 or if it also 
includes other DRG expressed TTX-S isoforms Nav1.1 and Nav1.6, TTX-S currents 
were isolated following incubation with 5 nM ProTox-II, a Nav1.7-selective toxin with 
100X greater specificity for Nav1.7 than Nav1.1 or Nav1.6 (Schmalhofer et al., 2008) 
The cumulative contributions by Nav1.1 and Nav1.6 currents were unchanged by 
expression of CRMP2-K374A demonstrating that currents via Nav1.1 and Nav1.6 are not 
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regulated by changes in CRMP2 SUMOylation, and that the observed reduction in total 
TTX-S current is entirely due to Nav1.7 (Figure 3.8A, B). 
While Nav1.7 is the predominant voltage-gated sodium channel isoform found in CAD 
cells, mRNA expression data suggest a secondary contribution by the Nav1.1 isoform 
(Wang et al., 2011b). Remarkably, in stark contrast to Nav1.7, HEK293 expressed 
Nav1.1 current density is not affected by expression of CRMP2-K374A, reinforcing that 
CRMP2 SUMOylation-dependent modulation of sodium current density may be specific 
to particular sodium channel isoforms (Figure 3.7, Table 3.2). Additional experiments 
also revealed that Nav1.3 and Nav1.5 currents measured in HEK293 cells display lack of 
regulation by CRMP2 SUMOylation (Figure 3.7, Table 3.2). Based on this data from 
HEK293 cells and also data from DRGs, I conclude that CRMP2 SUMOylation 
preferentially regulates Nav1.7 VGSC subtype trafficking. 
In a study of CRMP2 functions not related to Nav1.7 current density, I analyzed 
both CRMP2-mediated regulation of neurite outgrowth, as well as CRMP2-mediated 
enhancement of sodium channel slow inactivated state for effects of CRMP2 
SUMOylation. Regulation of axonal specification and dendrite complexity is the 
canonical function of CRMP2 (Arimura et al., 2000a, Inagaki et al., 2001a). In analysis of 
cortical neuron outgrowth, CRMP2-K374A mutant produced functional proteins as 
assessed by propensities to increase outgrowth relative to EGFP-transfected neurons. 
  
 109 
  
  
Figure 3.12. Model of CRMP2 SUMOylation and Nav1.7 trafficking. (1) Nav1.7 
current density is not affected by co-expression of wild type CRMP2 (PDB code: 
2GSE (Deo et al., 2004)), with an intact SUMOylation motif (illustrated in yellow 
spheres). (2) SUMO-1 (PDB code: 1A5R (Bayer et al., 1998), dark blue) can be 
added by the E2-conjugating enzyme Ubc9 to CRMP2 at lysine K374. (3) Removal 
of SUMO by sentrin/SUMO-specific protease (SENP) 1 or SENP2 reduces Nav1.7 
current density via a reduction in surface expression. (4) Nav1.7 current density is 
significantly reduced by co-expression of CRMP2-K374A (CRMP2 structure in red 
without yellow spheres). (5) Surface expression of Nav1.7 is reduced in CAD cells 
expressing CRMP2-K374A mutant. (6) Mutant CRMP2 without an intact SUMO 
motif cannot be SUMOylated. (7) When compared to EGFP-transfected neurons, (8-
9), neurite outgrowth facilitated by CRMP2 is not affected by disruption of 
SUMOylation motif. (10) Nav1.1 currents, which represent the second largest 
fraction of sodium currents in CAD cells, are not affected by co-expression of 
CRMP2-K374A mutant, suggesting selectivity in the mechanism by which SUMO 
regulates Navs. (11) Sodium channel slow inactivation, which is enhanced by the 
anti-epileptic drug Lacosamide (LCM; green stick model) is not affected by 
expression of either CRMP2 SUMOylation incompetent mutants. Exemplar traces at 
-50 mV are shown to illustrate extent of slow inactivation. 
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That augmented neurite outgrowth was recapitulated to near wild type CRMP2 
levels suggested that the mutant CRMP2 proteins are neither misfolded nor unable to 
oligomerize despite the placement of the SUMO target lysine 374 within the 
oligomerization domain (amino acids 8-134 and 281-435) of CRMPs (Wang and 
Strittmatter, 1997c). A regulation of VGSC slow inactivation by CRMP2 was observed 
when treating CAD cells with the antiepileptic, VGSC blocking, VGSC slow inactivation 
enhancing drug (R)-lacosamide (LCM). LCM has primary action on sodium channels but 
also binds to CRMP2 (Wilson and Khanna, 2014, Wilson et al., 2014, Moutal et al., 
2015). Blocking LCM binding to CRMP2 blunts VGSC slow inactivation by ~80% so I 
tested whether this function of CRMP2-LCM binding was affected by SUMOylation by 
probing VGSC slow inactivation (Wang et al., 2010a). Cells expressing CRMP2 and 
CRMP2-K374A mutant displayed equivalent VGSC slow inactivation in both the 
absence and presence of LCM (Figure 3.11C). Therefore I concluded that CRMP2 
SUMOylation therefore has no effect on VGSC slow inactivation. In other experiments 
the kinetic properties of fast inactivation and activation were probed, for which CRMP2-
K374A also had no effect (Table 3.1). This is in contrast to the fine-tuning of channel 
function reported for potassium channels Kv1.5 (Benson et al., 2007) and Kv2.1 (Plant et 
al., 2011): loss of Kv1.5 SUMOylation, by either disruption of the conjugation sites or 
expression of the SUMO protease SENP2, lead to a selective ~15 mV hyperpolarizing 
shift in the voltage-dependence of steady-state inactivation (Benson et al., 2007) while 
SUMOylation of Kv2.1 in hippocampal neurons was shown to regulate firing by shifting 
the half-maximal activation voltage of channels up to 35 mV (Plant et al., 2011). 
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The trafficking of VGSCs has not been extensively investigated. Two examples of 
proteins that alter Nav1.X trafficking are Alzheimer's disease-related secretases beta-site 
amyloid precursor protein cleaving enzyme 1 BACE1 and presenilin (PS)/γ-secretase 
which are involved in trafficking on Nav1s via cleavage of auxiliary subunits from the 
channel complex (Kim et al., 2005, Kim et al., 2007). Other studies have shown that 
Nav1.1 mutants in familial epilepsy are trafficking defective and their function can be 
restored by incubation at low temperatures (<30°C), as well as through interactions with 
modulatory proteins or drugs (Rusconi et al., 2007). There is at least one report linking 
microtubule dynamics in the trafficking of cardiac Nav1.5 (Casini et al., 2010). For 
trafficking mechanisms that are specific to Nav1.7 subtype, very little is currently known. 
In neurons, Nav1.7 undergoes trafficking guidance by sodium channel beta 2 (β2) 
subunits, which promote surface expression of Nav1.7 via interactions with cell adhesion 
molecules and the cytoskeletal protein ankyrin (Malhotra et al., 2000, Lopez-Santiago et 
al., 2006). The β2 subunit expression is upregulated in sensory neurons in models of 
neuropathic pain and hypothesized to contribute to pain behavior by enhancing DRG 
excitability (Pertin et al., 2005). Increased surface expression of Nav1.7 can also be 
introduced by enhanced channel transcription that has been associated with pain resulting 
from diabetic neuropathy (Hong et al., 2004), and inflammation (Black et al., 2004). 
Endocytosis of Nav1.7 also mediates channel surface expression. This regulatory 
mechanism involves monoubiquitination of the channel by E3 ubiqutin ligase Nedd4-2 to 
target the channel for endocytosis. This process of Nedd4-2 activity and Nav1.7 
endocytosis is interrupted following spared nerve injury model to produce Nav1.7-driven 
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pain states that result from dysregulated channel surface trafficking (Laedermann et al., 
2013a).  
The results from this chapter of my thesis advance the field of Nav1.7 trafficking 
by describing a novel regulatory pathway for Nav1.7 via post-translational modification 
(SUMOylation) of a cytosolic interacting protein (CRMP2). CRMP2 SUMOylation at 
lysine-374 was demonstrated by a denaturing SUMO1 immunopreciptation that detected 
endogenously SUMOylated CRMP2 in CAD cells (Figure 3.9A and B). Cell surface 
biotinylation data from CAD cells (Figure 3.5) as well as Nav1.7 currents from CAD 
cells (Figure 3.3) and DRGs (Figure 3.6) revealed a decrease in Nav1.7 function when 
CRMP2 is unSUMOylated. These relationships between CRMP2 and Nav1.7 along with 
other results from Chapter 3 are summarized in Figure 3.12. Remarkably, data separating 
current contributions in DRG neurons as well as from HEK293 cells expressing single 
VGSC subtypes demonstrated that VGSC modification by CRMP2 is likely limited to 
Nav1.7. This specificity in control of Nav1.7 is an exciting finding that should spur future 
studies targeting this novel pair of proteins. Given the unequivocal link between pain and 
Nav1.7, these channels have emerged as an attractive target for drug discovery and this 
chapter elucidates a novel pathway by which these channels can possibly be regulated. 
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CHAPTER 4.  
 
INTERPLAY BETWEEN CDK5/FYN PHOSPHORYLATION AND 
SUMOYLATION OF CRMP2 DETERMINES NaV1.7 CHANNEL 
TRAFFICKING VIA A NUMB/EPS15 ENDOCYTIC PATHWAY   
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4.1. Introduction 
 Although the mechanisms that modulate SUMOylation remain largely unknown, 
protein phosphorylation has been reported to either enhance or inhibit SUMOylation, 
depending on the substrate protein. For example, for the kainate receptor (KAR) subunit 
GluK2, protein kinase C–mediated phosphorylation of GluK2 at serine 868 promotes 
GluK2 SUMOylation at lysine 886 and both of these events are necessary for the 
internalization of GluK2-containing KARs that occurs during long-term depression of 
KAR-mediated synaptic transmission at rat hippocampal mossy fiber synapses 
(Konopacki et al., 2011). It is now apparent that for many SUMOylated proteins, there is 
a dynamic crosstalk between protein SUMOylation and phosphorylation (see a limited set 
of examples in Table 1.3). Either of these modifications can enhance or prevent the other 
in a substrate-specific manner (reviewed in (Henley et al., 2014)).  
Many functions of CRMP2 are subject to modification following phosphorylation 
of the protein (Khanna et al., 2012); but whether Nav1.7 trafficking and activity are 
controlled by phosphorylation are unknown and are primary questions of this chapter. In 
addition, if CRMP2 phosphorylation is determined to be important for Nav1.7 activity, 
then a secondary question of this Chapter is to determine the nature of the interplay 
between the modifications in possible control of Nav1.7 activity. Put another way, which 
modification is dominant over the other? The activity-regulated cytoskeleton-associated 
(Arc) protein is an example of a SUMOylated protein that can regulate trafficking of a 
membrane protein, the AMPA receptor, by altering interaction of the receptor with 
endocytic machinery (Chowdhury et al., 2006, Craig and Henley, 2012, Craig et al., 
2012). CRMP2 may resemble the Arc protein as my data so far demonstrates that the 
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SUMOylation status of CRMP2 allows it to control trafficking of Nav1.7, perhaps via 
recruitment of proteins that aid in internalization of the channel. Therefore, the 
relationship between CRMP2 SUMOylation and phosphorylation as well as the 
relationship between CRMP2 SUMOylation and endocytic machinery will be additional 
questions addressed in this Chapter. 
As stated earlier in the Introductory Chapter of this thesis, CRMP2 is extensively 
C-terminally phosphorylated at five residues (threonine-509, threonine-514, serine-518, 
serine-522, and threonine-555) by four different kinases (GSK3β, Cdk5, RhoK, 
CaMKII). In addition, CRMP2 is also phosphorylated at least two other upstream 
phosphorylation sites (Y32 by Fyn, Y479 by Yes). The previous Chapter identified 
CRMP2 as a novel SUMO substrate, however, how CRMP2 SUMOylation is regulated is 
incompletely understood. One possibility is that CRMP2 phosphorylation affects CRMP2 
SUMOylation. To ascertain whether CRMP2 phosphorylation and CRMP2 SUMOylation 
are interdependent, dsRed-CRMP2 constructs were created wherein phosphorylation and 
SUMOylation resides were selectively mutated and the effects of these constructs on 
sodium channels were investigated. Both single phospho-null mutants as well as double 
phospho-null/SUMO-null mutants were produced to eliminate targeting by each kinase 
(Figure 4.1A). Additional studies, in some cases, also involved use of overexpression of 
the kinases themselves or of phospho-mimetic CRMP2 mutations – both manipulations 
designed to act as a gain of phosphorylation.  
Previous reports describe CRMP2 as a trafficking protein that may provide 
insights as to how CRMP2 regulates Nav1.7. CRMP2 has been reported to function as a 
membrane trafficking protein for the adhesion molecule L1-CAM (L1-cell adhesion 
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molecule) in a process that also requires CRMP2 to interact with the endocytic adaptor 
protein Numb (Nishimura et al., 2003a). Numb protein scaffolds further interactions with 
endocytic machinery including proteins involved in clathrin-mediated endocytosis 
(Santolini et al., 2000). Numb’s interaction(s) with E3 ubiqutin ligases allow the ligase to 
monoubiqutinate proteins, which can then become endocytosed. This process involves 
epidermal growth factor receptor substrate 15 endocytic adapter protein (Eps15) protein 
binding the monoubiquitylated membrane cargo to induce membrane curvature in the 
initiating steps of clathrin-mediated endocytosis (Santolini et al., 2000, Woelk et al., 
2006, Horvath et al., 2007). A recent study reported that removal of Nav1.7 channel 
protein from the cell membrane was under control of monoubiqutination of the channel 
by the E3 ubqiutin ligase Nedd4-2 (Laedermann et al., 2013a). However, other than this 
publication and one from 2004 on Nav1.7 regulation by Nedd4-2 in oocytes (Fotia et al., 
2004), nothing else linking Nav1.7 to the endocytic pathway or CRMP2 has been 
reported. 
 
4.2. CRMP2 SUMOylation does not alter CRMP2 phosphorylation or total Nav1.7 
expression 
 SUMO1 immunoprecipitation (Figure 3.9) revealed endogenous SUMOylation of 
CRMP2 at lysine-374. To determine if loss of CRMP2 SUMOylation affected CRMP2 
phosphorylation, lysates from CAD cells expressing wildtype CRMP2 and SUMO-null 
CRMP2-K374A were probed with phospho-specific CRMP2 antibodies and quantified 
(Figure 4.1 B-D). For all commercially available phospho-specific CRMP2 antibodies – 
Fyn (pY32), Yes (pY479), GSK3β (pT509/T514), or Cdk5 (pS522) – no changes in 
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CRMP2 phosphorylation were observed when SUMOylation was blunted (Figure 4.1D). 
From this data, I conclude that CRMP2 SUMOylation does not regulate CRMP2 
phosphorylation. Consistent with previous biotinylation experiments presented in this 
thesis, total Nav1.7 protein expression was unchanged by loss of lysine-374 
SUMOylation. Taken together, these data demonstrate that deSUMOylated CRMP2-
dependent loss of Nav1.7 surface expression does not involve reduced translation of the 
channel (Figure 4.1C). 
 
4.3. CRMP2 phosphorylation mediates effects on Nav1.7 
 CRMP2 is extensively post-translationally modified by phosphorylation by Fyn, 
Yes, GSK3β, Cdk5, and RhoK kinases (Figure 4.2A). To test the possibility that CRMP2 
phosphorylation, in addition to SUMOylation, may regulate Nav1.7, I asked if loss of 
phosphorylation alone or in combination with SUMOylation could affect Nav1.7 
currents. CAD cells were transfected with CRMP2 phospho-null mutants (i.e. Y32F, 
Y479F, S509A/514A, S522A, and S555A), CRMP2-K374 SUMO-null mutant, or 
mutants that combined both phospho- and SUMO-null mutants. Compared to CAD cells 
expressing wildtype CRMP2, Nav1.7 current density was reduced by ~60% in CAD cells 
expressing CRMP2-K374A alone or in phospho-mutants also harboring the SUMO-null 
mutation (Figure 4.2B; hatched bars) with two notable exceptions. First, Nav1.7 currents 
in CAD cells expressing Y32F (i.e. the Fyn phospho-mutant) alone or in combination 
with the SUMO-null mutant (Y32F/K374A) were no different from CAD cells 
expressing wildtype CRMP2 (Figure 4.2B, blue bars).   
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Figure 4.1. CRMP2 SUMOylation does not affect CRMP2 
phosphorylation (A) CRMP2 (Mus musculus, GenBankTM 
accession number NM_009955.3) sequence indicating sites of 
SUMOylation and phosphorylation (kinases identified above the 
specific residues). The residues were mutated to alanine or 
phenylalanine to create CRMP2 SUMO-null and CRMP2-phospho 
null mutants. (B) Western blot of lysates from CAD cells expressing 
dsRed, dsRed-CRMP2 or dsRed-CRMP2-K374A probed for 
antibodies against Nav1.7, CRMP2, and phospho-specific CRMP2 
phosphorylation. (C) CRMP2 SUMOylation does not affect total 
Nav1.7 expression. (D) CRMP2 SUMOylation does not affect 
CRMP2 phosphorylation states. Data is presented as mean ± SEM. 
Experiment performed by Dr. Aubin Moutal. 
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Figure 4.2. CRMP2 modifications regulate Nav1.7 currents. 
(A) CRMP2 sequence and residues mutated for these studies. (B) 
Peak current density (pA/pF) measured at 0 mV for CAD cells 
transfected with the various constructs as indicated by color code 
in A. Closed symbols contain indicate a lysine at residue 374 and 
open symbols indicate SUMO-null substitution of lysine 374 for 
alanine. Data are normalized to the wild type CRMP2 condition. 
Box plot borders represent SEM and median, square indicates 
mean, diamonds are individual data points. Asterisks indicate 
statistically significant differences compared to wildtype 
CRMP2 expressing control cells (p < 0.05, one-way ANOVA 
with Tukey’s post-hoc test; n=5–9). 
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Second, Nav1.7 currents in CAD cells expressing S522A (i.e. the Cdk5 phospho-mutant) 
alone, without the additional presence of the SUMO-null mutant (K374A/S522A), were 
reduced by ~53% compared to those in CAD cells expressing wildtype CRMP2 (Figure 
4.2B, red bar). All other single phospho-null mutants had no effect on Nav1.7 current 
density. These data demonstrate that both Fyn- and Cdk5-mediated phosphorylation of 
CRMP2 are therefore involved in regulating Nav1.7. As Cdk5 is considered to be a 
‘priming kinase’ (Cole et al., 2006) for CRMP2, I next asked if the loss of Cdk5-
mediated phosphorylation of CRMP2 could also affect currents in a native system like 
DRGs.  
Following transfection of CRMP2 mutants, sodium currents were recorded from 
DRGs and first separated by tetrodotoxin sensitivity into TTX-S Nav1.1, Nav1.6, and 
Nav1.7 and TTX-R Nav1.8 and Nav1.9 contributions. Both CRMP2-S522A and CRMP2-
K374A/S522A mutants reduced TTX-S Na+ currents in DRGs by ~46% and ~50%, 
respectively, compared to currents from DRGs transfected with wildtype CRMP2 (Figure 
4.3A and B). In contrast, TTX-R currents were not affected by expression of either 
mutant (Figure 4.3C and D). To further determine the identity of the TTX-S current, I 
performed additional experiments using the H-infinity protocol in the presence of 5 nM 
ProTox-II to block Nav1.7 currents and analyze contributions of the remaining Nav1.1 
and Nav1.6 currents (Figure 4.3E and F). These experiments demonstrated no differences 
in TTX-S/ProTox-II-R currents compared to similarly-treated DRGs expressing wildtype 
CRMP2, demonstrating that loss of CRMP2 phosphorylation at serine-522 results in 
CRMP2 regulation of only the Nav1.7 VGSC isoform in DRGs. Consistent with the 
specificity of the regulation, the Nav1.7-specific modulation by CRMP2-S522A was 
 121 
  
recapitulated in HEK293 cells expressing Nav1.1, Nav1.3, Nav1.5, or Nav1.7 wherein it 
was observed that co-expression of CRMP2-S522A caused an ~64% reduction in 
currents only in the Nav1.7 cell line (Figure 4.3G). 
 Since both the CRMP2-K374A and CRMP2-S522A mutants impaired Nav1.7 
currents, I next tested whether the biochemical mechanism of regulation of Nav1.7 was 
similar between these SUMO- and phospho-null CRMP2 states. A denaturing SUMO1 IP 
was performed from lysates expressing wildtype CRMP2, CRMP2-K374A and CRMP2-
S522A, or CRMP2-K374A/S522A. In SUMO- and phospho-null only or combination-
null CRMP2 states, the amount of SUMOylated CRMP2 was reduced compared to 
wildtype CRMP2 (Figure 4.4A, B). Therefore, from these data I can conclude that (i) 
Cdk5-mediated phosphorylation is important for maintaining Nav1.7 current density, and 
(ii) Cdk5 phosphorylation regulates CRMP2 SUMOylation. 
 To determine if the changes in current density observed in the above experiments 
translated to changes in surface Nav1.7, a series of biotinylation experiments were 
performed on wildtype and all phospho-, SUMO- and combination-null CRMP2 mutants. 
Representative immunoblots of one such experiment is illustrated in Figure 4.5A 
demonstrating surface (i.e. streptavidin-enriched) and total Nav1.7 as well as dsRed-
CRMP2. Immunoblotting for Nav1.7 in streptavidin-enriched complexes from 
biotinylated CAD cells showed reduced Nav1.7 surface expression in CAD cells 
expressing CRMP2-K374A (53.8 ± 1.6% of wildtype CRMP2 levels; purple hatched bar) 
or CRMP2-S522A (19.0 ± 4.8% of wildtype CRMP2 levels; red bars) when normalized 
to total Nav1.7 expression (Figure 4.5B). 
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Figure 4.3. CRMP2-S522A, the Cdk5 site mutant, expression causes a selective 
reduction in Nav1.7 currents. (A) Representative TTX-S current traces from DRGs. (B) 
Box plot of peak TTX-S current density. CRMP2-S522A and CRMP2-K374A/S522A 
expression reduced TTX-S currents. Box plot borders represent SEM and median, square 
indicates mean, diamonds are individual data points. Filled symbols indicate presence of 
lysine (K) 374 in CRMP2 construct, whereas open symbols indicate SUMO-null mutation 
CRMP2-K374A. Key is shown as inset in B. (C) Representative TTX-R current traces 
from DRGs. (D) Box plot of peak TTX-R current density. Neither CRMP2 mutant affects 
TTX-R currents, eliminating possibility of contribution to effect by Nav1.8 and Nav1.9. 
(E) Representative TTX-S/ProTox-II-R current traces from DRGs. (F) Box plot of TTX-
S/ProTox-II-R current density. CRMP2-S522A does not affect these currents eliminating 
possibility of contribution to effect by Nav1.1 or Nav1.6. (G) Bar graph of normalized 
current densities from HEK293 cells expressing Nav1.1, Nav1.3, Nav1.5, or Nav1.7 along 
with CRMP2-S522A. CRMP2-S522A expression decreased only Nav1.7 currents when 
compared to those expressing wildtype CRMP2. All DRG and HEK293 cell current 
densities were normalized to cells expressing wildtype CRMP2. Asterisks indicate 
statistically significant differences compared to wildtype CRMP2 expressing control cells 
(p < 0.05, one-way ANOVA with Tukey’s post-hoc test; n=6–11). 
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Figure 4.4. CRMP2-S522A, the Cdk5 site mutant, expression causes loss of 
CRMP2 SUMOylation. (A) Lysates of CAD cells expressing the indicated 
constructs, following denaturation and immunoprecipitation with a SUMO1 antibody 
probed with CRMP2 (top) or dsRed-CRMP2 (bottom). (B) Loss of Cdk5-mediated 
CRMP2 phosphorylation, CRMP2 SUMOylation, or both reduces native CRMP2 
SUMOylation. Data are normalized to wildtype CRMP2 condition, error is ± SEM. 
Asterisks denote statistical significance by one-way ANOVA, * p < 0.05. 
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Figure 4.5. CRMP2 modifications mediate Nav1.7 surface expression. 
(A) Representative immunoblots of streptavidin-enriched surface (top) and 
total (middle) fractions probed with a Nav1.7 antibody. The bottom blot of 
lysates was probed with CRMP2 antibody to verify expression of 
transfected constructs. (B) Bar graphs summarizing mean surface Nav1.7 in 
CAD cells transfected with the indicated plasmids. Data are normalized to 
total Nav1.7 protein and then to the CRMP2 in each lane and finally plotted 
as ratio of the wild type CRMP2 condition. Asterisks indicate statistically 
significant differences compared to wildtype CRMP2 expressing control 
cells (p < 0.05, one-way ANOVA with Tukey’s post-hoc test; n=3). Pound 
symbol denotes statistical significance by Student’s t-test, # p < 0.05. 
Experiment performed by Aubin Moutal. 
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Consistent with earlier electrophysiology experiments, Nav1.7 surface expression 
was unchanged in cells expressing CRMP2-Y32F/K374A (102.1 ± 11.3%). These data 
therefore recapitulate the three major findings of CRMP2 regulation of Nav1.7 current 
density from previous patching experiments; (i) reduction of Nav1.7 surface expression 
by expression of SUMO-null CRMP2-K374A, (ii) reduction of Nav1.7 surface 
expression by expression of phopho-null CRMP2-S522A, and (iii) prevention of Nav1.7 
surface reduction by SUMO- and phospho–null CRMP2-Y32F/K374A. Reduced channel 
surface expression without altered channel availability (equivalent kinetics) is also 
consistent with previous data for the CRMP2-K374A mutant. All biotinylation results for 
other CRMP2 mutants were consistent with the patching results, with the exception of 
K374A/Y479. This mutant failed to meet significance by one-way ANOVA, but met 
significance by a Student’s t-test (#) (Figure 4.5B). 
 
4.4. CRMP2 phosphorylation by Cdk5 is dominant in preventing effects of CRMP2 
deSUMOylation on Nav1.7 currents 
 The whole-cell patch clamp electrophysiology and cell surface biotinylation 
experiments revealed that loss of Cdk5-mediated CRMP2 phosphorylation reduces 
Nav1.7 current density by reducing surface expression. To further investigate the 
mechanism by which Cdk5 phosphorylation of CRMP2 controls Nav1.7 current density, I 
tested if a constitutively active phospho-mimetic CRMP2-S522D mutant or 
overexpression of Cdk5 kinase to boost Cdk5 levels would be sufficient to overcome the 
current reduction imposed by loss of CRMP2 phosphorylation at the S522 site or CRMP2 
SUMOylation at the K374 site. In patching experiments, both overexpression of Cdk5 
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and CRMP2-S522D prevented the current reduction imposed by CRMP2 
deSUMOylation; Nav1.7 currents in CAD cells expressing Cdk5 and CRMP2-K374A, 
were 84.3 ± 17.3% of control (i.e. wildtype CRMP2) levels (Figure 4.6A) while those in 
CAD cells expressing CRMP2-K374A/S522D were 100.8 ± 11.8%, and those in CAD 
cells expressing the Cdk5-phospho-mimetic and deSUMOylation machinery (i.e. 
CRMP2-S522D + SENP1 + SENP2) were 112 ± 10.4% (Figure 4.6B). Expression of the 
Cdk5-phospho-mimetic or the CRMP2-K374A/S522D mutant alone did not affect 
Nav1.7 current densities compared to cells expressing wildtype CRMP2. These results 
show that forcing Cdk5-mediated phosphorylation of CRMP2 does not enhance currents, 
but is sufficient to overcome the reduction in Nav1.7 currents imposed by CRMP2 
deSUMOylation. Thus, CRMP2-pS522 phosphorylation is dominant over CRMP2 
deSUMOylation in control of Nav1.7 currents. 
Expression of a CRMP2-S522A mutant, which is not phosphorylated by Cdk5, 
along with the Cdk5 kinase provided a positive control and demonstrated a reduction in 
Nav1.7 currents to 41.3 ± 8.5% compared to cells expressing wildtype CRMP2 (Figure 
4.6A), consistent with results obtained with CRMP2-S522A mutant alone (Figure 4.2B). 
This demonstrates that CRMP2 is the sole mediator of Cdk5 regulated changes to Nav1.7 
currents. Experiments in DRG neurons verified the dominance of CRMP2-S522D mutant 
over deSUMOylation of CRMP2 because there was no difference in TTX-S Nav1.7 
currents in neurons expressing wildtype, S522D, or K374A/S522D CRMP2 constructs 
(Figure 4.6C). 
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Figure 4.6. Forcing Cdk5 phosphorylation of CRMP2 overrides CRMP2 deSUMOylation loss of Nav1.7 current 
density. (A, B) Peak current density (pA/pF) measured at 0 mV for CAD cells transfected with the constructs as indicated. 
Data are normalized to the wildtype CRMP2 condition. Overexpression of Cdk5 kinase prevents loss of current density 
observed with CRMP2-K374A. Symbol key to data is above the panels. Closed black symbols indicate wildtype CRMP2 
expression and open symbols indicate presence of CRMP2-K374A mutant. Grey symbols indicate Cdk5 expression, blue 
symbols indicate CRMP2-S522D expression, and red symbols indicate CRMP2-S522A expression. Asterisks indicate 
statistically significant differences compared to wildtype CRMP2 expressing control cells (p < 0.05, one-way ANOVA with 
Tukey’s post-hoc test; n=8–14). The phospho-mimetic S522D CRMP2 mutation prevents loss of current density associated 
with both CRMP2-K374A and SENP expression in CAD cells. Dashed red line indicates mean of peak current density for 
CAD cells expressing CRMP2-S522A, re-plotted from Figure 4.2. (C) Peak TTX-S current densities isolated from small 
DRGs and normalized to wildtype CRMP2 condition. The phospho-mimetic S522D CRMP2 mutation prevents loss of TTX-S 
current density associated with the CRMP2-K374A mutation. Box plot borders represent SEM and median, square indicates 
mean, diamonds are individual data points. 
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4.5. Loss of Fyn phosphorylation is dominant in preventing effects of CRMP2 
deSUMOylation on Nav1.7 currents  
Whole-cell patch clamp electrophysiology and cell surface biotinylation 
experiments on CRMP2 mutants that contained the SUMO-null K374A mutation to 
prevent SUMOylation all had the general effect of reducing Nav1.7 currents and surface 
expression. There was one notable exception; the double CRMP2-Y32F/K374A mutant, 
harboring a mutant Fyn phosphorylation site of CRMP2 when combined on the K374A 
mutation, prevented the current reduction imposed by the CRMP2-K374A mutant. 
Maintenance of wildtype control level currents and surface expression in CRMP2-
Y32F/K374A expressing cells lead to the conclusion that loss of Fyn phosphorylation is 
dominant over loss of SUMOylation in Nav1.7 regulation.  
Within the solved CRMP2 high-resolution crystal structure (Deo et al., 2004, 
Majava et al., 2008), the site of Fyn phosphorylation, tyrosine-32, lies on the surface of 
the protein in proximity to the SUMOylation motif at lysine-374 (Figure 4.7). Recent 
evidence suggests that even different parts of the protein that come together in the folded 
protein can form consensus recognition motifs for kinases (Duarte et al., 2014). No 
evidence exists linking secondary, tertiary, or quaternary protein structure to relationship 
of phosphorylation and SUMOylation. However, there are several examples of 
phosphorylation-dependent SUMOylation motifs have phosphorylation sites within ~10 
amino acids to the SUMOylation (reviewed in (Hietakangas et al., 2006)). This suggests 
that relationships between phosphorylation and SUMOylation modifications may be 
proximity-dependent but do not rule out the possibility that “structurally-formed” 
consensus motifs that are non-proximal may also play a role. 
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 The hypothesis that loss of Fyn phosphorylation is dominant over loss of 
SUMOylation in Nav1.7 regulation was supported by electrophysiology data in DRG 
neurons in which data where TTX-S Nav1.7 currents where equivalent between CRMP2-
Y32F/K374A and wildtype CRMP2 expressing cells, 91.7 ± 13.4% of wildtype CRMP2 
levels (Figure 4.8A), versus the previously reported CRMP2-K374A mutant alone, 36.0 ± 
5.5% (see Figure 3.7). Dominance of Y32F was next tested in combination with other 
conditions that resulted in reduced Nav1.7 current including overexpression of the 
deSUMOylating machinery or phospho-null CRMP2-S522A mutant (Figure 4.8B). The 
reduction in Nav1.7 currents imposed by SENP1/SENP2 overexpression or CRMP2-
S522A mutant was overcome by the additional presence of the CRMP2-Y32F mutant 
(Figure 4.8B). 
Another tool available to test loss of pY32-CRMP2 phosphorylation is the 
dominant negative Fyn kinase (DNFyn) that constrains kinase activity. DNFyn contains a 
point mutation (K299M) within the ATP binding pocket of the kinase that renders it 
unable to bind and transfer phosphate groups to its substrates, including CRMP2 
(Osterhout et al., 1999). This plasmid was coexpressed in CAD cells along with (i) 
CRMP2 mutants that reduced Nav1.7 current density (i.e., CRMP2-K374A, CRMP2-
S522A, or CRMP2-K374A/S522A) or (ii) CRMP2 mutants that prevented the reduction 
of Nav1.7 current density (i.e., CRMP2-S522D or CRMP2-K374A/S522D). 
In all conditions, sodium currents from CAD cells that co-expressed DNFyn were 
equivalent to those from CAD cells expressing wildtype CRMP2 (Figure 4.9A). 
Therefore, loss of Fyn phosphorylation is dominant over all known negative regulations 
of Nav1.7 currents (purple and red boxes, Figure 4.9A). 
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Figure 4.7. Fyn site, tyrosine-32, is adjacent to the SUMOylation motif 
within the crystal structure of CRMP2. Structural representation of 
CRMP2 monomer (PDB code: 2GSE (Deo et al., 2004)) with SUMOylation 
motif (top) and Fyn-targeted tyrosine-32 (bottom) represented by purple and 
white ball and chain structures. The color of CRMP2 ribbon structure is a 
gradient from N-terminal (blue) to C-terminal (red). The proximity of the 
SUMOylation motif and tyrosine-32 on the same surface of CRMP2 is 
hypothesized to endow interdependence between the modifications. Figure 
generated using Pymol by Dr. May Khanna (University of Arizona). 
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Figure 4.8. The Fyn kinase incompetent CRMP2 mutant, CRMP2-
Y32F, overrides the reduction in Nav1.7 current density associated with 
loss of CRMP2 SUMOylation and loss of CRMP2 phosphorylation by 
Cdk5. (A) Box plots summarizing peak TTX-S current densities isolated 
from small DRGs after transfection with the indicated constructs. The 
CRMP2-Y32F mutation prevents loss of TTX-S current density imposed by 
the CRMP2-K374A mutation. (B) Peak current density (pA/pF) measured 
at 0 mV for CAD cells transfected with the constructs as indicated. Data are 
normalized to the wildtype CRMP2 condition. Asterisks indicate 
statistically significant differences compared to wildtype CRMP2 
expressing control cells (p < 0.05, one-way ANOVA with Tukey’s post-hoc 
test; n=9–11). The CRMP2-Y32F mutation prevents loss of Nav1.7 current 
density in CAD cells associated with loss of CRMP2 SUMOylation, loss of 
CRMP2 phosphorylation by Cdk5, or both combined.  
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Figure 4.9. Introduction of a kinase-dead mutant of Fyn suppresses loss of 
Nav1.7 current density imposed by CRMP2-K374A and CRMP2-S522A 
mutants. (A) Peak current density (pA/pF) measured at 0 mV for CAD cells 
transfected with the constructs as indicated. Data are presented as normalized to the 
wildtype CRMP2 plus dominant negative DNFyn condition. Current densities of 
CAD cells expressing CRMP2 constructs and DNFyn normalized to wildtype 
control do not produce any changes to Nav1.7 current. (B) Peak TTX-S current 
densities isolated from small DRGs after transfection with the indicated constructs. 
The reduction in TTX-S currents observed following transfection with CRMP2-
K374A or CRMP2-S522A mutants is completely prevented by DNFyn expression. 
Box plot borders represent SEM and median, square indicates mean, diamonds are 
individual data points. n=8-13 cells per condition.  
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To assess any cumulative effects of Cdk5 phosphorylation with loss of Fyn 
phosphorylation, DNFyn was coexpressed with CRMP2-S522D and CRMP2-
K374A/S522D mutants. Expression of the DNFyn kinase mutant or the CRMP2-S522D 
mutation alone prevented the current density decrement associated the SUMO-null 
CRMP2-K374A mutant. When expressed together, the lack of increase in observed 
Nav1.7 currents (Figure 4.9A, blue boxes) suggests that these manipulations have shared 
mechanism. DNFyn transfection in small DRG neurons was used to evaluate the 
dominance of DNFyn in regulation of Nav1.7 currents in native neurons. In DRGs, TTX-
S Nav1.7 currents were no different between any of the conditions tested, confirming 
dominance of the DNFyn kinase over CRMP2-K374A– and CRMP2-S522A–mediated 
Nav1.7 current reductions (Figure 4.9B; purple and red boxes). 
 
4.6. Fyn phosphorylation of CRMP2 reduces Nav1.7 current density by promoting 
CRMP2 deSUMOylation 
 To further elucidate the effect of CRMP2 tyrosine-32 modification in regulation 
of Nav1.7, a competent Fyn kinase was overexpressed to promote CRMP2 Y32 
phosphorylation. Although this strategy is less specific than a CRMP2 mutant as it affects 
global Fyn phosphorylation, there are no phospho-mimetic substitutions possible for 
tyrosine targeted phosphorylation. The Fyn kinase was overexpressed in CAD cells with 
CRMP2 mutants that had previously been demonstrated to produce reduced Nav1.7 
currents – CRMP2-K374A, CRMP2-Y32F, CRMP2-S522A, CRMP2-K374A/S522A, 
CRMP2-522D, or CRMP2-K374A/S522D – and Nav1.7 currents were recorded and 
compared to wildtype control (Figure 4.10A). In electrophysiology experiments with 
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CAD cells, Fyn expression revealed a new component of CRMP2’s regulation of Nav1.7:  
a significant ~46% reduction in current density was observed in CAD cells co-expressing 
wildtype CRMP2 and Fyn kinase (Figure 4.10A). With Fyn overexpression, all CRMP2 
mutants that previously reduced CAD cell sodium current density (CRMP2-K374A 
(purple boxes) and CRMP2-S522A (red boxes), Figure 4.10A) still produced currents 
that were diminished in comparison to cells expressing wildtype CRMP2. Mutants that 
were previously shown to prevent CRMP2-K374A SUMO-null mediated current 
reductions, that is, CRMP2-S522D and CRMP2-Y32F, also maintained their effects (blue 
and cyan; Figure 4.10A). Expression of CRMP2-Y32F mutant with Fyn kinase served as 
a positive control for Fyn-mediated effects on Nav1.7 current density. Control level 
Nav1.7 currents in this condition, where Fyn cannot target CRMP2, verify that Fyn-
mediated reduction of Nav1.7 CAD cell currents are mediated solely by phosphorylation 
of CRMP2 and no other Fyn targets. Importantly, the finding that overexpression of Fyn 
kinase together with wildtype CRMP2 reduced Nav1.7 currents was recapitulated in 
small DRG currents where the TTX-S, presumptive Nav1.7 current was reduced by 
~41% compared to similar currents from DRGs transfected with wildtype CRMP2 
(Figure 4.10B). TTX-R current densities were unchanged between the two conditions 
(Figure 4.10B).  
As there was not a synergistic effect of Fyn expression and previous 
manipulations that reduced Nav1.7 currents (CRMP2–K374A and CRMP2–S522A), it 
was predicted that this phosphorylation was part of the same regulatory mechanism as 
Cdk5 phosphorylation and SUMOylation. 
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Figure 4.10. Gain of CRMP2 phosphorylation by Fyn restricts Nav1.7 currents. (A) Box plots summarizing peak 
current densities (pA/pF) measured at 0 mV for CAD cells transfected with the indicated constructs. Data are normalized to 
the wildtype CRMP2 condition. Asterisks indicate statistically significant differences compared to wildtype CRMP2 
expressing control cells (p < 0.05, one-way ANOVA with Tukey’s post-hoc test; n=8–12). CRMP2 phosphorylation by Fyn 
reduces Nav1.7 current density (compare second black bar to cyan bar). (B) Peak TTX-S and TTX-R current densities 
isolated from small DRGs after transfection with the indicated constructs. The Fyn kinase reduces the TTX-S current 
fraction. Asterisk indicates a statistically significant difference from wildtype CRMP2 (p < 0.05, one-way ANOVA with 
Tukey’s post-hoc test; n=11-16). Box plot borders represent SEM and median, square indicates mean, diamonds are 
individual data points. 
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Figure 4.11. Fyn phosphorylation restricts CRMP2 SUMOylation. (A) 
Lysates of CAD cells expressing the indicated constructs, following 
denaturation and immunoprecipitation with a SUMO1 antibody probed with 
CRMP2 (top) or dsRed-CRMP2 (bottom). (B) Summary of amount of 
SUMOylated CRMP2 Overexpression of Fyn kinase prevents CRMP2 
SUMOylation. Asterisk denotes statistical significance compared to wildtype 
CRMP2 alone (p < 0.05, Student’s t-test; n=3). Experiment performed by Aubin 
Moutal, a postdoctoral fellow in the Khanna laboratory. 
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Consequently, SUMO1 immunoprecipitation from CAD cell lysates wherein 
wildtype CRMP2 was coexpressed with Fyn kinase led to a significant reduction in the 
amount of SUMOylated CRMP2 (39.0 ± 5.6% of control wildtype CRMP2 alone, Figure 
4.11A, B). I conclude from this data that Fyn phosphorylation of CRMP2, akin to Cdk5 
phosphorylation, is a determinant of CRMP2 SUMOylation and regulation of Nav1.7. 
 
4.7. CRMP2 modifications alter its interaction with endocytic proteins and may explain 
the Nav1.7 current density changes 
While the data presented thus far in my thesis demonstrates the importance of 
CRMP2 modifications in orchestrating Nav1.7 surface trafficking and current density, the 
mechanism by which this surface loss of Nav1.7 is choreographed is not known. CRMP2 
has been previously described as a trafficking protein of the adhesion molecule L1-CAM 
in which CRMP2 interaction with the endocytic adaptor protein Numb regulated L1-
CAM endocytosis (Nishimura et al., 2003a, Jauffred et al., 2013). As an endocytic 
adapter protein, Numb promotes endocytosis of transmembrane proteins by recruiting 
components of clathrin-mediated endocytosis machinery including epidermal growth 
factor receptor substrate 15 (Eps15) endocytic adaptor protein and E3 ubiquitin ligases 
and relocating cargo to endocytic organelles (Santolini et al., 2000, Tang et al., 2005, 
Krieger et al., 2013). Numb has been reported to interact with ubiquitin E3 ligase LNX 
(Dho et al., 1998), Mdm2 (Juven-Gershon et al., 1998), Itch (McGill and McGlade, 2003, 
McGill et al., 2009), Siah-1 (Susini et al., 2001) – all of which can then monoubiqutinate 
target proteins to mark them for endocytosis. Numb stabilizes the interaction of Eps15 to 
monoubiquitinated proteins and induces plasma membrane curvature in the early steps of 
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clathrin-mediated endocytosis (Santolini et al., 2000, Woelk et al., 2006, Horvath et al., 
2007). 
There is one report that demonstrates regulation of Nav1.7 surface expression by 
the Nedd4-2 E3 ubiquitin ligase (Laedermann et al., 2013a). This E3 ubiquitin ligase 
monoubiquitinates Nav1.7 to signal downregulation of the channel resulting in a decrease 
in surface expression and current density (Laedermann et al., 2013a). CRMP2 or CRMP2 
interaction with Numb endocytic adaptor protein may facilitate interaction with Nedd4-2 
ligase. In this case clathrin-mediated endocytosis of Nav1.7 could be dependent on 
CRMP2 interaction with Numb and Nedd4-2. 
In a pilot experiment to further this line of inquiry, CRMP2 and CRMP2-K374A 
interaction with endocytic proteins Numb, adapter protein Eps15, and ubiquitin ligases 
Itch and Nedd4-2 were examined (Figure 4.12A). These proteins were selected for 
analysis because Numb has well described interaction with CRMP2 (Nishimura et al., 
2003a), as well as with endocytic adaptor protein Eps15 (Santolini et al., 2000), and Itch 
(Di Marcotullio et al., 2006). Nedd4-2 was selected due to described interaction with 
Nav1.7 and similarity to the E3 ubiqutin ligase Itch which interacts with Numb (McGill 
and McGlade, 2003, McGill et al., 2009, Laedermann et al., 2013a). For each endocytic 
protein, interaction with CRMP2-K374A was significantly greater than with wildtype 
CRMP2 (Figure 4.12B). This data indicates that unSUMOylated CRMP2 can facilitate 
interactions with endocytic machinery. 
To determine if these enhanced interactions promote endocytosis of Nav1.7, 
specific siRNA of each individual endocytic protein were used to knockdown their 
expression. The siRNAs were validated by Western blots in CAD cells (Figure 4.12C and 
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D) because the transfection efficiencies in DRGs precluded determination in these native 
neurons. Between 63.5-86.5% reduction in these proteins was observed (Figure 4.12C). 
CRMP2 was over-expressed along with the specific siRNAs to ensure that there were no 
spurious effects on CRMP2 expression. 
To determine if the knockdown of these proteins could impact CRMP2 regulation 
of Nav1.7 currents in DRGs, the siRNAs were then co-transfected with CRMP2 
constructs in DRGs and TTX-S currents were analyzed (Figure 4.12E). The previously 
observed reduction in TTX-S currents by expression of CRMP2-K374A and CRMP2-
S522A plasmids was not affected co-transfection of control-scrambled siRNAs with 
decreases of ~57% and ~50%, respectively (Figure 4.12E). Knockdown of Numb (green), 
Eps15 (orange), or Nedd4-2 (red) (Figure 4.12E) prevented the reduction in TTX-S 
currents observed with the CRMP2-K374A and CRMP2-S522A plasmids to control 
levels. In contrast, knockdown of Itch had no effect on preventing the reduction inTTX-S 
current density reduction (Figure 4.12E, blue). Therefore, modulation of Nav1.7 by 
CRMP2 SUMOylation and Cdk5 phosphorylation requires the interaction of CRMP2 
with Numb, Eps15, and Nedd4-2, but not Itch. 
Epidermal growth factor substrate 15 (Eps15) is described to induce membrane 
curvature to initiate clathrin-mediated endocytosis (Santolini et al., 2000, Woelk et al., 
2006, Horvath et al., 2007). This process involves Eps15 interaction with 
phosphoinositide headgroups of membrane lipids and insertion of Eps15s epsin N-
terminal homology helix structure (ENTH domain) between membrane lipid headgroups 
just shallow of the hydrophobic core (Hurley and Wendland, 2002). This adds mass to the  
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 previous page…Figure 4.12. CRMP2 mediated Nav1.7 current reduction 
requires interaction with the endocytosis proteins Numb and Eps15 and the E3 
ubiquitin-protein ligase Nedd4-2. (A) Representative immunoblots of CRMP2-
immunoprecipitates from CAD cells expressing wildtype CRMP2 or CRMP2-K374A 
and probed with the indicated antibodies. (B) Summary of normalized binding of 
CRMP2 to the indicated proteins. In all cases, binding of Numb, Eps15, Nedd4-2, and 
Itch was higher for the CRMP2-K374A mutant than wildtype CRMP2. Asterisks denote 
statistical significance compared to wildtype CRMP2 alone (p < 0.05, Student’s t-test; 
n=3). (C) Representative blots of lysates from CAD cells transfected with control 
siRNA or siRNAs against Numb, Eps15, Nedd4-2, and Itch. CRMP2 was over-
expressed along with the specific siRNAs to ensure that there were no spurious effects 
on CRMP2 expression. These blots verify endocytic protein knockdown in CAD cells. 
Asterisks denote statistical significance compared to siRNA control (p < 0.05, Student’s 
t-test; n=3). (E) Peak TTX-S current densities isolated from small DRGs after 
transfection with the indicated plasmids and/or siRNAs. Knockdown of Numb, Eps15, 
and Nedd4-2, but not Itch, prevents the reduction in TTX-S Nav1.7 currents observed 
following expression of CRMP2-K374A and CRMP2-S522A mutants. Box plot borders 
represent SEM and median, square indicates mean, diamonds are individual data points. 
Asterisks indicate statistically significant differences compared to wildtype CRMP2 
expressing control cells (p < 0.05, one-way ANOVA with Tukey’s post-hoc test; n=6–
11). Biochemistry experiment illustrated in A-D performed by Aubin Moutal. 
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Figure 4.13. CRMP2 mediated endocytosis of Nav1.7 is clathrin-dependent and 
proteasome-independent (A) Box plots of peak TTX-S current densities isolated 
from small DRGs after transfection with the indicated plasmids and indicated 
treatment of 20 µM Pitstop2 or 0.1% DMSO control. Pitstop2 application for 30 
minutes rescued the decrease of TTX-S currents in cells expressing CRMP2-K374A 
and CRMP2-S522A. (B) Box plots of peak TTX-S (left) and peak TTX-R (right) 
currents expressing the indicated plasmids and indicated treatment of 10 µM 
Pitstop2 or 0.1% DMSO control. Lactacystin treatment did not prevent TTX-S 
current density reduction by CRMP2-K374A/S522A. Box plot borders represent 
SEM and median, square indicates mean, diamonds are individual data points. 
Asterisks indicate statistically significant differences compared to cells without 
Pitstop2 treatment (p < 0.05, Student’s t-test; n=7–13).  
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intracellular leaflet and bulges the membrane outward in relation to Eps15 and the 
intracellular cargo to produce membrane curvature (Hurley and Wendland, 2002). To 
resolve whether clathrin-mediated endocytosis is responsible for CRMP2 regulation of 
Nav1.7, I used the clathrin assembly inhibitor Pitstop2 on DRGs transfected with 
CRMP2, CRMP2-K374A, or CRMP2-S522A. Application of 20µM of Pitstop2 to DRGs 
for 30 min rescued the decrease of Nav1.7 currents imposed by CRMP2-K374A and 
CRMP2-S522A expressing DRGs and did not affect currents of cells expressing wildtype 
CRMP2 (Figure 4.13A). In another experiment to test determine if Nav1.7 trafficking by 
CRMP2 requires degradation of the channel, I treated DRGs expressing CRMP2-
K374A/S522A DRGs with 10µM Lactacystin for 24 hours to inhibit proteasome function 
(Fenteany et al., 1995). Lactacystin had no effect on preventing reduction of TTX-S 
currents in these cells (Figure 4.13B). Based on these DRG data following knockdown of 
Numb, Eps15, and Nedd4-2, inhibition of clathrin-mediated endocytosis, and inhibition 
of proteasome, I conclude that endocytosis, but not degradation, of the Nav1.7 channel 
brings about the observed reduction in Nav1.7 current density and surface expression 
seen with the CRMP2-K374A SUMO null plasmid. 
 
4.8. Discussion 
In this Chapter I built upon evidence from Chapter 3 that CRMP2 SUMOylation 
regulates Nav1.7 current density and surface expression. Here, I provide evidence that 
CRMP2 phosphorylation regulates CRMP2 SUMOylation to exert downstream effects on 
Nav1.7 trafficking. Of the multiple kinases that target CRMP2 (see section 1.2.2), I 
demonstrated that phosphorylation by Cdk5 and Fyn regulates CRMP2 SUMOylation. 
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Cdk5 phosphorylation is mandatory for CRMP2 SUMOylation and maintenance of 
Nav1.7 currents. Loss of phosphorylation by Cdk5 decreased the level of SUMOylated 
CRMP2 in CAD cells, which, in turn, resulted in decreased Nav1.7 current densities. 
Phosphorylation of CRMP2 by Fyn kinase blunted CRMP2 SUMOylation to decrease 
Nav1.7 current densities. Loss of Fyn phosphorylation prevented loss of Nav1.7 current 
densities associated with expression of the unSUMOylated CRMP2. The mechanism by 
which SUMO-null CRMP2 exerts effect on Nav1.7 was determined to be clathrin-
mediated endocytosis. This occurs by CRMP2-mediated recruitment of three proteins that 
initiate endocytosis – Numb, Eps15, and E3 ubiqutin ligase Nedd4-2. 
Phosphorylation introduces a double negative charge to amino acids that is not 
present in any amino acids incorporated into proteins. As a result, phosphorylation can 
introduce hydrogen binding between amino acid side chains that alters protein 
conformation (Johnson and Lewis, 2001). Therefore, the regulations of SUMOylation by 
phosphorylation could likely be due to altered protein conformation. SUMOylation of 
some proteins is reportedly altered by their phosphorylation state (some examples can be 
found in Table 1.3). In some cases, phosphorylation N-terminal (e.g., Heat-shock factors 
1 and 4b, and Estrogen receptor β) (Hietakangas et al., 2006, Picard et al., 2012) or C-
terminal (GluK2 receptor) (Konopacki et al., 2011) to the SUMOylation motif can trigger 
protein SUMOylation. In other cases, phosphorylation of immediately N-terminal 
residues prevents subsequent SUMOylation (e.g., for the transcription factor SATB1) 
(Tan et al., 2010). There are also cases where the primary amino acid sequence alone 
does not mediate the relationship between phosphorylation and SUMOylation. This is the 
case for the transcription factor Elk-1 where phosphorylation of a residue over 100 amino 
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acids C-terminal of the SUMOylation motif triggers the secondary modification (Yang et 
al., 2003). In the latter case it seems possible that the protein’s tertiary structure may 
change following phosphorylation allowing for a conformational change in the protein 
that facilitates subsequent SUMOylation, but this possibility has not been investigated. 
The relationship between CRMP2 SUMOylation and phosphorylation may also fall into 
this category as the SUMOylated residue lysine-374 is 341 residues away from the target 
of Fyn (tyrosine-32) and 147 residues away from the target of Cdk5 phosphorylation 
(serine-522).  
The solved crystal structure of rat CRMP2 (Deo et al., 2004) allows for atomic 
localization of the SUMOylation motif centered at CRMP2 lysine-374. The crystal 
structure also allows mapping of the phosphorylation site of Fyn, tyrosine-32. Because 
the existing CRMP2 structures are all C-terminally truncated, the exact location of the 
Cdk5 serine 522 is not known. The C-terminal domain is not present in the structure 
because the region is likely (i) susceptible to proteolysis and (ii) unfolded (Figure 4.7). 
The Fyn targeted tyrosine-32 and SUMO targeted lysine-374 lie within direct proximity 
to each other on the surface of CRMP2 monomers. This allows the possibility of a 
physical or hydrophobic block of the SUMOylation motif following Fyn 
phosphorylation. Such a relationship could explain the reduced SUMOylation of Fyn-
phosphorylated CRMP2 (Figure 4.11). Additionally, the CRMP2 SUMOylation motif lies 
on an accessible surface of the protein in monomeric (Figure 4.11) and tetrameric forms 
(data not shown). This is important because surface positioning of a SUMOylation 
consensus sequence is a requirement of SUMOylation. The majority of predicted 
SUMOylation consensus sequences are not SUMOylated and this is likely due to 
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presence of the motif in internal or buried parts of the protein (Pichler et al., 2005, 
Henley et al., 2014). For these predicted motifs, the simultaneous occurrence of another 
post-translational modification, e.g., phosphorylation, may modify the SUMOylation 
process. The structural context of the SUMOylation process is not yet fully understood, 
but it is safe to assume that lysine residues that are not surface-exposed will not qualify 
for SUMOylation Thus, a SUMOylation site is necessary, but not sufficient, for 
SUMOylation to take place. It is possible that CRMP2 phosphorylation by Fyn at 
tyrosine-32 modifies the SUMOylation process to bury SUMOylation motif within 
CRMP2 or that phosphorylation by Cdk5 at serine-522 modifies the SUMOylation 
process by exposing the motif during CRMP2 phosphorylation-dependent regulation of 
SUMOylation. An underdeveloped area of SUMOylation research is the participation of 
SUMOylation E3 ligases and their role in substrate recognition during Ubc9 binding. E3 
ligases bind to SUMO-conjugated Ubc9 and function to target SUMOylation to specific 
substrates. (Flotho and Melchior, 2013). The regulation of CRMP2 SUMOylation by 
phosphorylation may be facilitated by changes of access to lysine-374 by an, as of yet 
undescribed, E3 SUMO ligase. SUMOylation of CRMP2 by specific E3 proteins, and not 
others, would provide yet another layer of regulation to the growing model of CRMP2-
mediated Nav1.7 regulation. 
UnSUMOylated CRMP2 displays a reduced Nav1.7 binding in CAD cells (Figure 
3.9), which I first hypothesized to be the cause of reduced Nav1.7 surface expression. 
This would be the case if stability of Nav1.7 at the membrane was provided by 
interaction with CRMP2 and altered interaction shifted Nav1.7 membrane turnover. The 
data in Chapter 4 demonstrates that recruitment of endocytic machinery by 
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unSUMOylated CRMP2 aids in CRMP2-mediated Nav1.7 regulation (Figure 4.12). This 
data now supports an alternate hypothesis in which CRMP2 SUMOylation does not alter 
CRMP2 affinity for Nav1.7 and the reduced interaction of CRMP2 and Nav1.7 is instead 
the result of reduced Nav1.7 membrane expression where the interaction between 
CRMP2 and Nav1.7 occurs. In addition, the requirement of endocytic machinery may 
explain the dominant positive nature of CRMP2-S522D or CRMP2-Y32F where these 
CRMP2s do not display enhanced interaction with endocytic machinery regardless of 
SUMOylation status. This hypothesis should be tested in future works. 
CRMP2 phosphorylation by Cdk5 to prevent Nav1.7 endocytosis is an interesting 
mechanism that may connect CRMP2 regulation of Nav1.7 to painful conditions. In 
several studies, animals suffering from inflammatory (Yang et al., 2007, Zhang et al., 
2014) or neuropathic (Li et al., 2014, Yang et al., 2014) pain displayed increased levels of 
Cdk5 activity. Intrathecal injection roscovitine, a Cdk5-inhibiting compound, proved 
effective in alleviating neuropathic pain after chronic compression injury of DRGs (Yang 
et al., 2014). My work demonstrates the Cdk5 phosphorylation of CRMP2 prevents 
Nav1.7 internalization. Consequently, Cdk5 activity may bolster Nav1.7 currents in these 
painful conditions which is prevented by action of roscovitine. Akin to prevention of 
Nav1.7 currents by expression of CRMP2-S522A plasmid (Figure 4.2 and 4.3), the 
CRMP2-mediated function of reducing Nav1.7 currents could contribute to the 
roscovitine mechanism-of-action to provide pain relief. 
Fyn activity has been reported to be instrumental in the development of α-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and N-methyl-D-aspartate 
(NMDA) receptor-mediated sensitization to pain (Liu et al., 2014b). In this single study, 
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expression of a constitutively active Fyn produced mechanical allodynia and thermal 
hyperalgesia via enhanced expression of these receptors. AMPA and NMDA receptors 
are located at the post-synaptic membranes of second order neurons within the spinal 
dorsal horn (Liu et al., 2014b). This study indicates that increased Fyn activity in these 
cells promotes pain sensitization, whereas my data indicates that increased Fyn activity in 
DRG cells would restrict pain sensitization. The outcome of Fyn activity on pain is 
therefore incongruent in these two different cell types. As a result, targeting global Fyn 
activity could have inconsistent effects on pain behavior. 
Interestingly, Fyn activity can activate Cdk5 activity (Uchida et al., 2009). As 
CRMP2 phosphorylation by either kinase mediates Nav1.7 current densities in opposite 
directions, this could allow for variable levels of Fyn activity to have opposing effects on 
Nav1.7. Direct Fyn phosphorylation of CRMP2 reduces Nav1.7 currents, yet Fyn 
activation of Cdk5, and subsequent activity of Cdk5 on CRMP2, would prevent reduction 
of Nav1.7 currents (Figure 4.10, compare Fyn + CRMP2 condition to Fyn + CRMP2-
S522D Cdk5-phospho-mimetic). This relationship, however, is contradicted by data that 
shows CRMP2 SUMOylation is reduced when Fyn kinase is overexpressed (Figure 4.11). 
One possible explanation is that when CRMP2 is unSUMOylated and unphosphoryalted 
by Cdk5, the protein is primed for Fyn phosphorylation. Following Fyn phosphorylation, 
CRMP2 could become resistant to SUMOylation by presence of the phosphate group on 
Fyn-targeted tyrosine-32. Then, pY32 must first be removed in order to achieve 
SUMOylation. By this explanation, in spite of increased cellular Cdk5 activity, CRMP2 
could remain unSUMOylated. My data (Figure 4.11) supports this conclusion and could 
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be further supported by detection of increased Cdk5 activity, but not increased CRMP2 
SUMOylation in Fyn overexpressing CAD cells. 
Endocytosis of voltage-gated channels is an incompletely described mechanism 
for sodium channel regulation. It has been demonstrated that Nav1.1, Nav1.2, Nav1.5, 
Nav1.6, Nav1.7, Nav1.8 and the α, β, and γ epithelial sodium channels (ENaC) all 
contain PY domains that are targeted by E3 ubiquitin ligases (Staub et al., 2000, Fotia et 
al., 2004, van Bemmelen et al., 2004, Rougier et al., 2005, Cachemaille et al., 2012, 
Laedermann et al., 2013a). The same family of nine Nedd4/Nedd4-like E3 ubiquitin 
ligases targets all of these channels and the interaction occurs between the PY motifs of 
the channels to the WW protein-interacting domain of the ubiquitin ligases (Fotia et al., 
2004). The overexpression of Nedd4/Nedd4-like E3 ubiquitin ligases promotes an 
internalization of these channels to undefined endocytic compartments (Fotia et al., 2004, 
van Bemmelen et al., 2004, Rougier et al., 2005). A lack of diversity among E3 ligase-
sodium channel interactions is surprising despite the differential expression patterns of 
sodium channels required for diversity of neuron cell types (Catterall et al., 2005). It is 
also surprising because Nedd4/Nedd4-like E3 ubiquitin ligases are widely expressed 
throughout populations of excitable cells (Fotia et al., 2004, Rougier et al., 2005). 
Therefore, channel endocytosis by Nedd4/Nedd4-like E3 ligases is not the result of 
affinity between specific combinations of E3 ligases and channels, but instead the result 
of E3 ligase post translational modification or channel interactions that prevent the 
channel-E3 ligase interaction. 
Examples of blunted endocytosis following E3 modification include 
phosphorylation of Nedd4/Nedd4-like proteins by serum and glucocorticoid-regulated 
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kinase 1 (SGK1) and protein kinase B (Akt) to inhibit the endocytosis of ENaCs 
(Debonneville et al., 2001, Lee et al., 2007) or voltage-dependent potassium channel 
Kv7.1 (Andersen et al., 2013). Examples where channel endocytosis is prevented include 
association of ENaCs α–β subunit that has undergone phosphorylation by the G protein-
coupled receptor kinase, Grk2 (Dinudom et al., 2004). Through interaction with the 
modified accessory protein, ENaCs become resistant to ubiquitination and endocytosis. A 
similar case exists for L-type voltage-gated calcium channels which are resistant to 
ubiquitination, and therefore endocytosis, when interacting with their β subunit (Altier et 
al., 2011). As an accessory protein of Nav1.7, SUMOylated CRMP2 may function in a 
similar capacity to prevent Nav1.7 endocytosis. Studies addressing regulation of VGSC 
endocytosis are currently lacking. 
I demonstrated that inhibition of the proteasome, with the small molecule 
lactacystin, does not prevent nor enhance CRMP2-mediated Nav1.7 internalization. 
Therefore, it seems that CRMP2-mediate endocytosis of Nav1.7 does not require protein 
degradation and that internalized Nav1.7 may eventually be recycled to the cell surface. 
To further elucidate the process by which Nav1.7 endocytosis is regulated, a time course 
imaging study could be undertaken using extracellular epitope recognizing Nav1.7 
antibodies or a tagged Nav1.7 channel that could track cellular Nav1.7. Co-labeling for 
Nav1.7 channel protein and various markers of specific endocytic organelles could 
determine what happens to Nav1.7 during CRMP2-K374A mediated internalization and 
also provide substantial evidence that the channel is either recycled or degraded. 
My studies in this Chapter focused on regulation of Nav1.7 expressed in small 
diameter DRGs in part because of the high relevance of this cell type to a variety of 
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painful conditions (Dib-Hajj et al., 2013) but also due to the high fraction of TTX-S 
currents of the Nav1.7 subtype (Zhang et al., 2013) and endogenous expression of 
CRMP2 in these cells (Quach et al., 2004, Brittain et al., 2011b). In future studies 
SUMOylation of CRMP2 and regulation of Nav1.7 should be extended to different 
neuron types and paired with studies of injured animals. This would help to elucidate the 
role, if any, of CRMP2-mediated Nav1.7 regulation in pain and would validate targeting 
of the mechanisms described in Chapter 4 for the treatment of painful conditions. 
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CHAPTER 5.  
 
CONCLUSION AND DISCUSSION 
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5.1. Summary and consolidation of a working model of CRMP2-mediated Nav1.7 
trafficking 
 In this thesis I report several novel findings. First, I identified a novel interaction 
partner of Nav1.7, CRMP2. Second, I identified a novel modification of CRMP2, the 
addition of the small ubiquitin like modifier (SUMO). Third, I found that SUMOylation, 
which I showed to occur at lysine 374 of CRMP2, is a molecular switch for CRMP2 
regulation of Nav1.7; preventing CRMP2 from being SUMOylated at this residue blunts 
Nav1.7 surface expression and current densities without affecting kinetic properties of 
slow inactivation, fast inactivation, or activation. Fourth, I reported that CRMP2 
expression is necessary for constitutive Nav1.7 currents in CAD cells and in DRG 
sensory neurons. Fifth, I demonstrated that blocking CRMP2 SUMOylation has no effect 
on a classical function of CRMP2, that of CRMP2-mediated neurite outgrowth. Sixth, the 
reduction in Nav1.7 surface expression and current densities due to interference with 
CRMP2 modification was not because of increased Nav1.7 translation. Seventh, using 
pharmacological and electrical isolation of VGSC subtypes, I determined that CRMP2 
regulates only Nav1.7, while sparing other DRG expressed channel subtypes including 
Nav1.1, Nav1.3, Nav1.6, and Nav1.8 as well as the cardiac Nav1.5 channel. Eighth, I 
determined that CRMP2 SUMOylation was regulated positively by Cdk5 
phosphorylation and negatively by Fyn phosphorylation allowing for the interplay 
between multiple modifications of CRMP2 to choreograph Nav1.7 function. Finally, the 
molecular mechanism by which SUMO-null CRMP2 reduces surface Nav1.7 was 
discovered to require clathrin-dependent endocytosis involving activity of Numb, Eps15 
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and Nedd4-2 proteins which, scaffold interactions of endocytosis machinery, initiate 
endocytosis, and target Nav1.7 for internalization, respectively. 
 Collectively, my thesis has described CRMP2 as a novel modulator of Nav1.7 
endocytosis (Figure 5.1) and has laid deep and broad foundations for the CRMP2 and 
Nav1.7 trafficking fields. Given the unequivocal link between Nav1.7 activity and human 
pain, inhibiting CRMP2 SUMOylation represents an attractive therapeutic target for drug 
discovery, thus spurring translational studies based on my work.  
 
5.2. Discussion of CRMP2-Nav1.7 signaling model and future studies 
 This thesis work has identified and described many features of CRMP2s 
regulation of Nav1.7. Like many rewarding projects, new trajectories of experimentation 
have been uncovered by this work. Given adequate funding and time, the following 
projects could be considered to further advance the understanding of CRMP2-Nav1.7 
signaling. In the next section of potential future studies, I will place my findings on 
CRMP2 and Nav1.7 trafficking and function in the context of published reports. My 
thesis and these future studies serve to expand the field of Nav1.7 trafficking and provide 
novel targets to modulate this channels function in pain.  
 
5.2.1. Role of general cellular SUMOylation and CRMP2 SUMOylation in pain 
There are no reports linking SUMOylation to pain. The limited evidence that exists is 
very circumstantial. For example, some evidence exists linking global SUMOylation rate 
to the inflammatory disorder rheumatoid arthritis (Meinecke et al., 2007). In rheumatoid 
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Figure 5.1. Model describing how CRMP2 SUMOylation and 
phosphorylation co-opt to direct Nav1.7 endocytosis and trafficking. (A) 
CRMP2 SUMOylation (1) is prevented when CRMP2 phosphorylation by Cdk5 at 
S522 is prevented. UnSUMOylated CRMP2 (2) has an enhanced interaction with 
Numb, and subsequent phosphorylation by Fyn kinase (3) allows further 
recruitment of E3 ubiquitin ligase Nedd4-2. When phosphorylated by Fyn (4), 
CRMP2 SUMOylation is prevented and when unphosphoryalted by Fyn, effects 
of loss of CRMP2 SUMOylation are prevented (B) Nedd4-2 monoubiquitinates 
Nav1.7 (5) to trigger endocytosis which requires the endocytosis adapter protein 
Eps15 (6). Incubation of 20 µM Pitstop2 with unSUMOylted CRMP2-K374A 
expressing DRGs recovers TTX-S currents suggesting that CRMP2-mediated 
endocytosis of Nav1.7 is clathrin-dependent. 
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arthritis, SUMO1 expression and increased cellular SUMOylation results in nuclear 
sequestration of the proapoptotic adaptor molecule death-domain associated protein 
(DAXX) in synovial fibroblasts of patients. 
The mechanism of DAXX sequestration is unknown but it is known to prevent 
DAXX activity in promoting apoptosis. A resistance of fibroblasts to apoptosis is an 
underlying cause of chronic inflammation and pain in rheumatoid arthritis. Sequestration 
of DAXX is relieved by overexpression of the deSUMOylating protein SENP1, following 
which cell death is restored (Meinecke et al., 2007). Cellular SUMOylation, therefore, 
could possibly be targeted as a therapy for rheumatoid arthritis relief. A tenuous link to 
Nav1.7 and rheumatoid arthritis can be surmised from a report describing an enhanced 
susceptibility to symptomatic knee osteoarthritis and multiple regional pain in patients 
expressing the Nav1.7 R1150W (Valdes et al., 2011). My findings, along with this 
limited circumstantial evidence identify a plausible new link between this modification 
and pain. My data suggests that increased levels of DRG cellular SUMOylation could 
result in increased CRMP2 SUMOylation, prevent internalization of Nav1.7 to 
dysregulate channel trafficking, and ultimately cause Nav1.7-mediated pain. It is possible 
then that increased global SUMOylation serves as a general signal to trigger pain. 
However, not enough data exists to conclusively support this hypothesis. 
One possible link between global SUMOylation and pain involves activation of 
protein kinase B (or Akt). Following injury, Akt activation is increased where the kinase 
contributes to cell survival pathways including inactivation of apoptogenic factors 
(Noshita et al., 2001). Akt activity has recently been implicated in a feed forward process 
that promotes Akt SUMOylation that further enhances Akt activity. Targets of Akt 
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include the SUMOylation machinery proteins Ubc9 and SUMO1 and when either is 
phosphorylated by Akt, total cellular SUMOylation is increased (Lin et al., 2015). As an 
inactivator of apoptogenic factors (Noshita et al., 2001), this feed forward pathway to 
enhance global SUMOyaltion is in agreement with the previous example of 
SUMOylation in rheumatoid arthritis, in which pain is also linked to loss of apoptosis 
(Meinecke et al., 2007). The data from these publications supports the general idea that 
increases in Akt phosphorylation and SUMOylation due to enhancement of Akt 
expression following ischemia and injury (Li et al., 2015) may be linked to general pain 
pathways. Many examples of injury are also associated with increased Nav1.7 expression 
including lumbar 5 spinal nerve ligation (Fukuoka et al., 2015), intervertebral disc injury 
(Sadamasu et al., 2014), sciatic nerve compression (Mukai et al., 2014), and spared nerve 
injury (ligation of two of three sciatic nerve branches) (Laedermann et al., 2013a). In 
theory, Akt activation could facilitate global cellular SUMOylation, including that of 
CRMP2, to prevent endocytosis of Nav1.7 to increase channel surface expression leading 
to increased sodium currents, hyperexcitability and ultimately, pain. 
 From my data, I know that CRMP2 SUMOylation can be blocked to reduce 
Nav1.7 trafficking, but it is not yet known if this reduction can be linked to analgesia or 
whether dysregulation of CRMP2 SUMOylation may underlie the development of pain 
behavior. Studies of tissue(s) from injured animals (DRGs, spinal cord etc.) could link 
Akt activity, global SUMOylation, CRMP2 SUMOylation and CRMP2 regulation of 
Nav1.7 to pain behaviors. Participation of CRMP2 SUMOylation in the physiological 
development of pain would also validate the mechanism of CRMP2 SUMOylation as a 
target for drug development. In my thesis the Nav1.7 currents in isolated DRG cells are 
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likely at a maximum within my assay for CRMP2 SUMOylation because CRMP2 
overexpression did not increase currents above levels seen in cells without exogenous 
CRMP2. However, given the role of CRMP2 SUMOylation in trafficking Nav1.7, I 
cannot rule out the possibility that Nav1.7 in other sub-cellular locations including nerve 
terminals or axons may be increased upon enhancement of CRMP2 SUMOylation. Future 
studies in the Khanna laboratory will probe these putative relationships by performing a 
full biochemical workup of tissues between injured and uninjured animals in a model of 
neuropathic pain in which Nav1.7 had been implicated (Table 5.1). Through probing of 
dorsal spinal cord (where nociceptive DRG neurons innervate (Black et al., 2012)) and 
DRGs lysates for levels p-threonine-35 Ubc9 (Lin et al., 2015), phosphorylation of 
SUMOylation machinery by Akt could be compared. These tissues could be further 
analyzed for levels of SUMOylated and phosphorylated (particularly by Cdk5 and Fyn) 
CRMP2 to determine whether CRMP2 is participating in generation of pain by 
dysregulation of Nav1.7. Any combination of increased CRMP2 SUMOylation, increased 
Cdk5 phosphorylation, or decreased Fyn phosphorylation would support this link. 
 This biochemical data of injured tissues could also be paired with DRG whole-
cell recordings and transfection of CRMP2-K374A. If an increased Nav1.7 current 
density in DRGs of injured animals could be prevented by expression of CRMP2-K374A, 
then this study would serve as a proof-of-principle for targeting CRMP2 SUMOylation to 
treat pain. For greatest likelihood of success in initial studies, animal models of pain that 
include Nav1.7-dependent mechanisms should be utilized (Table 5.1).  
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Table 5.1. Animal models of pain behavior affecting Nav1.7. 
  
Type of 
Model 
Induction 
paradigm 
Induction & Onset of 
pain 
Pain 
Behaviors 
Effects 
on 
VGSCs 
Additional 
Nav1.7-related 
functions 
References 
Early painful 
diabetic 
neuropathy 
Streptozocin 
injection 
45mg/kg single dose 
Pain-like behaviors 
develop within 4 weeks 
Mechanical 
allodynia 
 
Thermal 
hyperalgesia 
Nav1.3 + 
Nav1.6 - 
Nav1.7 + 
Nav1.8 - 
Increased slow 
ramp currents 
(property of 
Nav1.7) 
(Calcutt et al., 
1996, Ahlgren et 
al., 1997, 
Malcangio and 
Tomlinson, 1998, 
Hong et al., 2004) 
Chemotherapy 
induced 
peripheral 
neuropathy 
Paclitaxel 
injection 
4 alternate day 
injections of 2mg/kg 
Pain like behaviors 
develop within 7-14 
days 
Mechanical 
allodynia 
 
Nav1.1 + 
Nav1.6 + 
Nav1.7 + 
Increased 
spontaneous 
DRG activity 
(Cavaletti et al., 
2000, Dougherty 
et al., 2004, 
Reeves et al., 
2012, Zhang and 
Dougherty, 2014) 
Inflammatory 
pain 
Carageenan 
injection 
4% in 150ul sterile 
saline (right plantar 
hind paw) 
Pain-like behaviors 
develop within 4 days 
Edema 
 
Mechanical 
allodynia 
 
Thermal 
hyperalgesia 
Nav1.3 + 
Nav1.7 + 
Nav1.8 + 
40% increase in 
DRG total 
sodium current 
(Iadarola et al., 
1988, Black et al., 
2004) 
Neuropathic Spared 
nerve injury 
Ligation of common 
peroneal and tibial 
branches of the sciatic 
nerve, sparing of sural 
nerve 
Pain-like behaviors 
develop within 7 days 
Mechanical 
allodynia 
 
Increased 
duration of 
heat 
withdrawal 
Nav1.7 + 
Nav1.8 + 
Increased 1.7 
expression along 
sciatic nerve but 
not DRG cell 
body 
(Decosterd and 
Woolf, 2000, 
Cachemaille et al., 
2012, 
Laedermann et al., 
2013a) 
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Another possible link to pain comes from my data on Cdk5. I determined that 
blocking Cdk5 phosphorylation of CRMP2 enhances Nav1.7 endocytosis and reduces 
current density. Increased Cdk5 activity has been linked to thermal hyperalgesia 
following CFA injection and mechanical neuropathic pain following chronic constriction 
injury (CCI) (Yang et al., 2007, Li et al., 2014, Zhang et al., 2014, Fang et al., 2015). 
Intrathecal administration of the Cdk5 inhibitor roscovitine prevents mechanical 
neuropathic by processes attributed to downregulation of NMDA receptors (Yang et al., 
2014) and also prevents inflammation-induced thermal hyperalgesia by blocking Cdk5 
activation of tumor necrosis factor-α (Fang et al., 2015). As stated earlier, the CRMP2 
phospho-null CRMP2-S522A mutant for the CRMP2 site in Cdk5 significantly reduces 
Nav1.7 currents (see Figure 4.2) while the CRMP2 phospho-mimetic CRMP2-S522D 
mutant does not exhibit changes in Nav1.7 current (Figure 4.6). Taken together, my data 
could support a scenario in which Cdk5 sensitized pain states involve a dysregulation of 
Nav1.7 trafficking brought about by CRMP2. It would be interesting to probe tissues 
from injured animals both before and after roscovitine treatment to determine if changes 
to CRMP2 SUMOylation correlate with animal pain behaviors. 
 In my thesis I did not test how phosphorylation by Cdk5 or loss of 
phosphorylation by Fyn is dominant over CRMP2 SUMOylation.  These phosphorylation 
statuses effectively block the phenotype of reduced Nav1.7 current associated with non-
SUMOylated CRMP2. Therefore, these modifications could be responsible for regulating 
onset of rodent or human pain behavior. I hypothesize that dominance of these 
phosphorylation events is endowed by requirement of CRMP2 interaction with endocytic 
proteins Numb, Eps15, and Nedd4-2 for endocytosis of Nav1.7. Should dominant 
 161 
  
modifications prevent CRMP2 interactions with endocytic proteins, it would sufficiently 
explain the lack of effect by non-SUMOylated CRMP2. 
 
5.2.2. Targeting CRMP2 SUMOylation for possible therapeutic relief of pain 
To develop my data on the importance of CRMP2 SUMOylation to Nav1.7 and 
then to link it possibly to animal pain behavior, I propose a series of experiments 
designed to mimic CRMP2 deSUMOylation to achieve a reduction in Nav1.7. This can 
be done by overexpression of the SUMO-null CRMP2-K374A in the DRGs of injured 
animals. While viral strategies may be advantageous here, using a non-viral transfection, 
CRMP2-K374A expression could be introduced to the DRGs of injured animals likely 
via a lumbar puncture or via an intrathecal route to the dorsal spinal cord or direct 
injection into DRGs. If successful, this strategy would permit expression in the 
superficial lamina layer I of the dorsal spinal cord where DRGs project to (Black et al., 
2012). This may be achievable using either lipid– (for example, Turbofect, Life 
Technologies) or polyethylenimine–complexed DNA transfection techniques which have 
shown efficacy when transfecting spinal cord tissue in vivo (Yao et al., 2012). By forcing 
expression of CRMP2-K374A after injury, a potential reversal of pain in response to 
CRMP2-K374A expression may be possible. Success of this strategy would provide 
proof-of-concept for further studies investigating CRMP2 SUMOylation as a novel 
pharmacological target for pain and could be paired with biochemistry and patch clamp 
methods to correlate behavior with alterations in level of CRMP2 SUMOylation and 
Nav1.7 currents. Failure of this experiment to correlate pain behavior and loss of CRMP2 
SUMOylation could occur if dominant positive CRMP2 phosphorylation by Fyn or Cdk5 
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is present. In this case it may be required to modulate both SUMOylation and 
phosphorylation for desired therapeutic benefit. Repeating behavior experiments with in 
vivo administration of CRMP2-K374A prior to the injury could help assess if CRMP2 
SUMOylation mediated Nav1.7 activity is important in the development of pain states. 
I have shown in this thesis that CRMP2 modulation of neurite outgrowth is not 
affected by CRMP2 SUMOylation. However, CRMP2 is a promiscuous protein with 
many functions in neurons (Khanna et al., 2012). Some of these functions regulate other 
ion channels that, like Nav1.7, can alter neuronal activity, i.e. NR2B subunit (Bretin et 
al., 2006), and Cav2.2 (Brittain et al., 2012). A role, if any, for CRMP2 SUMOylation in 
regulating these proteins has not yet been described. To validate CRMP2 SUMOylation 
as a druggable target for regulation of Nav1.7 with minimal off-target effects, the role of 
CRMP2 SUMOylation in these and other functions of CRMP2 will need to be analyzed. 
One important consideration in targeting CRMP2 SUMOylation is that the CRMP2 
SUMOylation motif, centered at lysine-374, conforms to the typical SUMOylation 
consensus motif. Therefore, pharmacological targeting of CRMP2 SUMOylation will 
need to only interfere with CRMP2 SUMOylation and no other targets of SUMOylation 
to avoid disrupting turnover of total cellular SUMOylation. 
 
5.2.3. Addressing specificity in regulation of Nav.x by CRMP2 and possibly other 
CRMPs 
A major finding of my thesis is that CRMP2 SUMOylation is a specific regulator 
of Nav1.7. By pharmacological and electrical isolation of current from endogenous 
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VGSC subtypes in DRGs, I determined that only Nav1.7 channels are affected (see 
Figures 3.6 and 3.8). Nav1.7 is a high-value target for the development of pain 
therapeutics. Thus, this remarkable specificity for Nav1.7 is a highly desirable 
characteristic of a drug target due to the established role of Nav1.7 in human painful 
conditions (Dib-Hajj et al., 2013) and also to avoid effects of targeting central nervous 
system, skeletal muscle, or cardiac expressed VGSC subtypes (Catterall et al., 2005). The 
molecular determinants of CRMP2 specificity for Nav1.7 were not determined in my 
thesis.  
Due to shared relationship between the majority of VGSCs (Nav1.1, Nav1.2, 
Nav1.5, Nav1.6, Nav1.7, Nav1.8) and the Nedd4/Nedd4-like E3 ubiquitin ligase family 
responsible for their endocytosis (Fotia et al., 2004, van Bemmelen et al., 2004, Abriel 
and Staub, 2005, Rougier et al., 2005), I predict that specificity of CRMP2 regulation for 
Nav1.7 is not determined by regulation of the endocytic machinery. Instead, I propose 
that specific regulation of Nav1.7 by CRMP2 is due to the specific affinity of CRMP2 for 
this Nav1.7 subtype. CRMP2 modulation of Nav1.7 currents was dependent on both 
CRMP2 expression, CRMP2 SUMOylation, and CRMP2 phosphorylation. Enhanced 
interaction of CRMP2 with endocytic machinery upon loss of SUMOylation readily 
explains the dependence on SUMOylation, but this was not further interrogated in this 
thesis. A possible scenario to explain dependence of Nav1.7 endocytosis on CRMP2 
expression is CRMP2 antagonism of Nav1.7 interaction with Nedd4-2 when CRMP2 is 
SUMOylated. When CRMP2 is not present at the membrane, Nedd4-2 may interact with 
Nav1.7 by a CRMP2-independent mechanism and recovery of CRMP2 expression would 
render the channel resistant to ubiquitination and endocytosis. Interactions of L-type 
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voltage-gated calcium channels and Kv7.1 voltage-gated potassium channels with their 
respective β subunits are examples where accessory proteins antagonize ubiqutination of 
channels (Altier et al., 2011, Andersen et al., 2013).  
Identification of domains involved in the CRMP2-Nav1.7 interaction could be 
used as a basis of comparison to advance the mechanistic understanding of CRMP2 
regulation of Nav1.7 and also investigate potential regulation of other VGSCs by other 
CRMP family member proteins. CRMP2 binding to Nav1.7 but lack of binding (or weak 
binding) to other VGSC subtypes may explain the specificity of action observed in my 
work. Alternatively, another protein that preferentially binds Nav1.7 maybe involved, 
which, in concert with CRMP2 SUMOylation, regulates Nav1.7. These possibilities were 
not studied in my thesis but should form the basis of future studies, as identifying the 
nature of how specificity of targeting Nav1.7 is achieved is very exciting and potentially 
highly translationally relevant.  
CRMPs are a family of five proteins (Khanna et al., 2012). In DRGs, expression 
of CRMP4 is very low in naïve conditions, but significantly increases following sciatic 
nerve axotomy (Jang et al., 2010). As my data places CRMP2 as a determinant of Nav1.7 
trafficking in DRGs (Figure 3.2), it would be interesting if CRMP4 could participate 
similarly following axotomy. An analysis of CRMP4 SUMOylation status and its effect 
on Nav1.7 trafficking in DRGs using a CRMP4-K374A mutant would allow for such a 
determination. If CRMP4 does not interact with Nav1.7 then a comparison of the 
homology between CRMP2 and CRMP4 could serve as a starting point to determine 
what sequences of CRMP2 are involved in interaction with Nav1.7. 
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CRMP2 likely interacts with intracellular domains of Nav1.7 as CRMP2 is a 
cytosolic protein (Khanna et al., 2012). To identify Nav1.7 domains responsible for 
CRMP2-Nav1.7 interaction, tagged intracellular domains of Nav1.7 could be expressed 
in a heterologous cell line and probed for interaction with CRMP2. A CRMP2 
immunopreciptation followed by immunoblotting with an antibody versus the tag motif 
would determine which domains of Nav1.7 interact with CRMP2. The five major 
intracellular domains of Nav1.7, the N-terminus, L1, L2, and L3 loops, and C-terminus, 
have been made available to the Khanna lab as part of a collaboration to perform such a 
study (Stamboulian et al., 2010). Other shorter pieces of the intracellular loops could also 
be tested. An alternative strategy would require identification of a VGSC subtype that 
does not interact with CRMP2. For example, assume Nav1.2 does not bind CRMP2. 
Then, a Nav1.7-Nav1.2 chimeric channel could be produced by substituting domains of 
Nav1.7 for domains of Nav1.2. Following expression in empty HEK293 cells, interaction 
of the chimera with CRMP2 and effect of CRMP2-K374A on current density could be 
probed with biochemical and electrophysiological techniques, respectively. Following 
identification of specific domain chimeras that prevent CRMP2-Nav1.7 regulation or 
interaction, smaller and smaller regions, i.e. 50 or 10 amino acid segments could be 
substituted until the specific channel regions required for CRMP2 binding are identified. 
CRMP2-Nav1.7 interaction could also be studied using a peptide spot blot of the 
Nav1.7 intracellular domains or CRMP2. The spot blot could then be probed with the 
opposite protein, purified CRMP2 protein, or channel fragments. Such a strategy was 
previously used in the Khanna laboratory to define interacting domains between CRMP2 
and the voltage-gated calcium channel Cav2.2 (Brittain et al., 2011b). By producing 
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overlapping 15 amino acid segments of Nav1.7 intracellular domains, the residues of 
Nav1.7 involved in CRMP2 binding could be identified. By flipping the spots blot to 
probe CRMP2 peptides against Nav1.7 domains, interacting residues on the surface of 
CRMP2 could be identified. The CRMP2 SUMOylation motif (4 residues) centered on 
lysine-374 is perfectly homologous to other CRMPs and the flanking sequences (14 
residues) is between 71.4% and 92.9% homologous to other CRMPs (as elaborated in 
Chapter 3.3). Additionally, the C-terminal domains of Nav1.1, Nav1.2, Nav1.3, Nav1.5, 
Nav1.6 Nav1.7, and Nav1.8 all contain an ubiquitin E3 ligase targeted PY domain (Fotia 
et al., 2004, Rougier et al., 2005). This suggests that if other CRMPs can bind VGSCs, 
SUMOylation of these CRMPs and endocytosis of these VGSCs may occur in a 
mechanism similar to CRMP2 and Nav1.7. Study of CRMP family proteins and VGSCs 
could progress as in this thesis and aim to identify endogenous SUMOylation of the other 
CRMPs which can then be combined with co-expression studies with SUMO-null 
CRMP.x variants with VGSC subtypes in heterologous cell lines. The most promising of 
these that exhibit Nav current reductions could then be recapitulated in primary cell 
culture based on the overlapping expression patterns of CRMPs and VGSCs in the 
nervous system (Quach et al., 2000, Bretin et al., 2005, Catterall et al., 2005, Jang et al., 
2010, Tsutiya and Ohtani-Kaneko, 2012). 
In addition to voltage-gated sodium channels, similarly structured voltage-gated 
calcium channels are candidates for regulation by CRMP2 SUMOylation. Cav2.2 is 
demonstrated to interact with CRMP2 (Brittain et al., 2012). This means that if regulation 
of Nav1.7 by CRMP2 is governed strictly by CRMP2 interaction with the channel, there 
is no obstacle for similar regulation of Cav2.2. If CRMP2 regulation of Nav1.7 is instead 
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derived from a CRMP2-Numb interaction, it is possible that CRMP2-Numb interaction is 
dependent on participation of Nav1.7 but does not occur for Cav2.2. This scenario could 
explain subtype specificity observed within the large family of similarly structured ion 
channels. 
 
5.2.4. Role of CRMP2 SUMOylation on DRG excitability and Nav1.7 in non-nociceptive 
neurons 
As a functional readout of neuron activity, DRG excitability is intimately linked 
to Nav1.7 activity and increases of activity correlate to pain-like behavior in animal 
models. The Nav1.7-I739V mutation causes a doubling of action potentials and 
represents a case where altered Nav1.7 is the sole determinant of neuropathic pain 
condition, small fiber neuropathy, in human patients with the mutation (Han et al., 2012). 
Examples of Nav1.7 mediated enhancement of DRG excitability and pain are numerous 
and involve channel mutations underlying paroxysmal extreme pain disorder and 
inherited erythromelalgia in addition to small fiber neuropathy (overview of mutations in 
(Dib-Hajj et al., 2013)). Chronic inflammatory pain can also produce increases to 
nociceptive C-fiber excitability (Weng et al., 2012). 
In addition to excitability driven by Nav1.7 in DRGs, recent evidence from John 
Woods’ group supports a role of non-nociceptor Nav1.7 currents in pain behavior. 
Nav1.7 knockout mice require deletion from sympathetic neurons, in addition to DRGs, 
to prevent neuropathic pain behavior (Minett et al., 2012). A different animal behavior 
study recapitulated this finding in wildtype mice by showing that blocking sympathetic 
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nerve activity after injury recovers baseline pain behavior (Iwase et al., 2012). Blocking 
of sympathetic nerve activity also produced reduced DRG excitability indicating that 
communication between neuronal subpopulations is involved during development of 
neuropathic pain. Therefore, electrophysiological analysis of CRMP2-mediated Nav1.7 
regulation is warranted in sympathetic neurons. A common regulation of Nav1.7 by 
CRMP2 in both DRGs and sympathetic neurons would extend the efficacy of CRMP2-
targted pain therapies to non-nociceptor mediated pain states, including neuropathic pain. 
In a continuation of my thesis work by the Khanna laboratory, Dr. Yuying Wang and Dr. 
Xiaofang Yang have collected excitability data from DRG neurons expressing wildtype 
CRMP2, CRMP2-K374A, and CRMP2-S522A (Figure 5.2). Compared to wildtype 
CRMP2 expressing DRGs, a significant decrease in the number of action potentials was 
observed in cells expressing CRMP2-K374A and CRMP2-S522A (Figure 5.2B) as well 
as an increased rheobase value for CRMP2-S522A expressing cells (Figure 5.2C). This 
change to rheobase for CRMP2-S522A expressing cells but not CRMP2-K374A 
expressing cells may indicate that CRMP2-S522A affects additional VGSC subtypes or 
gating properties compared to CRMP2-K374A. This will be elucidated in future studies 
and may reveal that CRMP2 SUMOylation is a better druggable target than CRMP2 
phosphorylation by Cdk5 due to greater specificity for effect on only Nav1.7 current 
density. The resting membrane potential was not different between any conditions 
(Figure 5.2D). These data suggest that CRMP2 mutants, that reduce Nav1.7 currents, also 
reduce DRG excitability. This exciting result allows prediction that CRMP2 mediated 
reduction of Nav1.7 surface expression would be beneficial in treating painful conditions 
where Nav1.7 induced DRG hyperexcitability is the underlying cause of pain.  
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Figure 5.2. CRMP2-K374A and CRMP2-S522A reduce DRG excitability. 
(A) Representative voltage responses to current injection of CRMP2, CRMP2-
K374A, and CRMP2-S522A expressing small DRGs. (B) The average number 
of action potentials in response to 1 second of current injection was reduced by 
CRMP2-K374A (purple) or CRMP2-S522A (red) expression. (C) Rheobase, 
the amplitude of current required to provoke an action potential, was 
significantly increased in CRMP2-S522A (red), but not CRMP2-K374A 
(purple) expressing DRGs. (D) The resting membrane potential, which when 
depolarized can induce hyperexcitability of DRGs, was unchanged between 
conditions. Errors are SEM. Asterisks indicate statistically significant 
differences compared to all other conditions (p < 0.05, one-way ANOVA with 
Tukey’s post-hoc; n=11–17). Experiment performed by Drs. Xiaofang Yang 
and Yuying Wang, postdoctoral associates in the Khanna laboratory. 
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The regulation of Nav1.7 via CRMP2-regulated trafficking may provide benefits 
compared to the more common strategy of channel antagonism. In a case where Nav1.7 
turnover is regulated by channel activity, a typical agonist may lead to upregulation of 
Nav1.7 surface expression due to prevention of activity. Then upon termination of 
treatment neurons may be sensitized or continued treatment may require higher doses. An 
example of this is morphine treatment for pain where sodium currents are potentiated by 
morphine-3-glucuronide, a morphine metabolite (Due et al., 2014). Targeting Nav1.7 
trafficking would prevent this complication by controlling the neurons potential for 
activity, not only the neurons current ability to produce activity. By the same logic, 
CRMP2-regualted trafficking of Nav1.7 could be paired with conventional Nav1.7 
channel antagonism to dramatically enhance efficacy of these strategies. 
 
5.2.5. Does CRMP oligomerization affect Nav1.7 trafficking and current density? 
 CRMP family proteins form tetramers with self and non-self CRMP monomers 
(Wang and Strittmatter, 1997b). Formation of tetramers occurs in vivo as evident by 250 
kDa CRMP immunoreactivity following size exclusion chromatography. This value is 
exactly 4x greater than the 62kDa mass of CRMP monomers. In solution, individual 
CRMP proteins display different dispositions to form homotetramers as a function of 
protein concentration (Ponnusamy and Lohkamp, 2013). As concentration increases, 
CRMP propensity to form tetramers also increases. These in vitro experiments showed 
that CRMP1 is found in roughly equal fractions of monomer and homotetramers, CRMP2 
is found primarily in homotetramers, and CRMP5 is found exclusively in monomers 
(Ponnusamy and Lohkamp, 2013). CRMP2 displayed the greatest increase of 
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tetramerization as a function of protein concentration. The formation of heterotetramers 
was described to occur between non-conserved residues, and as a result heterotetramers 
are more favorable conformations than homotetramers in vivo (Ponnusamy and 
Lohkamp, 2013). However, functions of CRMP2 monomers versus CRMP2 in homo or 
heterotetramers remain largely understudied.  
An example of how oligomerization may affect CRMP-mediated functions is 
illustrated by studies on CRMP5, the most distantly related CRMP member. The CRMP 
family member protein, CRMP5, has been shown to antagonize the effects of CRMP2 on 
neurite outgrowth. Following GSK3β-mediated threonine-516 phosphorylation of 
CRMP5 (Brot et al., 2014), CRMP5 competes with CRMP2 for tubulin binding which 
results in block of CRMP2-mediated outgrowth (Brot et al., 2010). The overexpression of 
CRMP2 is unable to recover outgrowth of hippocampal neurons when CRMP5 is 
expressed suggesting that CRMP5 is dominant over the effects of CRMP2 in this 
function (Brot et al., 2010). Based on this relationship between CRMPs, it seems possible 
that expression of CRMP family proteins, or CRMP heterotetramerization with CRMP2 
might modulate CRMP2s regulation of Nav1.7. To test these possibilities, CRMP 
proteins (e.g., CRMP5) could be co-expressed in CAD cells with wildtype CRMP2 or 
CRMP2-K374A. This would uncover any changes to CRMP2-mediated Nav1.7 
regulation induced by the presence of other CRMPs. Intriguingly, because CRMP5 
antagonizes CRMP2 function, it is tempting to speculate that its assembly within a 
CRMP heteromer might by itself be sufficient to regulate Nav1.7. Moreover, if CRMP5 
associates with the SUMO-null CRMP2-K374A, then perhaps the Nav1.7 current 
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reduction imposed by the homomeric CRMP2-K374A may be nullified by a heteromeric 
CRMP5-CRMP2-K374A protein. 
There is only a single report of a CRMP2 function being ascribed to a specific 
oligomeric form of CRMP2, the facilitation of tubulin heterodimerization by CRMP2 
monomers, and no studies have ascribed a specific role for CRMP2 tetramers (Fukata et 
al., 2002b). The authors used sucrose density gradient centrifugation to demonstrate that 
the purified CRMP2 and tubulin was 162.2 kDa in molecular weight which corresponded 
to a tubulin heterodimer (α tubulin = 52.2 kDa plus β tubulin = 49.9 kDa) plus a CRMP2 
monomer of ~60 kDa (Fukata et al., 2002b). In early studies of VGSCs, channel-binding 
toxins were used to purify channels from brain (Talvenheimo et al., 1982). If a Nav1.7 
specific toxin like Huwentoxin-IV (Xiao et al., 2010) or Protox-II (Schmalhofer et al., 
2008) were used to purify Nav1.7 from DRG or peripheral nerves, a similar sucrose 
density gradient centrifugation experiment could be performed to identify the weight of 
the CRMP2-Nav1.7 complex. A weight of ~310 kDa would indicate Nav1.7 interacts 
with a single CRMP2 monomer, whereas a weight of ~500 kDa would indicate Nav1.7 
interaction with a CRMP2 tetramer. A control for this study would be identification of 
CRMP2 tetramerization in the absence of Nav1.7 which can be induced by divalent 
cations calcium or magnesium (Ponnusamy and Lohkamp, 2013). 
Another experiment to test the effects of CRMP2 tetramerization on Nav1.7 
hinges on development of a small molecule inhibitor of CRMP2 SUMOylation as well as 
identification of a CRMP protein that does not interact with Nav1.7. In these cases, 
CRMP2 could be co-expressed in CAD cells with varying levels of a second CRMP 
family protein to identify effects of CRMP tetramerization on CRMP2 mediated Nav1.7 
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endocytosis. As an example, one could compare transfection of 1 µg CRMP2 and 1 µg 
CRMP1 versus 1 µg CRMP2 and 4 µg CRMP1 under the assumption that CRMP1 does 
not display affinity for Nav1.7. Then at higher levels of CRMP1 expression, CRMP2 will 
have tendency to associate into tetramers that contain less CRMP2. Application of a 
small molecule inhibitor of CRMP2 SUMOylation to these cells could then reveal 
alterations in Nav1.7 trafficking. A concentration within the linear range of effects versus 
concentration near the IC50 would best allow for identification of altered efficacy. If the 
CRMP2 ratio in tetramers is not important for regulation of Nav1.7 then each condition 
will display equivalent current densities. However, if presence of multiple CRMP2 copies 
within a tetramer is required for Nav1.7 internalization, then higher expression of 
CRMP1 will blunt the effect of the small molecule inhibitor. 
 
 
5.2.6. Identification of additional regulators/partners of CRMP2-Nav1.7 signaling 
 My studies identified Numb, Eps15 and Nedd4-2 as proteins required for Nav1.7 
internalization through interactions by CRMP2. The link between these proteins and the 
mechanism of endocytosis was supported by previous literature that established an 
interaction of Numb with CRMP2 (Nishimura et al., 2003a, Arimura et al., 2005) and 
dysregulation of Nav1.7 surface expression to reduced Nedd4-2 expression (Laedermann 
et al., 2013a). CRMP2 regulation of Nav1.7 is determinant on both CRMP2 expression 
and CRMP2 SUMOylation. CRMP2 SUMOylation status readily explains the facilitation 
of Nav1.7 endocytosis by the identified binding partners Numb, Eps15, and Nedd4-2. In 
the section 5.2.3 I hypothesize that CRMP2 expression may determine Nav1.7 expression 
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by antagonism of channel ubiquitination. Such a mechanism could involve channel 
interaction with SUMOylated CRMP2 or non-Fyn-phosphorylated CRMP2. The 
mechanism(s) by which CRMP2 SUMOylation and phosphorylation co-opt recruitment 
of endocytic proteins and by which CRMP2 expression maintains Nav1.7 surface 
expression may rely on participation of additional protein partners. 
Identification of additional protein partners of CRMP2 and/or Nav1.7 could kick-
start a search for proteins and mechanisms that serve this function. This could be 
accomplished by quantitative mass spectrometry of CRMP2 from empty HEK293 cells 
versus HEK293 cells expressing Nav1.7 with CRMP2. Then, any changes to CRMP2-
interacting proteins would be dependent on CRMP2 interaction with the channel. A 
reciprocal experiment would involve quantitative mass spectrometry of Nav1.7 from cells 
where CRMP2 expression was depleted by siRNA or enhanced by overexpression 
plasmids. 
 The VGSC accessory protein β2 is an identified binding partner of Nav1.7 and 
plays an important role in channel forward trafficking. This has been shown in β2-null 
mice that display reduced Nav1.7 protein expression, decreased TTX-S current densities, 
and decreased thermal and inflammatory pain thresholds (Lopez-Santiago et al., 2006). 
Whether this subunit is synergistic or competitive in CRMP2 regulation of the channel is 
unknown. The first identification of beta subunits noted that they interacted only with 
mature membrane expressed channels positing a role for these auxiliary subunits in 
biogenesis and trafficking (Schmidt and Catterall, 1986). If CRMP2 interaction with 
immature Nav1.7 enhances Nav1.7 interaction with β2 subunits, it could explain the 
Nav1.7 forward trafficking properties observed in response to changing CRMP2 
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expression. Additionally, β2 interaction with surface expressed Nav1.7 could alter 
channel ubiquitination either by CRMP2-dependent or -independent mechanisms. In 
addition to new CRMP2-interacting proteins, CRMP2 SUMOylation may also be 
regulated by other modifications of CRMP2. I have described interplay between CRMP2 
SUMOylation and phosphorylation, but CRMP2 also undergoes glycosylation and 
oxidation which have not yet been studied in combination with CRMP2 SUMOylation 
(Morinaka et al., 2011, Khanna et al., 2012). 
 Elaboration of these mechanisms, and completion of other studies listed in 
Chapter 5, will build upon the data presented in this thesis to expand the molecular 
mechanism(s) by which CRMP2 regulates Nav1.7. It is my fervent hope that these 
studies will also spur the translation of CRMP2-mediated Nav1.7 regulation for the 
eventual treatment of human pain. Given animal behavior data demonstrating complete 
lack of inflammatory and chronic pain following Nav1.7 knockout under Wnt1 promotor 
(Minett et al., 2012, Minett et al., 2014a), I propose that CRMP2-medaited trafficking of 
Nav1.7 could be targeted to treat a wide variety of human pain conditions, including 
those where efficacy of currently available drugs is limited. 
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